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Abstract 
Magnetic resonance imaging (MRI) is capable of three dimentional non-
invasive imaging of opaque tissues at near cellular resolution. Among the 
imaging techniques available, MRI has, perphaps, the greatest potential to 
exploit the possibilities that molecular imaging presents. Nanoparticles (1-
100 nm and 100-2500 nm in size) are the focus of intense interest, due their 
potential applications in the biomedicine and especially as labelling agents in 
imaging. This research is based on development of nanoparticles 
(immunoliposomes) as targeted contrast agents for molecular magnetic 
imaging of human multiple myeloma. It uses an application of antibody 
(CD138; syndecan-1) to target liposomes and other particles for delivery of 
MRI contrast agents to cell-surface based biomarkers. The use of 
gadolinium-loaded polychelating amphiphilic polymer (PAP) for incorporation 
into liposome membranes, and for conjugation with CD138 antibody was 
also examined. The diagnosis of human multiple myeloma currently requires 
the performance of a range of tests and the assessment of marrow 
specimens derived from invasive biopsy. The strategy undertaken in this 
research should provide an alternative and potentially more beneficial way of 
addressing this problem. 
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1.1 Introduction 
Molecular imaging is a relatively new and exciting area in diagnostic 
imaging. It can be defined as the in vivo characterisation and measurement 
of biological processes at the cellular and subcellular level (Allport and 
Weissleder, 2001). Magnetic Resonance Imaging (MRI) is achieved through 
a combination of imaging and active targeting of a contrast agent to 
disease-specific markers enabling minimally non-invasive, specific detection 
of biochemical markers. Molecular imaging differs from ‘traditional’ imaging 
approaches, which rely primarily on registering and interpreting differences 
in image contrast between tissues, normal or pathological, which represent 
the anatomical expression of disease. In contrast, molecular imaging looks 
to improve diagnostic accuracy through the visualisation of processes or 
components that cause disease (Lanza et al., 2003). Thus, the development 
of molecular imaging can be seen as complementary to well-established 
imaging techniques rather than a potential replacement for them. 
The most commonly used techniques for molecular imaging have been 
nuclear methods (positron emission tomography - PET and single positron 
emission computed tomography - SPECT) (Phelps 2000) and MRI 
(Weissleder et al., 1997). In more recent times ultrasound (Liang and 
Blomley, 2003) and optical techniques (Baeten et al., 2009) have also been 
applied. Each modality has advantages and disadvantages, some of which 
are outlined in Table 1.1. For example, nuclear methods (SPECT and PET) 
have high sensitivity but low spatial resolution and poor definition of 
anatomy. MRI, in contrast, exhibits good spatial resolution but low 
sensitivity, though this can be improved by the use of contrast agents with 
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high relaxivity. Ultimately, the specific molecular process that is being 
targeted will determine the choice of technique. However, among the 
approaches outlined MRI alone combines the benefits of high spatial 
resolution with the capacity to extract physiological and anatomical 
information (Smith et al., 1994; Phelps, 2000) and in this introduction the 
focus is on this particular modality’s role in molecular imaging. 
 
Table 1.1 Summary of the differences between imaging modalities and 
their possibilities for nanoparticle applications.  
Adapted from Kairemo et al. (2008). 
MODALITY SPATIAL 
RESOLUTION 
DEPTH TEMPORAL 
RESOLUTION 
SENSITIVITY 
(mol/L) 
PET 1-2 mm No limit 10s-min 10-11-10-12 
SPECT 0.5-1 mm No limit min 10-10-10-11 
MRI 25-100 µm No limit min-h 10-3-10-5 
CT 50-200 µm No limit min 10-2-10-4 
Ultrasound 50-500 µm mm-cm s-min 10-3-10-4 
 
1.2  Magnetic Resonance Imaging 
MRI exploits the remarkable range of physical and chemical properties of 
water protons e.g. hydrogen nuclei (Mulder et al., 2004) and has emerged 
as one of the leading minimally non-invasive imaging modalities (Aime et 
al., 2002). The signal detected in MRI is created through the interaction of 
total water signal (proton density) and the magnetic properties of the tissues 
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being imaged (Caravan et al., 1999). The magnetic properties in question 
are the longitudinal relaxation time, T1, and transverse relaxation time, T2. 
The reciprocal of these values represent the longitudinal and transverse 
relaxation rates (1/s), R1 and R2, respectively. Signal tends to increase with 
increasing R1 and decrease with increasing R2. Pulse sequences that 
emphasise changes in R1 are referred to as T1-weighted, those that 
emphasise changes in R2 T2-weighted scans. Proton longitudinal and 
transverse relaxation times are dependent upon the physiochemical 
environment of a given tissue and are modified in the presence of a 
pathological state (Aime et al., 2002). Hence, MRI enables differentiation 
between various tissues in the body as well as between normal and 
pathological tissues. 
 
1.2.1 Nuclear spin behaviour in a magnetic field 
When a nucleus with magnetic moment µ is placed in a uniform external 
magnetic field, B0, the nuclear spin, which are otherwise randomly oriented, 
will align in definite directions relative to the direction of B0. There are only 
two possible orientations of the magnetic moments allowed for a proton 
nucleus with spin ½. The moments can either be aligned parallel or 
antiparallel to the direction of B0, corresponding to a lower energy α-state 
or higher energy β-state, respectively. The population ratio between the 
number of nuclei in the higher and lower energy levels is described by the 
Boltzmann relationship: 
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The number of nuclei in the higher and lower energy level is dependent 
upon the absolute temperature of the sample, T, the strength of the 
magnetic field, and the nuclear magnetic moment. The value of ∆E is very 
low. The resulting slight excess of nuclei in the lower spin state produces a 
small net macroscopic nuclear magnetisation, aligned with B0, called the 
equilibrium magnetisation (Figure 1.1). 
 
Figure 1.1 Representation of the equilibrium distribution of nuclear 
spins in the presence of magnetic field, B0.  
 
Before applying the rf (radiofrequency pulse), the magnetic moments are in 
the α- or β-states each precesses around the z-axis. The frequency of 
precession, known as the Larmor frequency, is proportional to the field 
strength and the nuclear magnetic moment. The equilibrium magnetisation 
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vector M0 is the vector sum of all the individual moments of the proton 
nuclei and is aligned along B0 (Figure 1.2). 
  
 
 
 
 
 
 
 
 
Figure 1.2 Representation of ensemble of nuclear spins in the 
presence of a magnetic field applied along the z-axis. 
 
 
When a radiofrequency pulse (rf) is applied into the plane perpendicular to 
B0. Transitions between the spin states are induced. The perturbation will 
rotate the magnetisation away from its original position. The new 
magnetisation vector Mxy now precesses about the z-axis but produces a 
non-zero magnetisation component in the xy plane. After the rf pulse is 
switched off the individual nuclei begin to undergo relaxation by releasing 
the absorbed rf energy, re-establishing the thermal equilibrium Boltzmann 
population of nuclear spins. The RF coil, which acts as an antenna, is only 
sensitive to magnetisation in the xy-plane. The relaxation process can 
occur by two different mechanisms. 
B 
x 
y 
M0 
z 
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First, when the excitation pulse is discontinued, the individual nuclei can 
begin to undergo relaxation by releasing the absorbed rf energy to the 
surrounding lattice. This mechanism is known as longitudinal or spin-lattice 
relaxation (Figure 1.3). This corresponds to the sample magnetisation the 
return to its equilibrium position (to z-axis from y-axis).  
 
Figure 1.3 Schematic of magnetization undergoing longitudinal (spin-
lattice) relaxation in time followed the radiofrequency (rf) pulse. 
 
T1, the longitudinal (spin-lattice) relaxation time, is the characteristic time 
required for the magnetisation to return to equilibrium. 
The second type of relaxation mechanism is called transverse relaxation, or 
spin-spin relaxation (Figure 1.4). The nuclear spins slowly lose their phase 
coherence or order. This occurs, due to mutual simultaneous spin 
transitions, e.g. α to β and at the same time β to α. The T2 process can be 
more rapid than T1 process in some situations, but not reverse. 
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Figure 1.4 Schematic of magnetization undergoing tranverse (spin-
spin) relaxation in time. 
 
1.2.2 T1-weighted imaging 
Organs containing gadolinium ions will have increased ‘H NMR signal 
intensity if the image is recorded with T1-weighting. That means that T1-
weighting images can be obtained by reducing time between successive 
scans.  By performing successive scans without allowing full relaxation the 
signal obtained is weighted to that fraction at the ‘H magnetisation with 
shorter T1.  
 
1.2.3 Contrast Agents in MRI 
Contrast agents are used in imaging to increase the signal difference 
between the area of interest and the background. Currently, approximately 
35% of MRI examinations involve the use of contrast agents, but this 
percentage can be expected to increase further following the development 
of more effective and specific contrast media than those currently 
commercially available. 
The contrast agents used in MRI act through, hereby the water proton 
relaxation, thus increasing longitudinal and transverse relaxation rates (R1 
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and R2) and, therefore, the intensity of the MR signal, in the regions where 
they are distributed (Aime et al., 2002). Contrast agents increase both 
longitudinal and transverse rates but to varying degrees, depending on their 
nature as well as the applied magnetic field.  
There are two main classes of contrast agents for MRI: paramagnetic 
complexes and superparamagnetic iron oxide particles. The former class 
includes mainly chelates of Mn(II), Mn(III) and Gd(III) ions, with gadolinium-
based agents being the most commonly used. Paramagnetic agents 
increase R1 and R2 by similar amounts but are best visualised using T1-
weighted images since the percentage change in R1 in tissue is much 
greater than that in R2. Nanoparticulate contrast agents generally lead to a 
much larger increase in R2 than in R1 and are best seen with T2-weighted 
scans. The ability of a contrast agent to increase R1 and R2 per millimolar of 
agent is defined as its longitudinal or transverse relaxivity, r1 or r2, 
respectively, and is expressed in s-1.mM-1 (Caravan et al., 1999). T1 agents 
usually have r2/r1 ratios of 1-2, whereas the value for T2 agents, such as iron 
oxide particles, is as high as 10 or more. Paramagnetic agents directly 
affect water protons in their close vicinity and are highly dependent on local 
water flux. Hence, the influence of these agents is very local and they 
should ideally be in contact with water with adequate exchange rates. In 
contrast, superparamagnetic agents affect the magnetic field independent of 
their environment and, thus, their influence in terms of contrast extends well 
beyond their immediate surroundings (Lanza et al., 2004). 
However, MRI contrast agents are limited by their lack of specificity. 
Targeting of MRI contrast agents to distinct molecules associated with 
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tissue pathology would enable more specific diagnosis by MRI and provide 
the potential to characterise disease at the molecular level in vivo. The 
gadolinium contrast agents currently on the market require a tissue 
concentration in the order of 10-7 mol/g to obtain sufficient contrast in the 
resulting image (Gupta and Weissleder, 1996; Lanza et al., 2004). Such a 
number is too high to be able to image sparse molecular biomarkers 
expressed in the living body since typical receptors are normally present in 
low concentrations of 10-9 to 10-13 mol/g (Strijkers et al., 2005). An 
amplification strategy is required to overcome these sensitivity problems. 
One solution is to use nanoparticles since a high payload of a contrast 
agent can be incorporated in a single particle, thus increasing the effective 
relaxivity per particle; consequently, the signal detected during imaging 
increases (Glogard et al., 2002). 
 
1.3  Fast Field-Cycling NMR 
Fast Field-Cycling NMR (FFC NMR) is a technique used to obtain longitudinal 
relaxation times, T1 (R1, relaxation rate-reciprocal of T1) over a wide range of 
magnetic field strenghts. A plot of r1 (relaxivity) as a function of frequency is 
known as a nuclear magnetic relaxation dispersion (NMRD) profile.  
 
1.4 Nanoparticles 
Nanoparticles are small clusters of atoms, approximately 10 to 100 nm in 
diameter, and they present an opportunity to improve drug delivery as well 
as targeting of contrast agents. Many varieties of nanoparticles are 
available. A short overview of some that are relevant to medical diagnostics 
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and therapeutics is given here. A more in-depth analyses of the advances 
made in the field of nanomedicine, with a particular focus on molecular 
magnetic resonance imaging are described in two excellent reviews by 
Mody et al. (Mody et al., 2009) and Sun et al. (Sun et al., 2008). 
Lipid-based nanoparticles are among the most intensively studied group of 
nanoparticles, having been investigated since the 1970’s. Liposomes are 
closed vesicles composed of one or more amphiphilic bilayers. Lipids used 
to create such bilayers are amphiphilic phospholipids with hydrophilic heads 
and hydrophobic tails (Figure 1.5). These bilayered membrane vesicles can 
range from 50 nm up to 5µm in size and have been utilized for the delivery 
of small molecules (Dass and Choong, 2006), proteins (Meldrum et al., 
2003), peptides (Torchilin et al., 2001), DNA (Reimer et al., 1999) and MR 
imaging contrast agents (Torchilin, 2005). The in vivo behaviour of 
liposomes is well established with modifications such as PEGylation 
resulting in longer circulation times. Liposomes will be discussed in greater 
detail in section 1.5. 
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Figure 1.5 Illustration of a liposome.  
Liposomes are composite structures made of phospholipids, which are 
composed of hydrophilic head and hydrophobic tail.  
 
Solid lipid nanoparticles (SLN) represent an alternative lipid-based carrier 
system. They are colloidal particles of a lipid matrix that is solid at body 
temperature and may be stabilized by surfactant (Pardeike et al., 2009) 
(Figure 1.6). They have potential as carriers for parenteral administration of 
hydrophobic drugs and also for improving oral absorption of drugs such as 
cyclosporin A (Müller et al., 2000). SLN are commonly produced by high 
pressure homogenisation (HPH) or diluting warm micro-emulsions. 
Advantages of SLNs above other colloidal carriers include the use of 
physiological lipids in the lipid matrix (decreasing the danger of acute and 
chronic toxicity), production without use of organic solvents, prolonged 
physical stability and the possibility of protection of chemically labile active 
substances inside the particles. 
 
 
 
 
Phospholipid 
Hydrophobic tail Hydrophilic 
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Figure 1.6 Diagram of solid lipid matrix stabilized by surfactant.  
Solid lipid nanoparticles possess a solid lipid core matrix that can solubilize 
lipophilic molecules. The lipid core is stabilized by surfactants (emulsifiers), 
with hydrophilic heads and hydrophobic tails. 
 
Another type of colloidal carrier is the polymeric nanoparticle. Research has 
focussed on conjugating drugs with polymers to form co-polymers (Debbage 
et al., 2008) which are prepared as nanospheres or nanocapsules that 
generally increase the stability of volatile pharmaceutical agents and are 
easily and cheaply fabricated in large quantities. A polymeric coating of 
nanoparticles provides a steric barrier to prevent agglomeration and avoid 
opsonization. Furthermore, such coating provides a means to tailor the 
surface properties of nanoparticles such as surface charge and chemical 
functionality. Dextran, a polysaccharide, is one of the most widely utilized 
and successful polymer coatings in terms of in vivo applications (Gref et al., 
2000). Previously, many types of polymers were used as water-soluble drug 
carriers, e.g. Poly(ethylene glycol) (PEG) (Corot et al., 2006), poly (L-
glutamic acid) and N-(2-hydroxypropyl)methacrylamide (HPMA) 
Hydrophilic 
 head 
Hydrophobic  
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Introduction 
 41
copolymers. HPMA copolymer-drug conjugates have been used in clinical 
trials (Vasey et al., 1999) and HPMA polymer-drug conjugates, bearing a 
combination of two anti-cancer drugs differing in their mechanism of action, 
effectively inhibited growth of melanoma, solid tumours and metastases in 
mice (Poucková et al., 2001) (Soucek et al., 2002). Recently, HPMA 
copolymer-Gd-RGDfK conjugates demonstrated potential as effective 
targetable MR contrast agents for tumour imaging (Zarabi et al., 2009). 
Alternatively, polymeric micelles are nanocarriers that can water-solubilize 
hydrophobic drug molecules and/or contrast agents. These polymers are 
constructed with a branched, hydrophobic interior (core) and hydrophilic 
exterior (shell) to maintain physical properties characteristic of conventional 
micelles, but with enhanced thermodynamic stability. One example of 
polymeric micelles are the multifunctional cancer ligand-targeting polymeric 
micelles for controlled drug delivery and MRI contrast characterisation 
(Nasongkla et al., 2006). The micelles harbour the chemotherapeutic agent 
doxorubicin, which is released through a pH-dependent mechanism. To 
enable MRI detection, a cluster of superparamagnetic iron oxide (SPIO) 
nanoparticles is loaded inside the hydrophobic core of the micelles. In 
addition, a cRGD ligand that targets αvβ3 integrin on tumor endothelial cells 
and induces receptor-mediated endocytosis is incorporated to direct 
micelles to their appropriate target. 
Nanocrystals are single crystalline nanoparticles consisting of aggregates of 
hundreds of molecules combined in a single crystal with a thin coating as a 
surfactant. They are produced according to a technique called nanonization 
using dispersion in an aqueous surfactant solution (Möschwitzer et al., 
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2006); nanocrystals are being developed to improve the bioavailability of 
poorly soluble drugs. 
More complex structures, such as dendrimers and carbon nanotubes, are 
under development for targeted delivery of drugs. Dendrimers are synthetic, 
three-dimensional molecules with branching parts (see Figure 1.7). The 
branches are structured around a designed central core and, like a tree, 
expand outward via polymerisation reactions, which allow for exact shaping 
of the nanoparticle. The branched structure makes it possible to attach other 
molecules such as drugs and contrast agents (Tomalia et al., 2007). They 
are formed using a nano-scale, multistep fabrication process. 
 
Figure 1.7 Illustration of general dendrimer architectural topology.  
Imaging moieties (A) or small molecular therapeutic components (B) may be 
incorporated into the interior. Receptor-mediated targeting groups (C) may 
be attached to the surface for active targeting. Low-toxicity surface groups 
(Z), such as PEG-DSPE-carboxylic acid, may also be attached. 
 
Carbon nanotubes are sheets of atoms in the form of tubes, resembling tiny 
drinking straws (Martin et al., 2003) (see Figure 1.8). They are considered 
optimal vehicles for the delivery of genes, peptides and proteins (Bianco et 
al., 2005), although currently only used under experimental conditions. 
A or B 
C 
Z 
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Figure 1.8 Scanning electron micrograph of an array of carbon 
nanotubes (Adapted from Bianco et al. (2005)). 
 
1.4.1 Targeting of Nanoparticles 
A key feature in using nanoparticles as targeted contrast agents is the ability 
of the particles to accumulate in or be directed to the area of interest. Such 
targeting may be passive or active. 
 
1.4.1.1 Passive Targeting of Nanoparticles 
The small size of a nanoparticle allows preferential extravasation in many 
solid tumours because of abnormal vascular membranes associated with 
tumour angiogenesis (Huang et al., 1992). This is known as the enhanced 
permeability and retention (EPR) effect. It describes a phenomenon 
whereby relatively high molecular weight (40 kDa or higher), long circulating 
macromolecules, as well as various long-circulating nanoparticles, are 
capable of spontaneous accumulation in various pathological sites, e.g. 
solid tumors. Accumulation is due to ‘leaky’ vasculature at such sites, e.g., it 
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can be penetrated by large molecules and even small particles (Maeda et 
al., 2001). In general this ‘leakiness’ of endothelial barriers in newly 
vascularised tumours is due to wide inter-endothelial junctions, large 
numbers of fenestrations and transendothelial channels, and discontinuous 
or absent basement membranes. Pore sizes in such tumours vary from 100 
to 780 nm. By comparison, normal tissues outside the reticuloendothelial 
system (RES) generally have continuous and non-fenestrated vascular 
endothelia, and extravasation of liposomes is very limited (Ishida et al., 
2001); pore size is <2 nm in most tissues, 6 nm in post capillary venules, 
40-60 nm for the kidney glomerulus, and up to 150 nm for sinusoidal 
epithelium of the liver and spleen (Seymour, 1992). This phenomenon 
allows for the extravasation and accumulation of nanoparticles in an 
interstitial tumour. Also, in many tumors, the absence of any lymphatic 
system, which is responsible for draining macromolecules from normal 
tissues, contributes to accumulation. The enhanced permeability and 
retention effect allows for passive targeting of nanoparticles to tumors based 
on the ‘cut-off’ size of the leaky vasculature (see Figure 1.9). 
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Figure 1.9 Passive tumour targeting with nanoparticles.  
Long-circulating nanoparticles accumulate passively in solid tumor tissue by 
the enhanced permeability and retention effect. The hyperpermeable 
angiogenic tumour vasculature allows preferential extravasation of 
circulating nanoparticles. 
 
 
1.4.1.2 Active Targeting of Nanoparticles 
Although passive targeting mechanisms will increase the accumulation of 
nanoparticles in a tumor, however, they are unlikely to be sufficient to 
achieve the concentrations necessary for successful molecular magnetic 
resonance imaging. Furthermore, larger tumors show poor vascularization, 
especially inside necrotic areas, preventing the localisation of nanoparticles 
in the tumor. Hence, improved targeting of nanoparticles to tumors is 
necessary. This may be achieved by conjugating the nanoparticles to 
biological recognition moieties (ligands) that recognize cell surface antigens 
or receptors in the target tissue (Mulder et al., 2006). A wide variety of 
ligands can potentially be used to target cellular biomarkers including 
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antibodies (Park et al., 2002), other proteins (Yang et al., 2009), peptides 
(Chang et al., 2009) and polysaccharides (Sihorkar et al., 2001).  
Nanoparticles require certain characteristics to facilitate molecular imaging: 
their circulating half-life should be in on the order of hours to allow sufficient 
exposure and interaction with the binding site (cellular biomarker), they 
should bind specifically to the epitope chosen for their visualization, they 
should have an acceptable toxicity profile and they should fit easily into the 
clinical routine (Lanza et al., 2004). 
Perhaps the most common method for targeting such cellular epitopes is the 
use of monoclonal antibodies. These antibodies have been investigated 
extensively for cancer cell recognition and have been used successfully in 
the treatment of certain cancers especially non-solid tumours such as Non-
Hodgkin’s lymphoma (Wang et al., 2008). Many factors need to be taken 
into consideration when using monoclonal antibodies, including proper 
choice of target antigen, antibody function and antibody-nanoparticle linkage 
(Park et al., 1997). Thus, an appropriate tumor antigen must be identified 
and interaction with a given antibody determined. 
Identification of tumor-specific antigens has proven difficult because most 
tumors do not possess unique antigens, but express the same antigens as 
normal tissue but in greater quantities. Additionally, many tumors do not 
overexpress the antigens homogeneously throughout the primary tumour or 
may not express them in metastases. Some antigens may be shed or 
secreted, leading to potentially high levels of soluble antigen that could 
interfere with cell targeting.  
Introduction 
 47
Despite the potential difficulties, successful use of monoclonal antibodies 
(mAbs) such as herceptin® (Trastuzumab, antibody to the HER2 receptor) 
in immunotherapy suggests that antibody targeting may represent a viable 
approach. This antibody has been used to target liposomes carrying the 
chemotherapeutic agent doxorubicin, to breast cancer cells in mice. 
Doxorubicin encapsulated in herceptin®-targeted liposomes was found to 
be more effective than free doxorubicin or herceptin® alone in inhibiting the 
growth of cancer cells (Park et al., 2002). Similarly Fab1 fragments of the 
monoclonal rat anti-VEGFR-2 antibody DC101 were used to target 
liposomes carrying doxorubicin to tumor endothelium. These 
immunoliposomes caused a significant delay in tumor growth compared to 
empty DC101-conjugated immunoliposomes, free doxorubicin and 
HEPES/glucose, and resulted in a higher amount of necrotic areas in the 
tumors (Roth et al., 2007). Immunoliposomes conjugated to an antibody 
against CD166 scFv (single chain variable fragment) successfully delivered 
the chemotherapeutic agent topotecan to prostate cancer cells. Targeted 
delivery of liposomal topotecan achieved significantly greater cell killing 
than either non-targeted liposomes or free topotecan (Roth et al., 2007).  
Monoclonal antibodies have also been used to develop targeted contrast 
agents. Gold nanoparticles conjugated with monoclonal antibodies to three 
different proteins (the epidermal growth factor receptor, matrix 
metalloproteinases and E7 oncoprotein) were used successfully to optically 
image their target proteins (Sokolov et al., 2004). Qiao et al. (2011) 
demonstrated that Gd3+-chelated protein-based (ProCA1) MRI contrast 
moiety HER2-targeted affibody-conjugated showed higher relaxivity value 
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than non-targeted moiety in ovarian cancer (SKOV-3) and breast cancer 
(MDA-MB-231) cell lines in vivo. Further, Wang et al. (2011) prepared a 
novel monoclonal anti-BRCAA1 (protein overexpressed in 64% gastric 
cancer tissue) FMNPs (silica-coated quantum dots and super-paramagnetic 
nanopatricles) nanoprobes, which are effective for in vivo two modal 
imaging such as fluorescent imaging and magnetic resonance imaging. 
Endogenous chemicals, for which receptors are present in increased 
numbers in specific tissues, can be used for nanoparticle targeting. An 
example of this phenomenon is folate, which was used successfully to 
target nanoparticles to folate receptor-expressing cells (Hilgenbrink and 
Low, 2005). Significant tumor regression of a folate receptor-expressing 
cancer in mice was observed after doxorubicin-carrying micelles, with folate 
attached, were administered to the mice (Yoo and Park, 2004). Transferrin 
has also been used in this manner to target cancer as most tumor cells 
overexpress the transferrin receptor. Paclitaxel-loaded biodegradable 
nanoparticles were shown to have greater anti-tumor activity compared to 
the free form of the drug in the murine model of prostate cancer following 
conjugation to transferrin (Sahoo et al., 2004). 
 
1.5 Liposomes 
Liposomes are defined, quasi-spherical, self-closed structures formed by 
one or more concentric lipid bilayers containing an aqueous phase inside 
and between the bilayers (Torchilin, 2005) (see Figure 1.1). The lipids used 
in the formation of liposomes are usually comprised of a hydrophilic 
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headgroup and two hydrophobic fatty acyl chains. These amphiphilic 
molecules spontaneously assemble into aggregates in an aqueous 
environment. Water-soluble molecules occupy the aqueous compartment, 
whereas molecules of a more lipophilic character occupy the lipid bilayers. 
Liposomes can vary substantially in size and lamellarity. They are 
subdivided into multilamellar vesicles (MLV) consisting of several concentric 
bilayers, large unilamellar vesicles (LUV) and small unilamellar vesicles 
(SUV) that are less than 150 nm in diameter.  
Liposomes can be formed by a variety of methods. When they are prepared 
by hydration of the dried lipid mixture, they spontaneously form MLVs. Other 
procedures, such as prolonged exposure to ultrasound or pressure-driven 
filtration through small-pore filters, cause MLVs to form SUVs.  
Other procedures lead to the formation of LUVs (Sulkowski et al., 2005). For 
instance, large vesicles are prepared from an initial phosphatidylserine 
aqueous solution, which, when sonicated and subjected to ultrasound, 
produces small unilamellar vesicles (SUV) with diameters of 200-500 Å. 
After adding 1 to 10 mM (threshold 1-2 mM) calcium ion (Ca2+) and 
incubating for 30-60 min at a room temperature above 10°C (preferably 
37°C), intermediate cochleate (spiral-shaped) lipid cylinders form. Finally, 
addition of a calcium-chelating agent, such as EDTA or EGTA to these 
cochleate cylinders produces the desired large closed spherical unilamellar 
vesicles (LUV) by fusion (United States Patent 4078052). 
Liposomes (LUVs), with a large internal aqueous space and high capture 
capacity, are produced by reverse-phase evaporation (REV). The procedure 
is based on the formation of ‘inverted micelles’ - small water droplets which 
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are stabilized by a phospholipid monolayer and dispersed in excess of 
organic solvent. Slow removal of the organic solvent leads to transformation 
of these inverted micelles into a viscous gel-like state. At a critical point in 
this procedure, the gel state collapses and some of the inverted micelles 
disintegrate. The resulting excess of phospholipid contributes to the 
formation of a complete bilayer around the remaining micelles, leading to 
the formation of LUVs. 
 
1.5.1 Pharmacokinetics of liposomes 
The pharmacokinetics of liposomes depend on their physiochemical 
characteristics such as size, surface charge, membrane lipid packing, steric 
stabilization, dose and route of administration (Barenholz, 2003). In general, 
larger liposomes are eliminated from the blood circulation more rapidly than 
smaller ones (Senior et al., 1982). Binding of opsonins to liposomes 
depends on liposome size; consequently, the reticuloendothelial (RES) 
uptake of liposomes by the liver is size-dependent (Harashima et al., 1994). 
The action of the reticuloendothelial system results in rapid removal from 
the blood and accumulation in tissues such as liver and spleen.  
In vivo behaviour of liposomes is also determined by their constituent parts, 
viz., phospholipids and other amphiphilic molecules, cholesterol and 
molecules bound to the liposome surface. The circulatory half-life of 
liposomes can be significantly increased through use of sterically shielded 
lipids in their construction. ‘Steric stabilization’ refers to the colloidal stability 
resulting from the attachment of hydrophilic polymers or glycolipids on to the 
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liposome surface (see Figure 1.10). These liposomes are less reactive 
toward serum proteins and less susceptible to RES uptake than non-
stabilized liposomes (Allen et al., 1995). Hence, such liposomes show 
prolonged life-times in the circulation. The putative mechanism by which 
sterically stabilized liposomes are thought to decrease RES-mediated 
places the stabilizer in the space immediately adjacent to the liposomal 
surface effectively excluding other macromolecules from this space. 
Consequently, access to and binding of blood plasma opsonins to the 
liposome surface are hindered, preventing interactions with RES 
macrophages.  
Polyethylene glycol (PEG) is the most widely used polymeric steric 
stabilizer. PEG is a linear polyether diol with many useful properties. It is 
highly soluble in aqueous and organic media and possesses very low 
immunogenicity and antigenicity (Dreborg et al., 1990) and is non-toxic. It 
can be attached to the liposome surface in various ways, but the most 
widely used method is to anchor the polymer in the liposome membrane via 
a cross-linked lipid (PEG-DSPE) (Allen et al., 1995). The grafted polymer 
moiety extends about 50 Å from the lipid surface and exerts a strong inter-
membrane repulsive force (Needham et al., 1992). It was shown that steric 
stabilisation of liposomes with PEG increases their longevity in the 
circulation (Drummond et al., 1999). In a similar fashion, the glycolipid 
ganglioside, GM1, also prolongs circulatory life-time of liposomes when 
attached to the exterior wall (Gabizon et al., 1988). 
A supplementary method to ensure long circulation times involves adding 
cholesterol to the lipid bilayer. Cholesterol acts as a spacer between 
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phospholipids of the liposome membrane because of its inflexible structure, 
thus preventing demixing of the lipids and reducing PEG chain-chain 
interactions. This results in improved steric stabilization of the liposomes. 
Most optimal formulations for long circulation times contain more than 30% 
(w/v) cholesterol and low concentrations (5 mol%) of PEG (Strijkers et al., 
2005). 
The phospholipids used while concentrating liposomes affect the circulatory 
life-time of liposomes by altering membrane fluidity. This is most likely 
caused by increased protein binding to hydrophobic domains exposed by 
packing defects in gel-phase membranes (Drummond et al., 2008). The 
presence of charged lipids in liposome construction also tends to increase 
clearance from the circulation, though the relationship is complex 
(Drummond et al., 1999). However, charged lipids can be useful in attaching 
therapeutic substances to liposomes. 
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   Antibody 
                         Polyethylene glycol (PEG) 
                         Cholesterol     
    Phospholipid 
Figure 1.10 Sterically stabilized PEGylated paramagnetic 
immunoliposome.  
This schematic representation shows antibodies coupled to the distal end of 
the PEG-chains. 
 
 
 
 
1.6 Targeting of liposomes to cells or tissues 
The use of targeted liposomes was suggested to increase liposomal 
accumulation in desired tissues. This involves the coupling of ligands to 
liposomes leading to specific binding to the required target cells. 
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1.6.1 Immunoliposomes 
The term immunoliposome was coined to describe a liposome conjugated to 
an antibody or portions of an antibody (Siwak et al., 2002). 
Immunoliposomes appear to have immunogenic potential that is attributed 
to the constant region of the immunoglobulin (Harding et al., 1997). The use 
of chimeric or humanized monoclonal antibodies or antibody fragments can 
reduce or minimise a host’s immunologic response against the therapeutic 
antibody/fragment (Winter and Harris, 1993).  
Conjugation of the antibody to the liposome presents a challenge in the 
construction of immunoliposomes.  The location of the linkage is first 
considered. Studies on usage of conventional (‘PEG-free’) 
immunoliposomes (Type A in Figure 1.11) show that there is enhanced 
uptake by the RES (Aragnol et al., 1986). These immunoliposomes are 
effective in specific binding to target cells in vitro but their targeting 
efficiency in vivo is relatively low. 
 
 
 
 
 
 
Figure 1.11 Illustration of the conjugation of antibodies to liposomes.  
Type A: ‘PEG-free’ immunoliposomes with antibody directly linked to the 
lipid; Type B: PEG-immunoliposomes with antibody directly linked to the 
lipid; Type C: Pendant PEG-immunoliposomes with antibody conjugated to 
the distal end of the PEG chain. 
  
           TYPE A            TYPE B                          TYPE C 
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PEGylated liposomes are sterically stabilized with PEG, as discussed 
earlier, thus reducing RES uptake and consequently, prolonging their 
circulatory life-times. Such steric stabilization has been combined with 
antibody targeting of liposomes via attachment directly to the lipid bilayer 
(see Type B in Figure 1.9). However, the steric barrier of PEG decreases 
the protein coupling efficiency at the liposome surface as well as the target 
recognition, especially where higher concentrations of PEG (with high 
molecular weight) are used (Aragnol et al., 1986). 
In order to overcome these problems, antibodies were coupled to the 
terminal ends of PEG to increase antibody accessibility. A pendant-type 
PEG-immunoliposome was developed with monoclonal antibodies or their 
fragments attached at the distal ends of the PEG chains (see Type C in 
Figure 1.9) (Maruyama et al., 1995). These liposomes showed improved 
binding to their specific target when compared to both Type A and Type B 
due to the combined benefits of steric stabilization by PEG and improved 
antibody accessibility. 
 
1.6.2  Conjugation of Antibodies to Liposomes 
Various types of linkages can be used to attach antibodies, entire units or 
fragments, to liposomes in order to create immunoliposomes. Antibodies 
can be attached to lipids, such as phosphatidylamine (PE), either before or 
after liposome formation depending on the particular strategy employed. 
The bonds formed fall into two main categories, noncovalent and covalent. 
 
Introduction 
 56
1.6.2.1 Non-covalent conjugation 
Liposomes incorporating biotin-modified lipids can be easily prepared and 
used to attach a variety of avidin/streptavidin-linked targeting proteins. The 
primary advantage of this technique is that many different site-directing 
ligands can be used with a single well-defined liposome preparation. 
Examples of non-covalent conjugation procedures include the use of 
biotinylated ligands bound to streptavidin-conjugated liposomes (Pan et al., 
2008) or antibody bound to protein A - bearing liposomes (Machy et al., 
1984). Ligands such as avidin, streptavidin, protein A or protein G can be 
attached to liposomes by use of covalent conjugation procedures on section 
1.6.2.2.  
 
1.6.2.2 Covalent conjugation 
Two efficient and selective methodologies for conjugating antibodies to 
liposomes are examined here. 
 
a) Attachment of proteins and peptides to liposomes via amino groups 
An amide bond is formed in two stages to achieve conjugation. In the first 
stage, free carboxylates on the terminal end of a PEG chain are activated 
with water-soluble N,N'-dicyclohexylcarbodiimide (DCC). In the second 
stage, protein or peptide solutions are added at pH 8.0; the activated 
carboxyl groups react with amino groups on the protein to produce an amide 
bond (see Figure 1.12). 
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Figure 1.12 Amide bond formation 
Free carboxylated group on the terminal end of the phospholipid is activated 
with DCC reagent. Activated carboxyl group reacts with amino groups on 
the protein producing an amide bond. 
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b) Attachment of proteins to liposomes via maleimide derivatives 
Sulfhydryl groups present on proteins, peptides and other compounds are 
important in protein chemistry. SATA (N-hydroxysuccinimide S-
acetylthioacetate) is used in the formation of stable thioether bonds (R1-S-
R2) through a two-step reaction. In the first step, a stable covalent amide 
bond is formed from the reaction of the NHS esters present in SATA with 
primary amines on proteins. The amine reacts with the NHS ester by the 
nucleophilic attack, with consequent release of NHS as a by-product. In the 
second step, hydroxylamine is used to deacetylate the sulphur, resulting in 
a sulfhydryl group.  
Maleimide’s double bond on the terminal end of a PEG chain can undergo 
an alkylation reaction with sulfhydryl groups to form stable thioether bonds. 
Maleimide reactions are specific for sulfhydryl groups at pH 6.5-7.5. At pH 
7.0 the reaction of maleimide with sulfhydryl proceeds at a rate 1,000 times 
greater that its reactions with amines (see Figure 1.13). 
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Figure 1.13 Thioeter bond formation. 
Step 1 is the reaction of N-hydroxysuccinimide S-acetylthioacetate with a 
primary amine and step 2 is the deprotection with hydroxylamine to 
generate a sulfydryl. The sulfhydryl can subsequently react with maleimide 
group on PEG to form a thioether bond. 
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1.7 Gadolinium (Gd) - loading of liposomes for MR imaging 
In developing targeted contrast agents for molecular magnetic resonance 
imaging, paramagnetic or superparamagnetic ions need to be targeted in 
sufficient quantities to a relevant tissue-specific target. Gadolinium, a 
paramagnetic ion, is the most commonly used contrast agent in MRI and the 
use of this ion in the development of immunoliposomes for molecular MRI 
will be described.  
Loading liposomes with gadolinium presents a challenge in the development 
of targeted contrast agents. Three major methods have been explored: 
1) Gd encapsulated in the aqueous space of the liposome 
2) Gd incorporated into the lipid bilayer 
3) Gd carried on exterior of the liposome via polymerizable 
amphiphilic polymers 
Each of these methods will be examined in turn. 
 
1.7.1 Encapsulation of gadolinium within liposomes 
The first type of liposomal MRI contrast agents contain paramagnetic 
entities entrapped in the aqueous interior phase. Paramagnetic agents such 
as MnCl2 (Unger et al., 1993; Yang et al., 2009), Gd-DTPA (Devoisselle et 
al., 1988), Mn-DTPA (Caride et al., 1984) and macromolecular contrast 
agents, such as Mn2+ bound to serum proteins, can be encapsulated in 
liposomes (Navon et al., 1986). Results have been largely unsuccessful 
because of poor encapsulation efficiency, poor stability, toxicity and poor 
relaxivity. Contrast agents of this type have been used successfully to 
improve the detection of tumors in the liver of rats with hepatic metastases 
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(Unger et al., 1989). A more in-depth analysis of the advances made in 
development of manganese-based nanoparticles as contrast probes for 
magnetic resonance imaging is described in review by Zhen et al. (Zhen et 
al., 2012). Application of the freeze-thaw extrusion process to the synthesis 
of Gd-DTPA liposomes has helped overcome problems with encapsulation 
efficiency and stability. This method creates small liposomes, which yield 
greater contrast enhancement because of their larger surface-area-to-
volume ratio, and, as a result, exchange with bulk water is improved (Caride 
et al., 1984). This suggests that small liposomes with a permeable bilayer 
are desirable. However, permeable liposomes (created by varying the 
nature of lipids used in their production) are usually less stable (with 
reduced longevity in the circulation) in serum than liposomes with a more 
rigid bilayer (Mulder et al., 2006). Also, leakage of gadolinium from such 
liposomes reduces their efficacy as targeted contrast agents. 
 
1.7.2 Incorporation of gadolinium into the lipid bilayer 
Gadolinium-DTPA can be bound to two fatty acid chains to form an 
amphiphilic molecule that can be incorporated into the lipid bilayer of 
liposomes, thus making gadolinium an integral part of the liposome surface 
(Kabalka et al., 1987). Gadolinium (Gd)-DTPA can be incorporated as a 
hydrophilic segment accompanying hydrophobic stearate (Schwendener et 
al., 1990) or acryl chains (Kabalka et al., 1991). A schematic representation 
of this scenario, along with antibodies attached to the terminal end of the 
PEG chains, is displayed in Figure 1.14. This approach results in improved 
relaxivity of the metal compared to encapsulation of the paramagnetic 
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molecules in the liposomal lumen (Strijkers et al., 2005). Gadolinium-
incorporating liposomes also pose less risk of leakage of potentially toxic 
metals in the body (Torchilin, 2007). The addition of considerable amounts 
of gadolinium-containing lipid apparently does not negatively affect the 
stability of the cholesterol-containing liposomes. The membrane 
permeability of liposomes with and without gadolinium-containing lipid was 
shown to be equivalent when measured with a calcein-leakage assay 
(Mulder et al., 2004).  
The application of this kind of liposomal contrast agent is broad. For 
example, Trubetskoy et al. used PEGylated liposomes to detect of lymph 
nodes (Trubetskoy et al.,1995) and to achieve sustained contrast 
enhancement in tumors (Bertini et al., 2004). Also, the biodistribution of 
cationic liposomes bound to DNA was analysed over time using liposomes 
incorporating Gd-lipid amphiphiles (Leclercq et al., 2003). Neointimal lesions 
in mice were effectively detected using liposomes incorporating gadolinium 
in the lipid bilayer (Leclercq et al., 2003).  
More recently, a novel paramagnetic lipid molecule, Gd-DOTA-DSPE, was 
developed (Hak et al., 2009). The ionic relaxivity of the Gd(III)DOTA-DSPE 
incorporated in liposomes was shown to be significantly higher than that of 
Gd(III)DTPA-BSA in liposomes. It is thought that water molecules have 
greater access to the paramagnetic complex since the Gd-DOTA moiety 
extends from the liposomal membrane; contrarily, Gd-DTPA-BSA, when 
incorporated into liposomes, lies at the liposomal membrane-bulk water 
interface. This development could dramatically improve the detection of low 
concentration biomarkers in MRI-based molecular imaging studies. 
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Antibody 
                     Polyethylene glycol (PEG) 
                     Cholesterol     
                     DSPC (1,2-Distearoyl-sn-Glycero-3-Phosphocholine) 
             Gd-DTPA-Lipid  
Figure 1.14 Immunoliposome with gadolinium-DTPA incorporated into 
the amphiphile bilayer via conjugation with two fatty acid chains. 
 
1.7.3 Gadolinium carried on the exterior of liposomes 
Another method of loading gadolinium into liposomes is through the use of 
polychelating amphiphilic polymers (PAPs). These molecules are capable of 
carrying multiple gadolinium ions and can be incorporated into the liposome 
structure by binding to an amphiphilic molecule, such as N-glutaryl-
phosphatidylethanolanime (NGPE) (see Figure 1.10). In contrast to 
amphiphilic gadolinium-containing molecules described in the previous 
section, PAPs carry gadolinium on the exterior of liposomes. PAPs consist 
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of a main hydrophilic chain with multiple chelating side groups capable of 
binding many gadolinium atoms and a hydrophobic terminal group that 
anchors the molecule into the liposome membrane (Torchilin, 2000; 
Torchilin, 2007) (see Figure 1.15). This technique increases the number of 
gadolinium atoms per vesicle, which significantly increases the relaxivity of 
PEGylated liposomes. The contrast properties of the liposomes are 
enhanced as a result (Torchilin, 2007). An interesting example of the 
application of PAP-nanoparticles in vivo is the MR imaging of lymphatic 
system components with the Gd-loaded nanocarriers (investigating 
metastases in lymph nodes). Trubetskoy and Torchillin have studied 
liposomes and micelles as delivery vesicles to the lymphatic system. 
Tumors have also been targeted successfully using this method. Gd-loaded 
PAP-containing immuno-liposomes carrying the monoclonal antibody 2C5 
delivered elevated amounts of Gd to the surface of various cancer cells in 
vitro compared to ’antibody-free’ Gd-liposomes or Gd-liposomes modified 
with non-specific antibody (Erdogan et al., 2006). In a separate study, using 
mouse models of cancer, these immunoliposomes allowed for fast and 
specific tumor imaging in vivo (Erdogan et al., 2008). 
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Polychelating amphiphilic polymer with multiple 
chelating groups 
 
N-glutaryl-phosphatidylethanolanime (hydrophobic tail)  
 
Figure 1.15 The incorporation of the amphiphilic polychelating 
polymer into the liposome membrane.  
Each polychelating chain contains multiple chelating groups carrying 
gadolinium and a hydrophobic tail to anchor with the liposome. 
 
1.7.4 Motions of gadolinium-containing lipid incorporated into 
liposomes 
There are various parameters that can influence the relaxation rate of water 
molecules within contrast agent’s vicinity. τM is the average time 
(nanoseconds) a water molecule remains co-ordinated to the metal ion in 
the first inner spher. τr is how fast the contrast agent tumbles in water, which 
is measured by the rotational correlation time and τD is the translational 
diffusion time of the outer sphere water molecules. The relaxivity of 
paramagnetic liposomes has been shown to be mainly effected by the 
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exchange rate (τM) of the coordinated water molecule to the Gd metal centre 
of the membrane anchored paramagnetic lipid. In addition to the exchange 
rate, the coordination number and the rotational correclation time (τr) are 
also factors that affect the relaxivity of macromolecular contrast agents 
(Mulder et al., 2006). Possible motions of the Gd chelate head group are 
displayed in Figure 1.16. As all these dynamic proccesses will change 
depending on the composition of the agent, the nature of the liposome 
formulation can be used to determine the relaxivity. 
 
 
Figure 1.16 Possible motions of Gd lipid chelate head. 
τr represents the rotational motion of the whole paramagnetic liposome in 
water; τD(transl) – the translational diffusion of individual Gd chelates 
protruding from the paramagnetic liposome surface; τD(rot) – the rotational 
diffusion of the entire Gd lipid in the paramagnetic liposome membrane. 
Figure was based on Mulder et al. (2006). 
 
1.8 Challenges encountered in the use of immunoliposomes as 
targeted molecular MRI contrast agents 
Immunoliposomes show huge promise in targeted drug and contrast agent 
delivery to tumors. Park et al. indicated that doxorubicin-loaded anti-
p185HER2 immuno-liposomes are markedly and specifically cytotoxic against 
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p185HER2-overexpressing tumor cells in vitro and demonstrated it is a 
promising therapeutic vehicle for the treatment of p185HER2-overexpressing 
human cancers. A PEGylated liposome encapsulating doxorubicin and 
attached to a monoclonal antibody fragment named GAH showed superior 
cytotoxic activity against several human stomach cancer cells compared 
with doxorubicin or doxorubicin-incorporated PEG liposomes with any 
antibody fragment (Matsumura et al., 2004). However, major challenges lie 
ahead before this promise can be transformed into improved clinical 
outcomes. 
Issues pertinent to MRI include sensitivity and target specificity. Sensitivity 
can be improved by maximising the payload of gadolinium per liposome. 
Target specificity can be achieved through identification of suitable target 
antigens and receptors and subsequent development of suitable targeting 
moieties such as antibodies. 
Immunogenicity of immunoliposomes is a problem as it increases their 
clearance from the circulation. Thus, if repeated administration of the 
immunoliposome is planned, the targeting ligand should not be 
immunogenic. Immunoliposomes prepared using full IgG molecules were 
shown to succumb to an increased rate of clearance compared to non-
targeted liposomes (Drummond et al., 2008). This is due to recognition of 
the Fc portion of the antibody by Fc receptors on the surface of 
macrophages. Use of antibody fragments such as Fabs or scFvs does not 
appear to increase liposomal uptake by macrophages. Also, human or 
humanised antibodies are preferred as xenogenic protein sequences may 
result in immunogenicity in humans.  
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Achieving optimal liposome size represents another challenge. Smaller 
liposomes have longer circulatory life-times and increased access to 
tumors. However, below a certain size, suggested to be 80 nm, any 
advantage is lost since liposomes of diminutive sizes are cleared more 
quickly from the tumor.  Liposome sizes between 100-120 nm appear to be 
optimal for accumulation in solid tumors (Drummond et al., 2008).  
Clearly, despite the enormous strides made in the development of 
immunoliposomes as targeted contrast agent for molecular magnetic 
resonance imaging, there remain significant challenges to be overcome 
before this exciting field delivers significantly improved clinical outcomes.  
 
1.9 CD138 (syndecan-1) protein and multiple myeloma malignancy 
Multiple myeloma is the second most common form of haematological 
malignancy in the Western World after non-Hodgkin’s lymphoma. The most 
common symptoms of multiple myeloma can be summarised as the tetrad, 
CRAB: C=Calcium, R=Renal failure, A=Anemia, B=bone lesion (Figure 
1.17). 
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Figure 1.17 Representation of the most common symptoms of human 
multiple myeloma. 
 
 
Multiple myeloma is characterised by uncontrolled proliferation of plasma 
cells within the marrow. Normal bone marrow contains no more than 4% of 
the plasma cells. In unhealthy bone marrow there are more than 10% of 
malignant plasma cells. 
The uncontrolled proliferation of plasma cells leads to disruption of the 
balance between osteoblastosis and osteoclastosis within the bone, which 
leads to bone lesions. This is caused by overproduction of tumour necrosis 
factor-related induced cytokines (TRANCE) and inactivation of 
osteoprotegerin resulting in unrestricted osteoclastic activity. It generates 
lytic bone deposits on plain film radiography. Calcium, released from bones, 
is found in urine. Hypercalcemia may result in the development of renal 
failure. The anemia results from the replacement of normal bone marrow by 
infiltrating tumor cells and inhibition of normal red blood cell production.  
In about 75% of all cases of multiple myeloma the paraprotein present (M 
protein) will correspond with one type of abnormal immunoglobulin. In about 
CRAB 
Calcium 
 Renal 
failure 
Anemia 
Bone 
lesions 
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60% of cases an abnormal protein, known as Bence-Jones protein may also 
be found in the urine. 
Multiple myeloma cell growth is dependent on interactions between the 
multiple myeloma cells and the bone marrow cells. The mutiple myeloma 
cells bind to the bone marrow stroma cells via adhesion molecules, such as 
LFA-1 (leukocyte-associated antigen-1) (CD11a/CD18) and ICAM-1 
(intracellular adhesion molecule-1) (CD54). Adhesion initiates a cascade of 
signalling events which result in cell proliferation, migration, angiogenesis, 
and ultimately enhanced cell survival. Multiple myeloma is one of the best 
studied disease states, in particular IL-6 has been shown to be a potent 
autocrine and paracrine growth factor which induces maturation of B cells 
into antibody-producing cells. IL-6 is a multifunctional cytokine which is 
responsible for regulating growth, differentiation and proliferation (Kishimoto 
et al., 1995). IL-6 secreted from bone marrow stromal cells (BMSC) is 
integral for multiple myeloma cell proliferation in vivo. The stromal cell-
derived IL-6 acts on the multiple myeloma cells, causing them to secrete 
their own IL-6. IL-6 signal trasduction commences with IL-6 receptor 
(IL6/gp80) binding, followed by interaction with the signal transducer gp130 
and homodimerization (Schaper et al., 1998). 
There are three pathways downstream of the initial receptor-binding events 
that are likely to be involved in multiple myeloma growth (Figure 1.18). The 
first pathway is the jun-activated kinase (JAK) pathway, which activates 
STAT3 and STAT1 transcription factors that regulate cell survival (Catlett-
Falcone et al., 1999). The second is the mitogen-activated protein kinase 
(MAPK) pathway that is involved in multiple myeloma cell growth and 
Introduction 
 71
proliferation (Heinrich et al., 1998). The third pathway is the phosphatidyl 3-
kinase (PI3K)/Akt pathway, which leads to NF-қB activation. This facilitates 
multiple myeloma cell growth and survival by NF-қB-mediated transcription 
of pro-survival/anti-apoptotic mediators, via PI3K/Akt-induced cell-cycle 
activation, via JAK-STAT pathway (Tu et al., 2000). 
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 Figure 1.18 IL-6 signal transduction in multiple myeloma cells.  
IL-6 is a growth and survival factor for multiple myeloma. Tis cytokine is 
regulating various aspects of growth, differentation and proliferation. There 
are three pathways downstratem of the initial receptor-binding event that are 
likely involved in multiple myeloma growth. A – the mitogen-activated 
protein kinase (MAPK) pathway; B – the jun-activated kinases (JAK) 
pathway; C – anti-apoptotic, pro-survival signals via activation of the 
phosphatidyl 3-kinase (PI3K)/Akt kinases pathway. Figure was created 
based on Greenstein et al. (2003). 
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Multiple myeloma (MM) malignancy appears during B cell maturation 
proccess in bone marrow. In bone marrow, syndecan-1 is only expressed 
on precursor B lymphocytes and lost before maturation (Sanderson et al., 
1989). Terminally differentiated plasma cells express relatively few surface 
antigens and do not express very common B cell markers, such as CD19 
and CD20, CD38 and CD138 (Rawstron, 2006). Thus, syndecan-1 is a good 
marker for multiple myeloma cancer cells (Bernfield et al., 1992) and Reed-
Sternberg cell identification (Wijdenes et al., 1996). 
CD138 or syndecan-1 is a glycoprotein expressed on simple epithelia (150-
250 kDa), stratified epithelia (80-150 kDa), mesenchymal cells (220-300 
kDa) and lymphocytes (80-150 kDa). The core of protein is composed of 
extracellular (251 residues), transmembrane (34 residues) and intracellular 
(25 residues) parts. The protein bears heparan and chondroitan sulfates. 
The ectodomain contains five putative glycosaminoglycan (GAG) 
attachment sites (Figure 1.19). Ridley et al. (1993) suggested that 
syndecan-1 plays major role in plasma cell adhesion to bone marrow 
stroma, especially to collagen type I. 
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Figure 1.19 Schematic representation of CD138 (syndecan-1) 
transmembrane protein. 
CD138 is composed of extracellular, transmembrane and intracellular parts. 
The protein has heparan, chondroitan sulfates and glycosaminoglycan 
(GAG) attachment sites. 
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Aims of research 
The aims of the research described in this thesis were: 
• To develop a targeted contrast agent (e.g. an antibody-modified 
liposome) for early and minimally non-invasive diagnosis of human 
multiple myeloma. 
Gadolinium (Gd) will be used as a paramagnetic contrast agent to 
enhance magnetic signals from imaged tissue. Immunoliposomes will 
be prepared and gadolinium ions will be incorporated onto the 
liposome surface for targeting CD138 (syndecan-1) glycoprotein 
overexpressed on human multiple myeloma cancer cells.  
Nowadays, the diagnosis of this form of cancer usually requires the 
performance of a range of tests and the assessment of marrow specimens 
from invasive biopsy. Diagnosis of this disease is often delayed. Faster 
diagnosis of this disease can allow better prognosis for patients. The main 
aim of the project was to develop a minimally non-invasive diagnostic agent 
for non-curable malignancy. 
• The ability of anti-CD138-conjugated-liposomes to target human 
multiple myeloma cell lines will be investigated in vitro. 
• Contrast Gd-PAP-liposomes modified with anti-CD138 monoclonal 
antibodies will be targeted to human multiple myeloma cell lines. 
• Visualization of targeted contrast anti-CD138-liposome interaction will 
be performed using magnetic resonance imaging (MRI) analyses at 
1.5 T to assess its binding ability to cancer cells in vitro and contrast 
signal on MRI scans. 
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• The overall aim is to prepare sufficient targeted contrast agent to 
enhance visualization of multiple myeloma to allow effective 
minimally non-invasive diagnosis of this malignancy in humans. 
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2.1 Materials 
2.1.1 Equipment 
Table 2.1 Equipment used and suppliers. 
EQUIPMENT SUPPLIER 
Extruder (Mini model) 
Polycarbonate membranes (100 nm) 
Gas tight syringes (2) 
Extruder stand 
Stabilizer block 
O-rings 
Filter supports 
 
Avanti Polar Lipids, Inc. Instruchemie 
B.V. Zwet 269932, AB Delfzyl, The 
Netherlands. 
HPPS (High Performance Particle 
Sizer) (Nano S90) 
 
  
Malvern/Zetasizer Nano 3000 HS, 
10 Southville Road, 
Southborough, MA 01772, USA. 
 
Desalting column Pierce, Medical Supply Co. Ltd., 
Damastown, Mulhuddart, Dublin 15, 
Ireland. 
 
pH meter (230V; 50/60Hz) 
(Orion3Star) 
Fisher Scientific, Suite 3, Plaza 212, 
Blanchardstown Corporate Park 2, 
Ballycoolin, Dublin 15, Ireland. 
 
CO2 Tissue Culture Incubator (3111) 
Thermo Scientific 
Bio-sciences, 3 Charlemont Terrace, 
Crofton Road, Dun Laoghaire,  
Co. Dublin, Ireland. 
 
Microscope (Nikon Diaphot) 
(30/02381) 
 
Micron Optical Co. Ltd., Ballybeg-
Screen, Enniscorthy, Co. Wexford, 
Ireland. 
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EQUIPMENT SUPPLIER 
Laminar Flow Unit (Model: Holten 
Laminar A/S, HB2448K) 
Sonicator & Waterbath (120V 50/60Hz) 
(15-220) 
A.G.B. Scientific Ltd., Orion 
Business Campus, Northwest 
Business Park, Ballycoolin, Dublin 
15, Ireland. 
 
Millipore Filtration Apparatus (Academic) 
DNA gel apparatus Bio-Rad (Wide-Mini-
Sub®CellGT) 
Trans-Blot®SD Semi-Dry Transfer cell 
Bio-Rad 
 
Alpha Technologies Ltd.,  
The Leinster Technology Centre, 
Blessington Industrial Estate, 
Blessington, Co. Wicklow, Ireland. 
 
Spectrophotometer UV Visible (UV-160A) Allegheny-Singer Research 
Institute, 
320 East North Avenue, 
11th floor - South Tower, 
Pittsburgh, USA. 
 
Centrifuge (2K15) 
Rotor 11192 (Sigma) 
 
 
Centrifuge (5804R) 
Rotor A-4-62 (Eppendorf) 
 
 
 
Centrifuge (2102, Z 233 MK-2) 
(HERMLE LaborTechnik) 
Sigma Centrifuges, 
37507 Osterode am Harz, 
Germany. 
 
Eppendorf UK Ltd., Endurance 
House 
Vision Park, Histon, Cambridge,  
CB24 9ZR, United Kingdom. 
 
BioExpress, 420 N. Kays Drive, 
Kaysville, UT 84037, USA. 
 
Ultracentrifuge OptimaTM L-100 K 
Rotor 70 Ti (Beckman Coulter) 
Labplan, Allenwood Enterprise 
Park, Naas, Co. Kildare, Ireland. 
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EQUIPMENT SUPPLIER 
Buchi Vacuum Controller,  
Rotovapor R-200 
New Brunschwick Scientific-Excella E24 
Incubator 
Tomy Autoclave SX-700E High Pressure 
Steam Sterilizer 
Mason Technology Ltd., 
Greenville Hall, 228 South Circular 
Road, Dublin 8, Ireland. 
 
Biometra T GRADIENT PCR machine LABREPCO, 
101 Witmer Road, Suite 700, 
Horsham, PA19044, USA. 
 
NonodropTM ND-1000 NanoDrop Technologies, Inc., 
3411 Silverside Road, 100BC, 
Wilmington, DE19810-4803, USA. 
 
Gene Pulser XcellTM electroporation 
system 
BioRad Laboratories, Inc., 
2000 Alfred Nobel Drive, 
Hercules, CA94547, USA. 
 
Safire 2 plate reader Tecan Group Ltd., 
Seestrasse 103, 
CH-8708 Mannedorf, Switzerland. 
 
Vibra CellTM sonicator Sonics and Materials, Inc., 
53 Church Hill Road, 
Newtown, CT06470-1614,  
USA. 
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EQUIPMENT SUPPLIER 
Freeze Dry System / Freezone 4.5 Labconco Corporation, 
8811 Prospect Avenue, 
Kansas City, Missouri 64132-2696, 
USA. 
 
UV trans-illuminator 
Model: 80-6246-82 
 
Amersham Pharmacia Biotech, 
800 Centennial Ave., 
Piscataway, NJ 08855, USA. 
 
FACS Calibur 
 
BD Biosciences, BD PharminogenTM,  
The Danby Building, Edmund Halley 
Road, Oxford Science Park, 
OX4 4DQ Oxford, United Kingdom. 
 
Philips MRI scanners –  1.5T 
Gyroscan Intera  
MagNET, 
Eindhoven,  
The Netherlands. 
 
Fast Field-Cycling NMR relaxometer 
SpinMaster FFC2000 1T C/DC 
 
STELAR s.r.l., 
4 Enrico Fermi Street, 
27035 Mede (PV), Italy. 
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2.1.2 Consumable items 
2.1.2.1 Plastic and glass consumables 
Table 2.2 Consumables used and suppliers. 
ITEM SOURCE 
Eppendorf tubes, sterile universal 
containers, tips 
Sarstedt Ltd., Sinnottstown Lane, 
Drinagh, Co. Wexford, Ireland. 
 
2 mL glass tubes Lennox, John F. Kennedy Drive, 
Naas Road, Dublin 12, Ireland. 
 
Round bottom flasks 
Nunc Maxisorp TM plates 
Fisher Scientific, Suite 3, Plaza 212, 
Blanchardstown Corporate Park 2, 
Ballycoolin, Dublin 15, Ireland. 
 
25 mL ultracentrifugation bottles,  
thick-wall polycarbonate  
Labplan, Allenwood Enterprise Park, 
Naas, Co. Kildare, Ireland. 
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2.1.3 Reagents and chemicals 
Table 2.3 Reagents and chemicals used and suppliers. 
REAGENT SUPPLIER 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N- 
[carboxy(polyethylene glycol)2000]- 
carboxylic acid  
(PEG-DSPE-carboxylic acid), 
Cholesterol, 
L-α-phosphatidylcholine, hydrogenated 
(egg, chicken) (egg PC), 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-
[metoxy(polyethylene glycol)-
2000](ammonium salt) (DSPE-PEG- 
Metoxy), 
1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (ammonium salt) 
(Rhodamine-PE), 
1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-DTPA 
(Gadolinium salt), 
1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(glutaryl) 
(sodium salt) (NGPE) 
 
Avanti Polar Lipids, Inc. Instruchemie 
B.V. Zwet 269932, AB Delfzyl, The 
Netherlands. 
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REAGENT SUPPLIER 
Chloroform 
Methanol 
Dichloromethane 
Pyridine 
DMSO 
NaCl                                                 
Trypan blue 
Trypsin 
Formaldehyde 
Penicillin/Streptomycin 
Gadolinium hexahydrate 
1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) 
DMF 
DCC 
NHS 
Poly-ε-CBZ-DL-lysine (MW 5,500) 
Hydrogen bromide (33 wt%) 
Diethyl ether 
Succinic anhydride 
GdCl3•6H2O 
Acetic acid 
Triethylamine 
Iodine 
MTT 
Silica plates 
Micro Lowry assay with Peterson’s 
modification 
Alkaline phosphatase conjugated goat 
anti-mouse IgG 
Sigma-Aldrich, Riedel de-Haen AG, 
Wunstorfer, Strabe 40, D-30926, 
Hannover, Germany. 
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REAGENT SUPPLIER 
Sephadex G-25 Pierce, Medical Supply Co. Ltd., 
Damastown, Mulhuddart, Dublin 15, 
Ireland. 
 
Mouse anti-human CD138:FITC AbD Serotec, MorphoSys UK Ltd., 
Endeavour House, Langford Business 
Park, Langford Lane, Kidlington, Oxford, 
OX5 1GF, United Kingdom. 
 
FITC mouse IgG1κ isotype control 
Purified mouse anti-human CD138 
FACS flow 
FACS rinse 
FACS clean 
FACS tubes 
 
BD Bio-sciences, BD PharminogenTM, 
The Danby Building, Edmund Halley 
Road, Oxford Science Park,  
OX4 4DQ Oxford, United Kingdom. 
Gd-DTPA-BSA monohydrate Azopharma, 11810 Borman Drive, 
St. Louis, MO 63146, USA. 
 
Rituxan® (human anti-CD20) 
Avastin® (human anti-VEGF-A) 
Herceptin® (human anti-HER2) 
 
Mater Misericordiae University Hospital, 
Eccles Street, Dublin 7, Ireland. 
Mouse 2C5 monoclonal antibody to 
nucleosomes 
Pharmaceutical Biotechnology and 
Nanomedicine,  
Northeastern University,  
360 Mugar Building,  
MA 02115, Boston, USA. 
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REAGENT SUPPLIER 
Dialysis tubing (300,000 Da) 
Dialysis tubing (50,000 Da) 
Dialysis tubing (3,500 Da) 
Page RulerTM Plus Prestained 
Protein Ladder 
 
AGB Scientific Ltd., Orion Business 
Campus, Northwest Business Park, 
Ballycoolin, Blanchardstown, 
Dublin 15, Ireland. 
 
Vivaspin column (5,000 Da) Sartorius Stedim Biotech GmbH, 
August-Spindler-Strasse 11, 
37079 Goettingen,  Germany. 
 
Foetal bovine serum (FBS) Invitrogen, 9704-CH-Groningen,  
The Netherlands. 
 
PCR primers Eurofins MWG Operon, 318 Worple 
Road, London, SW20 8QU, United 
Kingdom. 
 
Bacteriological agar 
Yeast extract 
Tryptone 
Cruinn Diagnostics Ltd., Hume Centre, 
Parkwest Business Park, Nanogor 
Road, Dublin 12, Ireland. 
 
Restriction enzymes 
T4 DNA ligase 
ISIS Ltd., Unit 1&2, Ballywaltrim 
Business Centre, Bogholl Road, Bray, 
Co. Wicklow, Ireland. 
 
DNTP mix 
Go Taq® DNA Polymerase 
Medical Supply Company Ltd., 
Damastown, Mulhuddart, Dublin 15, 
Ireland. 
 
RPMI 1640 
DMEM 
Bio-sciences, 3 Charlemont Terrace, 
Crofton Road, Dun Laoghaire, Ireland. 
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2.1.4 Standard solutions 
Table 2.4 Preparation of standard solutions. 
SOLUTIONS CONSTITUENTS 
FACS buffer 0.1 M PBS, pH 7.4 
2% (v/v) FCS 
0.05% (w/v) NaN3 
 
Protein electrophoresis buffer 25 mM Tris base (3.0 g) 
129 mM Glycine (14.4 g) 
0.1% (w/v) SDS (1.0 g) 
adjust pH to 8.3 
The components were dissolved in a 1L, 
pH was adjusted, and solution was stored RT 
 
SDS Sample buffer 1 M Tris-HCl, pH 6.8 (0.6 mL) 
50% (w/v) Glycerol (5.0 mL) 
10% (w/v) SDS (2.0 mL) 
2-Mercaptoethanol (0.5 mL) 
1% (w/v) Bromophenol blue (1.0 mL) 
dH2O (0.9 mL) 
The components were mixed thoroughly 
and stored at RT. 
 
Ammonium Persulphate Solution Ammonium persulphate (0.1 g) 
dH2O (1.0 mL) 
The components were mixed thoroughly 
and stored at RT. 
 
Transfer buffer Trizma base (3.0 g) 
Glycine (14.4 g) 
Methanol (200 mL) 
dH2O (make up to 1L) 
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SOLUTIONS CONSTITUENTS 
1M Phosphate Buffered Saline 
pH 7.3-7.4 (PBS) (1L) 
NaCl (80 g) 
KCl (2 g) 
Na2HPO4 (14.4 g) 
KH2PO4 (2.4 g) 
adjust pH to 7.3 by addition of 1M HCl 
 
1 x (0.1 M) Phosphate 
Buffered Saline – Tween 
PBST 
pH 7.3-7.4 
 
0.1 M PBS, pH 7.3 
0.05 % (v/v) Tween 20 
MES buffer, pH 5.5 10 mM MES 
20 mM NaCl 
adjust pH to 5.5 and store at RT 
100 x 5O5 Glycerol 50% (v/v) 
Glucose 50% (v/v) 
 
 
2.1.5 Constituents of buffers for SDS-PAGE (Sodium Dodecyl Sulphate-
PolyAcrylamide Gel Electrophoresis) and Western blotting 
Constituents of buffers for SDS-PAGE (Sodium Dodecyl Sulphate-PolyAcrylamide 
Gel Electrophoresis) and Western blotting are outlined in Table 2.5. 
Stock Solutions: 
(A) 30% (w/v) acrylamide containing 0.8% (w/v) bis-acrylamide 
(B) 1.5 M Tris-HCl, pH 8.8, containing 0.4% (w/v) SDS 
(C) 0.5 M Tris-HCl, pH 6.8, containing 0.4% (w/v) SDS 
(D) 10% (w/v) ammonium persulfate 
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Table 2.5 The quantities of stock solutions required for the preparation of 
resolving and stacking gel used for a polyacrylamide gel electrophoresis. 
SEPARATING GEL (12%) STACKING GEL (5%) 
1 M Tris-HCl, pH 8.8 1.5 mL 
 
1 M Tris-HCl, pH 6.8 0.63 mL 
30% (v/v)Acrylamide 2.5 mL 
 
30% (v/v)Acrylamide 0.84 mL 
2% (v/v) Methylene 
bisacrylamide 
 
1 mL 2% (v/v) Methylene 
bisacrylamide 
0.34 mL 
distilled water 
 
0.93 mL distilled water 3.10 mL 
10% (w/v) SDS 
 
0.03 mL 10% (w/v) SDS 0.05 mL 
10% (w/v) ammonium 
persulfate 
 
0.03 mL 10% (w/v) ammonium 
persulfate 
0.05 mL 
TEMED 6 µL TEMED 5 µL 
 
 
2.1.6 Culture media compositions 
The recipes of various media used for culturing bacterial cells are presented in 
Table 2.6. 
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Table 2.6 Bacteriological media used in this study. 
CULTURE MEDIA CONSTITUENTS 
2x Tryptone and yeast extract 
(TY) medium 
Tryptone                 16 g/L 
Yeast Extract          10 g/L 
NaCl                         5 g/L 
 
Luria Bertani broth (LB) 
medium / agar 
Tryptone                 10 g/L 
Yeast Extract          10 g/L 
NaCl                         5 g/L 
Agar                          5 g/L 
 
Super Broth (SB) Media MOPS                     10 g/L 
Tryptone                 30 g/L 
Yeast extract          20 g/L 
 
2.1.7 Bacterial strains 
Two bacterial strains used for cloning and expression were purchased from 
Stratagene, LaJolla, California, USA are listed in Table 2.7. 
 
Table 2.7 E. coli cells used for expression. 
 E. coli  XL10-GOLD strain: endA1 glnV44 recA1 thi-1 gyrA96 relA1 
lac Hte ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 tetR F'[proAB 
lacIqZ∆M15 Tn10(TetR Amy CmR)] 
E. coli Rosetta(DE3)pLysS strain: F- ompT hsdSB(RB
- mB
-) gal dcm 
λ(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) pLysSRARE (CamR) 
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2.1.8 Commercial kits and their suppliers 
Different commercial kits along with their suppliers are listed in Table 2.8. 
 
Table 2.8 Commercial kits used and their suppliers. 
COMMERCIAL KITS SUPPLIER 
Superscript III reverse transcriptase kit Invitrogen Corporation, 
5791 Van Alley Way, 
Carlsbad, CA92008, USA. 
QIAquickTM gel extraction kit Qiagen, 
28159 Avenue Stanford, 
Valencia, CA91355, USA. 
Wizard Plus SV MiniprepTM kit Promega, 
2800 Woods Hollow Road, 
Madison, WI 53711, USA. 
 
2.1.9 Cell lines 
U266 and RPMI8226 human multiple myeloma cell lines were purchased from 
DSMZ (Deutsche Sammlung von Mikroorganismem und Zellkulturen GmbH, 
Inhoffenstrasse 7B, 38124 Braunschweig, Germany). 
L428 and RAMOS cell lines were kindly donated by Dr. Dermot Walls, School of 
Biotechnology, Dublin City University, Ireland. 
B16F10 cells were kindly donated by Prof. Vladimir Torchilin, Northeastern 
University, Boston, USA. Different cell lines used in this study are outlined in Table 
2.9. 
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Table 2.9 List of cell lines and relevant culture media used in this study. 
CELL LINE DSZM NO. OR 
DONOR 
DESCRIPTION CULTURE 
MEDIUM 
U266 ACC 9 Human Multiple 
Myeloma 
RPMI 1640+ 
10% (v/v) FBS 
 
RPMI8226 ACC 402 Human Multiple 
Myeloma 
RPMI 1640+ 
10% (v/v) FBS 
 
L428 Dr. Dermot Walls 
(Dublin City 
University) 
Hodgkin’s disease- 
derived 
RPMI 1640+ 
10% (v/v) FBS 
 
RAMOS Dr. Dermot Walls 
(Dublin City 
University) 
Human Burkitt’s 
Lymphoma 
RPMI 1640+ 
10% (v/v) FBS 
B16F10 Prof. Vladimir 
Torchillin 
(Northeastern 
University, Boston, 
USA) 
Murine Melanoma DMEM+ 
10% (v/v) FBS 
 
2.2 Methods 
2.2.1 Mammalian cell culture  
2.2.1.1 Cell lines and media preparation 
The cell lines used in the experimental work (Table 2.5) were cultured in RPMI 
1640 or DMEM medium supplemented with 10% (v/v) FBS and 1% (v/v) 
antibiotics penicillin/streptomycin. 
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2.2.1.2 Recovery of frozen cells 
Cells were recovered from liquid nitrogen with special care by thawing rapidly at 
37°C and transferring to a sterile universal tube containing 10 mL of RPMI 1640 
(with 10% (v/v) FBS). The cells were centrifuged at 342 g for 5 min (Sigma 
centrifuge) resuspended in fresh medium, transferred to culture flasks and 
incubated at 37°C in a humid 5% (v/v) CO2 incubator.  
 
2.2.1.3 Culture of cells in suspension and adherent cells 
The cells were sub-cultured, using a split ratio of 1:2 every third day, maintaining 
a density of 1 × 106 cells/mL. Cells were flushed off the surface of the flask using 
a Pasteur pipette, collected and centrifuged at 342 g (Sigma centrifuge) at room 
temperature. The pellet was then resuspended in 2 mL of fresh culture medium. 
Cells were then transferred to T-75 flasks containing 14 mL of fresh RPMI 1640 
medium 
Adherent cells (B16F10) were detached with 1 mL 0.05 % (v/v) trypsin for 5 min 
at 37ºC. Trypsin was neutralized by adding 5 mL of medium supplemented with 
serum. Cells were then centrifuged at 342 g and resuspened in fresh medium. 
Cells were then transferred to flasks. 
 
2.2.1.4 Cell counts and viability testing 
Trypan Blue was used routinely to determine cell numbers and viability. Trypan 
Blue stain (Sigma, 0.25% (w/v)) was mixed 1:1 with 20 µL cell suspension and 
allowed to incubate for 2 min. A sample of this mixture was loaded onto the 
counting chamber of an improved Neubauer Haemocytometer slide and cell 
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numbers and viability were determined. Viable cells excluded the dye and 
remained white, while dead cells stained blue. The cell count was performed 
within 5 min after applying the Trypan Blue stain. 
 
2.2.1.5 Long-term storage of cells 
Cells required for long-term storage were frozen in liquid nitrogen. Harvested 
cells were pelleted and resuspended in freezing medium (90% (v/v) FBS, 10% 
(v/v) DMSO) to a concentration of 1 x 106 cells/mL. Aliquots of 1 mL were then 
transferred to sterile cryotubes and lowered slowly into the N2 gas and liquid 
before being eventually immersed in liquid nitrogen. 
 
2.2.2  Preparation of fluorescently-labelled liposomes 
2.2.2.1 Preparation of lipid cake (film) 
DSPE-PEG-COOH and cholesterol (1:1) were resuspended in 2 mL of 4:1 
chloroform / methanol and throughly mixed by gentle vortexing. The solvent was 
removed by evaporation in a nitrogen gas flow for 1.5 h at room temperature to 
obtain a dry lipid cake (film). 
 
2.2.2.2 Hydration of lipid film 
The lipid film was resuspended in 1 mL 0.1 M PBS, pH 7.3, containing 25 µg/mL 
fluorescein isothiocyanate solution. The lipid solution was then freeze-thawed for 
3-5 cycles between –80°C and 37°C, vortexed and sonicated for 15 min in a 
water-bath. The lipids were then extruded 15 times through a 100 nm 
polycarbonate membrane using an Avanti Polar Lipids mini-extruder to create 
uniform liposomes between 100 and 200 nm in diameter. The extruder was pre-
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warmed to 50ºC before extrusion to allow the liposomes pass through the 
polycarbonate membrane.  
 
2.2.2.3 Separation of fluorescent label-encapsulated liposomes from free 
fluorescent dye using size exclusion chromatography 
Size exclusion chromatography with Sephadex G-25 (column size 0.5 × 6 cm) 
was used to separate fluorescent liposomes from free fluorescent dye. The 
column was equilibrated using 0.1 M PBS, pH 7.3, and the solution of lipid was 
added to the column. Fractions of 0.5 mL were collected and the fluorescence of 
the collected samples analysed in a Tecan Safire fluorescence reader (excitation 
492 nm; emission 521 nm) to monitor the separation of fluorescent liposomes. 
 
2.2.3 Fluorescently-labelled immunoliposome preparation 
2.2.3.1 Attachment of antibodies to lipid via carboxylic groups 
An amide bond was formed in two stages to achieve conjugation between DSPE-
PEG-COOH phospholipid and antibody containing amine group. In the first stage, a 
free carboxylic group on the terminal end of a PEG chain in phospholipid was 
activated with water-soluble N,N'-dicyclohexyldiimide (DCC) and N-
hydroxysulfosuccinimide (NHS). DSPE-PEG-COOH activation bases on carboxylic 
group esterification by DCC reagent. In the second stage, antibody was 
resuspended in 50 mM K2HPO4 buffer, pH 8.5, using a Vivaspin column (‘cut-off’ 
5,000 Da) and was pooled together with phospholipid. A forty molar excess of this 
esterified lipid was conjugated to antibody by incubation in 50 mM K2HPO4 buffer, 
pH 8.5, overnight at 4°C. This lipid-antibody solution was dialyzed using 3,500 Da 
dialysis tubing against 0.1 M PBS, pH 7.4 for 2 h (‘cut-off’ 50,000 Da) to remove 
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DMSO in which esterified lipid was resuspended. The activated carboxyl groups 
reacted with amino groups on the antibody to create an amide bond (Figure 2.1). 
Subsequently, lipid-antibody linkage can be used for reverse-phase evaporation 
(REV) or co-incubation method. 
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Figure 2.1 Amide bond reaction scheme  
Carboxylic acid group activation (Step 1) facilitates conjugation with peptide 
containing amine group (Step 2). 
 
N C N
DCC 
DCC-activated lipid 
Lipid with carboxylic acid 
group 
C
O
NN
H
O
OH
O
NH2
N
H
O
 
 
 
Step 1 
Step 2 
Materials and Methods 
 98 
2.2.3.2 Thin Layer Chromatography (TLC) 
Esterification of DSPE-PEG-COOH was confirmed using thin layer 
chromatography (TLC). Confirmation of DSPE-PEG-COOH esterification was 
performed just before pooling this compound together with antibody for 
conjugation. Unmodified DSPE-PEG-COOH and esterified DSPE-PEG-COOH 
lipid were run on a Fluka silica plate (60 Å pore diameter) in chloroform/methanol 
(2:1) mobile phase and developed in iodine vapour. DSPE-PEG-COOH is a polar 
compound and is strongly attracted to the polar silica, whereas the non-polar 
esterified form of DSPE-PEG-COOH is less polar and runs further up the plate.  
 
2.2.3.3 Immunoliposome preparation by Reverse Phase Evaporation 
(REV) 
60 mol% DSPC, 30 mol% cholesterol, 9.9 mol% DSPE-PEG-COOH and 0.1 
mol% rhodamine-PE phospholipids were resuspended in chloroform. DSPE-
PEG-CO-NH-Ab conjugated (lipid-Ab), suspended in 0.1 M PBS, pH 7.3, was 
added to the chloroform lipid mixture. Aqueous and organic phases were 
observed. The lipid mixture was sonicated until it became a clear one-phase 
homogenous dispersion. Then, the mixture was placed on a rotary evaporator 
and organic solvent was slowly removed under reduced pressure at room 
temperature. The procedure was performed slowly taking care to avoid the 
formation of bubbles or foam. An excess of organic solvent allowed the 
creation of ‘inverted micelles’ (small water droplets) that were stabilized by the 
phospholipid monolayer. Slow removal of the organic solvent led to the 
transformation of these ‘inverted micelles’ into a viscous ‘gel-like’ state.  At the 
critical point in this procedure, the gel state collapses and some of the inverted 
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micelles disintegrate. Subsequently, phospholipid concentration increases, due 
to evaporation of chloroform, which contributes to the formation of a complete 
bilayer of liposomes. Liposomes prepared by the REV method are mainly 
unilamellar, composed of one lipid bilayer (Szoka and Papahadjopoulos, 1978). 
 
2.2.3.4 Immunoliposome preparation by co-incubation method 
Briefly lipids were resuspended in chloroform and mixed together. The solvent 
was evaporated under nitrogen gas or with a Rotovap R-200 vacuum. The lipid 
film was hydrated in 1 mL 0.1 M PBS, pH 7.3, by vortexing. Liposomes were 
then extruded through a 100 nm polycarbonate membrane. Then, two mol% of 
DSPE-PEG-COOH was first esterified using DCC and NHS reagents. Forty 
molar excess of esterified DSPE-PEG-COOH was used for antibody 
conjugation (section 2.2.3.1). For immunoliposome preparation, DSPE-PEG-
CO-NH-Ab in 100 µL 0.1 M PBS, pH 7.3, was co-incubated with previously 
prepared liposomes overnight at 4ºC while stirring. 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 100 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 2.2 Co-incubation method for immunoliposome preparation.  
Lipid-modified antibody was incorporated into the liposome membrane creating 
antibody-targeted liposomes (immunoliposomes). 
 
2.2.3.5  Purification of immunoliposomes (IL) by ultracentrifugation 
Separation of unbound antibodies from fluorescent immunoliposomes was 
performed by ultracentrifugation for 1 h at 149,008 g at 4°C. Ultracentrifugation 
of prepared 1 mL volumes of immunoliposomes was carried out twice and the 
supernatants collected. Following centrifugation and decanting of the 
supernatants the immunoliposome pellet was resuspended in 0.1 M PBS, pH 
7.3 buffer. 
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2.2.3.6 Purification of immunoliposomes (IL) by dialysis 
Separation of antibodies, which did not link to fluorescent liposomes from 
fluorescent immunoliposomes, was performed by dialysis against 0.1 M PBS, 
pH 7.3, for 2 days (‘cut-off’ 300,000 Da) at 4°C. 
 
2.2.3.7 Liposomes and immunoliposome size determination and stability by 
Photon Correlation Spectroscopy (PCS) 
Immunoliposomes were extruded through a polycarbonate membrane (100 nm 
pore size) and filtered (0.2 µm ‘cut-off’). The hydrodynamic sizes of the 
immunoliposomes were determined using Photon Correlation Spectroscopy 
(Malvern / Zetasizer Nano 3000HS), HPPS, in the School of Chemical Sciences 
at Dublin City University. Liposomes (0.1 mg/mL of lipids) were placed in a 
plastic disposable 12.5 x 12.5 x 45 mm cuvette, and then inserted into the 
instrument. 
Light from a 3mW He-Ne laser operating at a wavelenght of 633 nm was focused 
onto the sample held in a cuvette. A thermal equilibration time of 5-10 min 
preceded all measurements. Sample temperature was maintained constant at 
25°C by the internal heating system of the instrument. The intensity of the 
scattered light was detected at a 173° angle to the incident beam. This is known 
as backscatter detection. This  optical configuration results in an 8-fold increase 
in the detected scattering volume when compared with classical 90° scattering 
detection, resulting in an 8-fold increase in the count rate observed at the 
detector (Kaszuba et al., 2008). 
Photon Correlation Spectroscopy (PCS) can also provide information about the 
zeta potential of liposomes. The zeta potential is important in the assessment of 
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liposome stability and propensity for aggregation. Zeta potential indicates the 
degree of repulsion between adjacent, similarly charged particles in dispersion. 
For molecules and particles that are small enough, a high zeta potential will 
confer stability, e.g., the solution or dispersion will resist aggregation. When the 
potential is low, attraction exceeds repulsion and the dispersion will break and 
flocculate. Colloids with high zeta potential (negative or positive) are electrically 
stabilized while colloids with low zeta potentials tend to coagulate or flocculate 
(ASTM Standard, 1985). 
 
2.2.3.8 Protein determination using the micro Lowry assay with 
Peterson’s modification 
Bovine Serum Albumin (BSA) protein standard solutions (50 - 400 µg/mL), 
blank (plain liposomes) and samples were prepared. 100 µL of the 
deoxycholate (DOC) 0.15% (v/v) was added to each solution and mixed 
thoroughly. After 10 min 100 µL of the 72% (v/v) TCA (trichloroacetic acid) 
solution was added. The solution was centrifuged in 15 mL tubes in an 
Eppendorf centrifuge for 5 min at 3220 g. The resulting pellet was resuspended 
in 1 mL of Lowry reagent solution and allowed to stand for 10 min at room 
temperature. Folin & Ciocalteu’s phenol reagent (0.5 mL) was then added and 
the samples were mixed immediately. Colour was allowed to develop for 25 
min and the absorbance was read at 600 nm using a Tecan Safire 2 
spectrophotometer.  
A calibration curve of BSA protein standards was prepared and used to 
determine the protein concentration in each sample. 
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This method was used for the quantification of soluble proteins. The procedure 
is based on Peterson’s modification of the micro Lowry method and utilizes 
sodium dodecylsulfate (included in the Lowry reagent) to facilitate the 
dissolution of relatively insoluble lipoproteins. For many proteins, the Lowry 
reaction can be used directly with the protein solution. However, interference in 
the direct Lowry procedure is commonly caused by other chemicals in the 
protein solution, such as Tris, ammonium sulfate, EDTA, sucrose, citrate, 
amino acid and peptide buffers, and phenols. The protein precipitation 
procedure uses DOC (deoxycholate) and TCA (trichloroacetic acid), which 
eliminates all previously, mentioned interferences with the exception of 
phenols. The Lowry procedure is based on two chemical reactions. The first is 
the Biuret reaction, in which the alkaline cupric tartrate reagent complexes with 
the peptide bonds of the protein. This is followed by the reduction of the Folin & 
Ciocalteu’s phenol reagent, which yields a purple colour. Absorbance of the 
coloured solution is read at a suitable wavelenght between 500-800 nm.  
 
2.2.3.9 FLISA (Fluorophore-Linked ImmunoSorbent Assay) for 
immunoliposomes 
Two human multiple myeloma cell lines (U266; RPMI8226) were co-incubated at 
37°C for 1.5 h with 0.5 mg/mL of fluorescently-labelled immunoliposomes. 
Tubes (1.5 mL) were pre-blocked with PBS-FCS (fetal calf serum)-sodium azide 
solution overnight at 4°C. One million (106) cells were incubated with 
immunoliposomes for 30 min at 4°C. Cells were then centrifuged down at 3,000 
g. The cell pellet was resuspended in 200 µL of 0.1 M PBS, pH 7.4, and 
recentrifuged. Subsequently, cells were transferred to fresh tubes and washed 
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once with 0.1 M PBS, pH 7.4. Cells were then placed on a 96-well plate and the 
fluorescence was immediately determined (excitation 540 nm and emission 625 
nm) using a Tecan Safire 2 Plate Reader. 
 
2.2.4 FACS analyses for protein expression levels on cells 
Analysis of surface expression of surface proteins was performed by standard 
direct immunofluorescence. One million cells were centrifuged at 3,000 g for 5 
min using Z 233 MK-2 centrifuge and resuspended in FACS buffer (Table 2.4). 
Cells were then centrifuged at 3,000 g for 5 min and resuspended in 100 µL 25 
µg/mL of mouse anti-human CD138 antibody. Non-specific binding of antibodies 
was assessed by labelling cells with an isotype control antibody. Samples were 
well mixed and incubated for 30 min at 4°C. Finally, cells were washed three 
times by centrifugation at 3,000 g for 5 min using Z 233 MK-2 centrifuge and 
resuspended in 200 µL 4% (v/v) formaldehyde/PBS. Samples were transferred to 
FACS tubes and were analyzed immediately. Antibody-labelled cells were 
identified and analysed for surface fluorescence at 488/530 nm on a FACSscan 
flow-cytometer (Becton-Dickinson). Fluorescence data were collected and 
analysed by the CellQuest software (Becton Dickinson).  
 
2.2.5 FACS analyses - immunoliposome binding assay 
One million cells were centrifuged at 3,000 g for 5 min using Z 233 MK-2 
centrifuge and resuspended in 0.5 mg/mL of immunoliposomes in ‘serum-free’ 
medium. Cells were incubated with immunoliposomes for 1.5 h at 37ºC. Cells 
were subsequently washed three times at 3,000 g for 5 min with 0.1 M PBS, pH 
7.3 using Z 233 MK-2 centrifuge, and then resuspended in 200 µL 4% (v/v) 
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paraformaldehyde/PBS. Samples were transferred to FACS tubes and 
immediately analyzed using the FACS Calibur. Immunoliposome-labelled cells 
were identified and analysed for surface fluorescence for FITC (excitation 488 
nm; emission 530 nm) and for rhodamine B (excitation 540 nm; emission 625 
nm) on a FACSscan flow-cytometer (Becton-Dickinson). Fluorescence data were 
collected and analysed by the CellQuest software (Becton Dickinson).  
 
2.2.6 Synthesis of Polychelating Amphiphilic Polymer (PAP)  
2.2.6.1 NGPE-PLL-CBZ synthesis 
1 mL of 25 mg/mL NGPE (1, 2 – dioleoyl – sn – glycero – phosphoethanolamine 
– N - (glutaryl); Figure 2.3) in chloroform was activated with N - (3 - 
dimethylaminopropyl) - N' - ethylcarbodiimide hydrochloride (EDC) (20 mg) in the 
presence of N – hydroxysuccinimide (NHS) (13 mg) for 2-3 h at room 
temperature. Then, 40 µL of triethylamine was added to make the solution basic, 
to allow conjugation with poly – ε – CBZ (carbobenzyoxy) – DL – Lysine (PLL-
CBZ).  
Figure 2.3 Chemical structure of NGPE structure (1,2 - dioleoyl - sn - 
glycero - 3 - phosphoethanolamine - N - (glutaryl)). 
 
All NH2 groups of PLL-CBZ are protected by CBZ groups, except one which will 
link to the activated carboxylic group of NGPE. For this reaction to occur, 186 mg 
of PLL-CBZ was dissolved in 4 mL of DMF solvent and pooled together with 
activated NGPE phospholipids. The reaction was performed at room temperature 
for 12 h with stirring. Any chloroform present was evaporated from the mixture 
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and the product was precipitated using distilled water. The NGPE-PLL-CBZ 
product was freeze-dried for 48 h. NGPE-PLL-CBZ polymer was obtained      
(193 mg by weight).  
Poly-CBZ-lysine complex (10 mg) and NGPE-PLL-CBZ (10 mg) were dissolved 
in Cd4Cl3 and DMSO-d4 and separated into two vials and NMR analyses were 
performed for confirmation that synthesis was successfully achieved. 
 
2.2.6.2 NGPE-PLL-CBZ deprotection 
The NGPE-PLL-CBZ complex was deprotected from the CBZ group using 2 mL 
of 33% (v/v) hydrogen bromide in acetic acid for 2 h at room temperature with 
stirring. The complex was precipitated using diethyl ether and freeze-dried for 12 
h and 107 mg (by weight) of deprotected complex was obtained. Deprotection of 
the NGPE-PLL-CBZ complex generates up to 11 NH2 groups which are available 
to undergo reaction with DTPA (Torchilin et al., 1994). 
 
2.2.6.3 NGPE-PLL-DTPA (PAP) synthesis 
NGPE-PLL was treated with DTPA anhydride in the presence of triethylamine for 
16 h at room temperature with stirring. Succinic anhydride was added and the 
reaction was allowed to run for 1 h at room temperature followed by dialysis 
against distilled water (‘cut-off’ 3,500 kDa).  
All NH2 groups which did not react with the DTPA anhydride were blocked by 
succinic anhydride. 
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2.2.6.4 Loading of PAP with Gd ions 
GdCl36H2O was added to DTPA-PLL-NGPE suspended in 2 mL of pyridine 
and stirred for 4 h at room temperature. The reaction mixture was then dialyzed 
for 24 h against deionized water and vacuum dried at room temperature. 
 
2.2.7 Preparation of contrast liposomes and immunoliposomes  
Defined amount of lipids (described in 3.2.2, 4.2.2, 5.2.2, 5.2.3, 5.2.4, 5.2.6, 
5.2.7, 5.2.8 sections) were resuspended in chloroform in a round bottomed 
flask and the solvent was evaporated under nitrogen for 30 min at room 
temperature. The lipid film was dried for 15 min in a freeze dryer. The lipid film 
was then hydrated in 0.5 mL 0.1 M PBS, pH 7.3. The mixture was heated to 
50°C and vortexed. Liposomes were extruded through a 100 nm polycarbonate 
membrane. 
For immunoliposome preparation liposomes were co-incubated with the DSPE-
PEG2000-antibody complex for 12 h at 4°C. Separation of unbound antibody 
from immunoliposomes was performed by dialysis against 0.1 M PBS, pH 7.3, 
for 2 days (‘cut-off’ 300,000 Da) at 4°C. 
 
2.2.8 Cytotoxicity studies - MTT (1 - (4,5 – Dimethylthiazol – 2 - yl) - 3,5 - 
diphenylformazan) test 
The MTT assay is a colorimetric test based on MTT’s (tetrazole) reduction to 
purple formazan by living cells. This assay can be used to determine cell 
viability (Mosmann, 1983). In this research the MTT assay was used to 
determine the cytotoxic effect of contrast liposomes on cells. 
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B16F10 melanoma cancer cells were seeded in a 96-well plate with 8x103 
cells/100µL/well and incubated overnight at 37°C, in 5% (v/v) CO2. The 
medium was removed and the cells were treated with 100 µL of different 
concentrations of liposome formulations (1.4 – 0.01 mg/mL of lipids) in triplicate 
for 24 h at 37°C, 5% (v/v) CO2. After 24 h, the cells were washed once with 
DMEM ‘serum-free’ medium and immediately the MTT reagent was added. The 
cells were further incubated for 1.5 h. Subsequently, the MTT solution was 
removed, 100 µL of DMSO was added and the fluorescence was determined 
(540 nm (excitation)/690 nm (emission)). 
 
2.2.9 Gadolinium determination in contrast liposomes using Inductively 
Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES) 
The gadolinium concentration in contrast liposomes was determined using 
Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES). This is a 
technique used for detection and analysis of trace metals in a liquid sample. The 
sample is aspirated and aerosolised and introduced into a high temperature (2100 – 
2800ºC). The flame atomizes the sample (Figure 2.4). The atoms absorb radiation 
from the external light source at a characteristic wavelength, which stimulates a 
transition to an excited state energy level, allowing the quantitative measurement of 
the amount of emitted radiation.  
Contrast liposomes were resuspended in 0.1 M PBS, pH 7.3, containing 0.2 % (v/v) 
Triton X-100. Then, liposomes were resuspended in 1 M HNO3 for ICP-AES 
analysis. 
A calibration curve was prepared using gadolinium standards in 1 M HNO3. 
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Figure 2.4 Schematic of Inductively Coupled Plasma-Atomic Emission 
Spectroscopy (ICP-AES).  
The atomized sample absorbs radiation at a characteristic wavelength from the 
external light source and emittes light which can be quantitated. 
 
2.2.10 Fast Field-Cycling NMR (FFC NMR) 
Field-cycling NMR relaxometry involves the rapid switching of magnetic fields 
throughout the experiment in order to measure T1 over a wide range of low 
magnetic field strenghts. A plot of the spin-lattice relaxation rate R1 as a function 
of magnetic field, and hence resonance frequency, is known as a Nuclear 
Magnetic Resonance Dispersion (NMRD) profile. All field-cycling relaxometry 
experiments were performed on a Spinmaster FFC-2000 Fast Field-Cycling 
NMR Relaxometer (Stelar, Mede, Italy) using a sample volume of 0.5 – 1 mL. 
Measurements were carried out at 25°C. To measure T1 at frequencies higher 
than 20 MHz, a reconditioned Bruker WP80 variable field magnet was used. This 
allowed measurements of T1 from 35 – 75 MHz. 
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2.2.11 Magnetic Resonance Imaging (MRI) 
The experiments were carried out on a 1.5 T whole-body clinical scanning 
system (Philips MRI Scanner, Gyroscan Intera) in Cappagh National 
Orthopaedic Hospital, Finglas, Dublin 11, Ireland.  
Samples presented on the T1-weighted image scan were analyzed using ZEN 
Carl Zeiss software. The same area of the sample picture was selected and the 
mean of pixel intensity was calculated. 
 
2.2.12 CD138 protein fragment production 
2.2.12.1 Cloning of CD138 gene elements into pQE60 and pQETriSystem II 
vectors 
2.2.12.1.1 mRNA isolation from RPMI8226 cell line 
Two T-75 flasks with the RPMI8226 human multiple myeloma cell line were 
centrifuged for 10 min at at 342 g (Sigma centrifuge). The cell pellet was 
resuspended in Trizol. RNA extraction was performed according to Fanning et al. 
(2002) protocol. Cells harvested from one T-75 flask were resuspended in 0.5 
mL of Trizol in ’Rnase-free’ tubes and left for 5 min at RT. Then, 100 µL of 
chloroform was added to tubes and they were shaked for 15 s and incubated for 
2-3 min. Then, tubes were centrifuged at 14,000 g using Z 233 MK-2 centrifuge 
for 15 min at 4ºC. Three layers were observed. The upper (aqueous) layer was 
transferred to a fresh tube and 250 µL isopropanol was added and incubated for 
10 min at RT. Then, samples were centrifuged at 14,000 g for 10 min at 4ºC. The 
supernatant was discarded and the precipitated RNA was washed with 75% (v/v) 
ethanol. The mixture was then centrifuged at 14,000 g for 10 min at 4ºC. Ethanol 
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was decanted and pellet was dried at 37ºC for 10 min. RNA was resuspended in 
20 µL ’RNase-free’ water. For storage, RNA was resuspended in 100% (v/v) 
ethanol supplemented with 0.3 M sodium acetate. 
 
2.2.12.1.2 cDNA production from mRNA by reverse transcription 
5 µg RNA was used for reverse transcription. cDNA was synthesized using the 
SuperScript III Preamplification System for First Strand cDNA Synthesis 
(Invitrogen, Cat# 18080-093).  
Components used for reverse transcription are listed in Table 2.10 and Table 
2.11. 
First, 5 µg RNA was pooled together with primer oligo(dt) and dNTPs and co-
incubated at 65ºC for 5 min and then placed on ice for 1 min (Table 2.10). Then, 
reverse-transcroption buffer was pooled with MgCl2, DTT, RNaseOut inhibitor 
and SuperScript III reverse-transcriptase. Components, listed in Table 2.11, were 
pooled together with solutions prepared, as listed in Table 2.10, and then the 
mixture was incubated at 50ºC for 50 min. The reaction was terminated by 
heating at 85ºC for 5 min and then chilled on ice. One µL of RNaseH was then 
added and the reaction mixture was incubated for 20 min at 37ºC.  
 
 
 
 
 
Materials and Methods 
 112 
Table 2.10 List of components and their concentrations used in cDNA 
synthesis. 
COMPONENT VOLUME PER 
REACTION 
RNA (5 µg) 
Primer oligo(dt) (50 mM) 
dNTPs (10 mM) 
Molecular Grade H2O 
 
1 µL 
1 µL 
Make up to 10 µL 
 
Table 2.11 List of components and their concentrations used in cDNA 
synthesis. 
COMPONENT VOLUME PER 
REACTION 
MgCl2 (25 mM) 
10X Buffer 
RNaseOutTM ribonuclease 
Inhibitor (40 U/µL) 
DTT (0.1 M) 
Superscript III RT (200 U/µL) 
Molecular Grade H2O 
4 µL 
1X 
1 µL 
 
2 µL 
1 µL 
Make up to 20 µL 
 
2.2.12.1.3 Design of CD138 fragments primers for pQE60 and 
pQETriSystem II vector  
Primers were designed for further ligation into the pQE60vector (QIAGEN). 
The multi-cloning region of the pQE60 vector contains a NcoI site at the amino 
end of the sequence and a BamHI at the carboxyl end. Therefore, forward 
primers were designed to include the NcoI restriction site sequence and the 
Materials and Methods 
 113 
reverse primers were designed to contain the BamHI sequence. The primer 3 
programme was used for the design of primers. 
 
Figure 2.5 Diagram of the pQE60 vector used for the cloning of CD138.  
The plasmid contains a T5 promoter (PT5), lac operator (lac O), a ribosome 
binding site (RBS), a ATG start codon, a 6xHis tag sequence, a multiple 
cloning site (MCS) and a stop codon. The pQE60 vector has an amplicillin 
resistance gene and a Col E1 origin of replication.  
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The sense primer with the NcoI restriction site: 
5' TAT CCA TGG AT AGG CGC GCG GCG CTC TG 3' 
 
The anti-sense primer 1 (1-261 bp) with the BamHI restriction site: 
5' GAT GGA TCC AGC TGT AGC CTC CAG GCC GGT 3' 
 
The anti-sense primer 2 (1-759 bp) with BamHI restriction site: 
5' GAT GGA TCC CAG CAC CTC TTT CCT GTC CA 3' 
 
 
Figure 2.6 Diagram of the pQETriSystem vector used for the cloning of 
CD138. 
The plasmid contains a T5 phage promoter (PT5), a P CAG promotor, a P p10 
CMV/actin/globulin promotor, a lac operator (lac O), a ribosome binding site 
(RBS), a ATG start codon, a 8xHis tag sequence, a multiple cloning site (MSC),  
a stop codon and a pUK origin of replication. 
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The pQETriSystem vector contains a CAG, a T5, and p10 promoters that 
enable 6xHis-tagged protein expression in mammalian, E. coli, and 
baculovirus-infected insect cells, respectively. T5 promotor is recognized by 
RNA polymerase present in E.coli cells. The pQE vectors enable placement of 
the 6xHis tag at either the N- or C-terminus of the recombinant protein. 
The multi-cloning region of the pQETriSystem II vector contains a SacI site at 
the NH2 end of the sequence and a HindIII at the COOH end. Therefore, 
forward primers were designed to include the SacI restriction site sequence 
and the reverse primers were designed to contain the HindIII sequence. 
 
The sense primer with the SacI restriction site extra bases: 
5' - TAT GAG CTC ATG AGG CGC GCG GCG CTC TG – 3'  
The anti-sense primer (1 – 759 bp) with the HindIII restriction site: 
5' - GAT AAG CTT CAG CAC CTC TTT CCT GTC CA – 3' 
 
2.2.12.1.4 Plasmid isolation from bacterial cells 
XL10 Blue E. coli cells containing the pQE60 or pQETriSystem II vector were 
inoculated in 2 x TY medium supplemented with 100 µg/mL of carbenicillin at 37°C 
overnight, while shaking (250 rpm using New Brunschwick Scientific-Excella E-24 
Incubator).  
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The pQETriSystem II vector was isolated from cells according to the Promega 
Wizard Plus SV Miniprep protocol. A ten mL overnight culture was centrifuged at 
3,220 g for 5 min in Eppendorf (5804R) centrifuge. The pellet was resuspended in 
250 µL of cell resuspension solution. Next, 250 µL of cell lysis solution was added 
and microcentrifuge tube was inverted 4 times. It was left for 5 min and then alkaline 
protease solution was added to inactivate all endonucleases which could affect the 
quality of the isolated DNA. After adding 350 µL neutralization solution, and 
centrifugation (14,000 g for 10 min) in a microcentrifuge tube using the Hermle Z 233 
MK-2 centrifuge the lysate supernatant was added to the silica minicolumn. Plasmid 
DNA, which bound to the silica minicolumn, was washed once with 95% (v/v) 
ethanol (to remove salt) at 14,000 g. The plasmid DNA was eluted from the silica 
minicolumn using 100 µL ’nuclease-free’ water by centrifugation at 14,000 g for 1 
min at RT. 
 
2.2.12.1.5 Restriction analysis 
A restriction analysis was performed at 37ºC for 1.5 h for the pQE60 and 
pQETriSystem II vectors containing CD138 gene fragments as follows: 
REAGENT                               VOLUME 
DNA (5 µg) 
 
SacI (20 U / µL) 
HindIII (20 U / µL) 
NE buffer (10x) 
10x BSA (100x) 
H2O 
        depends on inserts and vector conc. 
                                     
                                     1 µL 
                                     1 µL 
                 15 µL 
                                    1.5 µL 
                        made up to 150 µL 
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REAGENT                               VOLUME 
DNA (5 µg) 
 
HindIII (20 U / µL) 
BamHI (20 U / µL) 
NE buffer (10x) 
10x BSA (100x) 
H2O 
        depends on inserts and vector conc. 
                                     
                                     1 µL 
                                     1 µL 
                 15 µL 
                                    1.5 µL 
                        made up to 150 µL 
 
Each digest was run on a 1% (w/v) agarose gel (section 2.2.10.3). 
 
2.2.12.1.6 Ligation of PCR products into pQE60 or pQETriSystem II 
vectors 
The ligation reaction was set up as follows: 
pQE60 vector 
1 –261 bp GENE 1 – 759 bp GENE 
ADDITIONS VOLUME ADDITIONS 
VOLUME 
• pQE60 
 
• cut 1 –261 bp 
insert 
• 5x buffer 
• T4 DNA  
     (40 U / µL) 
• H2O 
        11 µL  
        (0.05 µg) 
        1.6 µL  
       (0.3 µg) 
        4 µL 
   2 µL 
 
  1.4 µL 
• pQE60 
 
• cut 1 –759 bp 
insert 
• 5x buffer 
• T4 DNA  
     (40 U / µL) 
• H2O 
    11 µL 
(0.05 µg) 
     1.8 µL 
    (0.1 µg) 
     4 µL 
     2 µL 
 
     1.2 µL 
• Total volume       20 µL • Total volume     20 µL 
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pQETriSystem II vector 
1 –261 bp GENE 1 – 759 bp GENE 
ADDITIONS VOLUME ADDITIONS VOLUME 
• pQETriSystem II 
vector 
• cut 1 –261 bp 
insert 
• 5x buffer 
• T4 DNA  
     (40 U / µL) 
• H2O 
        8.2 µL  
       (1 µg) 
       1.3 µL  
      (1 µg) 
       4 µL 
  2 µL 
 
  4.5 µL 
• pQETriSystem II 
vector 
• cut 1 –759 bp 
insert 
• 5x buffer 
• T4 DNA  
     (40 U / µL) 
• H2O 
        8.2 µL  
       (1 µg) 
       3.4 µL  
      (1 µg) 
       4 µL 
  2 µL 
 
  2.4 µL 
• Total volume      20 µL • Total volume       20 µL 
 
The molar ratio of insert/vector was 3:1 for ligation. 
The ligation reaction was incubated in room temperature overnight and then 
used for transformation.  
 
2.2.12.1.7 DNA precipitation 
Ligated DNA was precipitated to remove PCR reagents and for concentration. 
Precipitation was performed by adding 1/10 original volumes 3M sodium 
acetate, pH 5.2, followed by adding 2x total volume of 100% (v/v) ethanol. The 
solution was incubated at -20°C overnight. It was then centrifuged for 20 min at 
19,500 g in Eppendorf centrifuge and the pellet was resuspended again using 
pre-chilled 75% (v/v) ethanol. The solution was centrifuged one more time for 
10 min at 14,000 g and pellet was left to dry. After ethanol evaporation the DNA 
pellet was resuspended in sterile water. 
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2.2.12.2 Transformation of pQE60 and pQETriSystem II vector into XL10 Gold 
and RosettaTM E. coli competent cells by electroporation  
 
2.2.12.2.1 XL10 Gold, RosettaTM E.coli competent cells - preparation and 
electroporation 
Twenty µL of stock E.coli XL10 Gold cells was inoculated in SB medium 
supplemented with 5 µg/mL of tetracycline and incubated at 37°C overnight. 
Then, 3 mL of inoculated cells were transferred into two 250 mL volume of SB 
medium without any antibiotic. The culture was grown at 37°C with shaking (250 
rpm) until an OD600 of 0.6 - 0.8 was reached. Next, the culture was chilled on ice 
and spun down in sterile tubes for 20 min at 4 °C (3,220 g) in an Eppendorf 
centrifuge. The pellets were resuspened in pre-chilled 10% (v/v) glycerol on ice 
and centrifuged as before. The supernatant was discarded and pellets 
resuspended in 10 % (v/v) glycerol, pooled together, made up to 250 mL with 
glycerol and spun down as before. The pellet was resuspended in 25 mL of 
glycerol and transferred to a 50 mL sterile tube. Cells were spun down as before 
(for 20 min at 3,220 g). The cell pellet was then gently resuspended in 5 mL of 
glycerol and immediately frozen in 0.5 mL aliquots in liquid nitrogen. Cells were 
also stored at -80°C. 
DNA (pQETriSystem II and pQE60 vector) was transformed into E. coli XL10 
Gold cells by electroporation to allow CD138 protein expression. Plain E. coli 
XL10 Gold competent cells (without plasmid) were thawed for transformation. 
Two µL of each ligation was added directly into the tube containing the 
competent cells and mixed by pipetting. Competent cells with the ligation 
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mixture were immediately put on the bottom of the pre-chilled cuvette (2 mm) 
and exposed to 2,500 V. 
Afterwards cells were immediately transferred to prewarmed SB medium and 
placed to 37°C with shaking (250 rpm) for 1 h. Transformants were then spread 
onto LB agar plates containing100 µg/mL of carbenicillin. Plates were inverted 
and placed at 37°C overnight. 
 
2.2.12.3 Agarose gel electrophoresis for DNA characterisation 
DNA was analysed by agarose gel electrophoresis. Gels were prepared by 
dissolving agarose (usually 0.9-1.5% (w/v) in 1x TAE buffer) with 0.5 µg/mL of 
ethidium bromide. Gels were run at 100 V for 0.5 h, then visualized on a UV 
trans-illuminator and photographed using a UV image analyser (Amersham 
Pharmacia Biotech). 
 
2.2.12.4 Colony PCR 
Transformants were analysed by colony PCR as follows: 
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1-261 bp GENE FRAGMENT 1-759 bp GENE FRAGMENT 
VOLUME (µL) COMPONENTS VOLUME (µL) COMPONENTS 
 
       10 µL           
    
        1 µL             
        2 µL 
        1 µL   
     
        1 µL     
                      
     34.7 µL          
       0.25 µL 
single colony 
Green GoTaq flexi 
buffer (5x) 
dNTP (10 mM) 
MgCl2 (25 mM) 
Sense primer 
(100 pmol / µL) 
Anti-sense 
(100 pmol / µL) 
sterile H2O 
GoTaq 
polymerase (5 U / µL) 
 
 10 µL 
 
   1 µL 
   2 µL 
   1 µL 
 
   1 µL 
 
      34.7µL 
        0.25 µL 
single colony 
Green GoTaq flexi 
buffer(5x) 
dNTP (10 mM) 
MgCl2 (25 mM) 
Sense   primer 
(100 pmol / µL) 
Anti-sense 
(100 pmol / µL) 
sterile H2O 
GoTaq 
polymerase (5 U / µL) 
 
                   Step 1: 95°C 2 min 
                   Step 2: 95°C 30 s 
                   Step 3: 58°C 30 s 
                   Step 4: 72°C 45 s 
                   Step 5: repeat Step 2  
                   to Step 4 (30 times) 
                   Step 6: 72°C 5 min 
                   Step 7: 4°C pause 
 
                Step 1: 95°C 2 min 
                Step 2: 95°C 30 s 
                Step 3: 59°C 30 s 
                Step 4: 72°C 45 s 
                Step 5: repeat Step 2    
                to Step 4 (30 times) 
                Step 6: 72°C 5 min 
                Step 7: 4°C pause 
 
2.2.12.5 IPTG induced protein expression 
Transformants were inoculated into 1 mL of SB medium supplemented with 
100 µg/mL carbenicillin, After overnight incubation at 37°C, 100 µL of bacteria 
was subcultured into 10 mL fresh SB medium supplemented with 1X 5O5 
medium (Table 2.4) and 100 µg/mL carbenicillin. Stock vials were prepared by 
adding glycerol (20% (v/v)) to the overnight grown culture and cells were then 
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stored at –80°C. The subcultured cells were grown until an OD of ~ 0.8 was 
reached followed by addition of isopropyl-β-D-thiogalactoside (IPTG) to a final 
concentration of 1 mM and inducing them overnight at 220 rpm at 30°C. The 
overnight culture was then spun down at 3,220 g for 20 min and the pellet was 
resuspended in 500 µL PBS. The resuspended culture was sonicated on ice for 
90 s (with 3 s intervals between each step) at an amplitude of 50%, using a 
microtip Vibra CellTM sonicator. Lysate was then centrifuged at 3,220 g for 20 
min at 4°C to remove cell debris. 
 
2.2.12.6 Polyacrylamide Gel Electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis (PAGE) was carried out using a 
discontinuous system, in the presence of sodium dodecyl sulphate (SDS), as 
described by Laemmli (1970). 12% (w/v) resolving and 5% (w/v) stacking gels 
were normally used and prepared from the following stock solutions as outlined 
in Table 2.5. Polymerisation of the separating gel acrylamide was catalysed by 
addition of ammonium persulfate solution and the accelerator TEMED 
(N,N,N',N'-tetramethyl-ethylenediamine) and the gel added to the space 
between the plates and covered with a layer of water. Once the gel had 
polymerised, the water was removed and the stacking gel placed was placed 
directly onto the separating gel. A plastic comb was placed in the gel to create 
the wells for sample application. When the gel had fully polymerised, the plates 
were placed in the elecrophoresis apparatus, the comb was removed and the 
chamber and wells filled with 1x electrophoresis buffer (25 mM Tris, 130 mM 
Glycine (electrophoresis grade), pH 8.3, and 0.1% (w/v) SDS) as outlined in 
Table 2.4. Excess sample buffer is essential to maintain reduction of protein 
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sulfhydryls and to prevent intra-molecular disulfide bond formation through 
oxidised cysteines. A 5 x stock solution of sample buffer was prepared to give 
the following final concentrations: 60 mM Tris-HCl, pH 6.8, 25% (w/v) glycerol, 
2% (w/v) SDS, 14.4 mM 2-mercaptoethanol and 0.1% (w/v) bromophenol blue. 
Samples were mixed 1:5 with sample buffer and heated 5-10 min at 95°C. 
Appropriate protein molecular weight markers were run in parallel with 
samples. A total sample volume of 20 µL was added to the wells on the gel. 
The power unit was run at 90-130V. 
 
2.2.12.7 Transfer of proteins from gels to nitrocellulose membranes and 
Western blotting 
Following electrophoresis, a sheet of nitrocellulose membrane was placed on 
top of three sheets of Whatman filter paper pre-soaked in transfer buffer. The 
gel was carefully placed on top of the membrane and any air bubbles removed 
by rolling a clean 10 mL pipette over the sheets. Three more of pre-soaked 
filter paper were added on the top of the gel and air bubbles removed. The 
proteins were transferred from the gel to the membrane using a Bio-Rad Semi-
dry Transfer system for 20 min at 15V at RT. After transfer the blotted 
membrane was blocked in 3% (w/v) milk Marvel in PBS for 1 h at RT. Following 
blocking, the blot was washed once with PBS and then incubated with mouse 
anti-human CD138 primary antibody at the 0.5 µg/mL in PBST containing 1% 
(w/v) milk Marvel solution for 1 h at RT. The blot was then washed three times 
with PBST then three times with PBS prior to incubation with 1:2,000 dilution of 
an enzyme-labelled secondary antibody (e.g. alkaline phosphatase-labelled 
goat anti-mouse IgG) in PBST containing 1% (w/v) milk Marvel for an 1 h at 
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RT. The blot was washed 3 times in PBST then PBS. Following this the 
membrane was developed using an appropriate substrate solution (e.g. 
3,3',5,5'-Tetramethyl-Benzidine (TMB) for HRP-labelled and 5-bromo-4-chloro-
3'-indolyphosphate / nitro blue tetrazolium chloride (BCIP/NBT) for alkaline 
phosphatase-labelled secondary antibodies). Color development was allowed 
to proceed at RT until the desired bands were apparent. The reaction was then 
stopped by washing extensively with distilled water. 
 
2.2.12.8 Production of 1-253 aa CD138 protein fragment and purification using 
IMAC 
Overnight cultures of selected clones were grown in LB medium, containing         
100 µg/mL carbenicillin. This was carried out by inoculating with 10 µL of the stock 
culture and growth overnight at 37ºC. A 5 mL volume of the culture was then 
inoculated into 500 mL LB media containing 100 µg/mL carbenicillin and 1 x 5O5 
media. The subcultured clone was incubated at 37ºC at 250 rpm until an OD ~0.8 
(OD 800 nm) was achieved. The cultures were then induced by adding IPTG to a 
final concentration of 1 mM and incubating at 30ºC (250 rpm) overnight. 
The overnight culture was then transferred to two 250 mL Sorval tubes and 
centrifuged at 18,500 x g in a GSA rotor for 20 min (‘brake on’) to pellet the bacterial 
cells. The supernatant was discarded. The pellet was thoroughly resuspended in 15 
mL of sonication buffer (0.1 M PBS, pH 7.4, 0.5 M NaCl, 20 mM imidazole, 8 M 
urea) and aliquoted into 1 mL volumes in 2 mL microcentrifuge tubes. Each tube 
was sonicated on ice for 30 s (with 3 second intervals between each pulse) at an 
amplitude of 40, using a microtip Vibra CellTM sonicator and the cell debris removed 
by centrifuging at 22,000 x g for 10 min at 4C. The lysate supernatant was then 
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passed through a 0.2 µm filter to remove any residual cell debris that might clog the 
resin column later. 
Purification of 1-253 aa CD138 protein fragment was performed using metal affinity 
chromatography (IMAC). It uses Ni+-NTA agarose resin (QIAgen). A 4 mL aliquot of 
Ni+-NTA agarose resin was added to a 20 mL column and allowed to settle down for 
10 min. The column was equilibrated using 30 mL running buffer (0.1 M PBS, pH 
7.4, 0.5 M NaCl, 20 mM imidazole, 8 M urea). The filtered lysate was then applied to 
the equilibrated column and the ’flow-through’ was collected in a 50 mL tube. The 
column was then washed with 30 mL of washing buffer to remove loosely bound 
non-specific proteins and the wash collected in a 50 mL tube. The CD138 protein 
fragment was then eluted using 100 mM sodium acetate, pH 4.4, and collected in 
400 µL aliquots in 1.5 mL micro-centrifuge tubes containing 100 µL of filtered 
neutralisation buffer (50 µL 100 mM NaOH and 50 µL of 1 mM PBS, pH 7.4.) The 
neutralised protein was then buffer exchange using a 5 kDa ‘cut-off’ VivaspinTM 6 
column. The buffered exchanged proteins were then transfered to 15 mL tubes and 
stored at –20ºC.  
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3.1 Introduction 
The overall aim of this project was to prepare sufficient targeted contrast agent for 
the diagnosis of human multiple myeloma in humans using MRI. 
There are different agents which can be used for this purpose e.g. solid lipid 
nanoparticles, liposomes, nanocrystals or carbon nanotubes. Liposomes were 
chosen to be used to target human multiple myeloma. Liposomes are artificially 
prepared vesicles consisting of phospholipid bilayers, which have been used 
extensively in drug and gene delivery. They are easily adapted for use in vitro, ex 
vivo and in vivo. The advantage of liposomal usage is that they remain in the 
circulation for a relatively long period of time and are not readily taken up by the 
macrophages in the RES, when containing either monosialoganglioside (GM1) 
(Allen et al., 1987) or polyethylene glycol (5-10 mol%) derivatives of 
phosphatidylethanolamine (Klibanov et al., 1990).  
There are several methods for liposome preparation. The most common method 
used is lipid film hydration which leads to multilamellar vesicle (MLVs) formation. 
This method involves drying a solution of lipids so that a thin film is formed on the 
bottom of a round bottom flask and then hydrating the film by adding aqueous buffer 
and vortexing the dispersion for some time. MLVs are simple to prepare by this 
method and a variety of substances can be encapsulated. The drawbacks of this 
method are low internal volume, low encapsulation efficiency and the size 
distribution is heterogeneous (Bangham et al., 1965, 1974). A different method for 
MLV generation was proposed by Kim et al. (1985). This solvent spherule method 
leads to preparation of liposomes of homogeneous size distribution. The process 
involves dispersing small spherules of volatile hydropohobic solvent in which lipids 
had been dissolved, in aqueous solution. MLVs are formed when controlled 
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evaporation of organic solvent is carried out e.g. in water bath at a required 
temperature. 
MLVs can be used for preparation of large unilamellar vesicles (LUVs). Mayhew et 
al. (1984) called this approach microfluidization of liposomes. Devices are available 
commercially under trade names such as LUVET and EXTRUDER for passing 
MLVs through 100 nm polycarbonate membranes resulting in production of LUVs. 
Riaz et al. (1994) prepared liposomes by this technique and showed that the 
liposomes were unilamellar, using freeze fracture electron microscopy. Large 
unilamellar vesicles have high internal volume/encapsulation efficiency and can be 
used for the encapsulation of drugs and macromolecules. In this research, large 
unilamellar vesicles (LUVs) were created by lipid film hydration followed by 
extrusion. 
A different method for preparation of LUVs is the reverse-phase evaporation (REV) 
method. First a two phase system containing phospholipids in organic solvent and 
aqueous buffer is formed and this is followed by a brief sonication. The organic 
solvent is removed under reduced pressure, resulting in the formation of a viscous 
gel. The liposomes are formed when residual solvent is removed by continued rotary 
evaporation under reduced pressure. In this study the REV method was used for 
immunoliposome preparation. Immunoliposomes, in which monoclonal antibody 
(mAb) fragments are conjugated to liposomes, represent the next generation of 
molecularly targeted systems. By combining the tumor targeting properties of mAbs 
with a contrast agent anchoring system, immunoliposomes can provide selective 
contrast agent accumulation on targeted tumor cells. 
The main aim of this chapter was to describe optimization of liposome and 
immunoliposome preparation. Experiments were performed to establish the best 
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method for immunoliposome preparation using antibodies kindly donated by the 
Mater Misericordiae University Hospital, Dublin, for research purposes. To optimize 
the procedure for immunoliposome preparation, different antibodies (Herceptin®, 
2C5 and Rituximab) were used. Herceptin® (Trastuzumab) is a humanized 
monoclonal antibody which interferes with HER2 receptors overexpressed on breast 
cancer cells. Cells treated with Herceptin® undergo arrest during the G1 phase of 
the cell cycle resulting in reduced proliferation. It was suggested that this antibody 
induces some of its effects by causing the downregulation of the HER2 receptor 
(Kute et al., 1994). 2C5 is a monoclonal antibody (produced in Prof. V. Torchilin’s 
group in Northeastern University, Boston, USA) which binds strongly to cancer cell 
lines which have higher number of nucleosomes attached to their outer cell 
membrane compared to normal non-cancer cells (Iakoubov et al.,1995). Rituximab 
is a chimeric antibody which binds to CD20, primarily found on the surface of B 
cells. This genetically engineered chimeric anti-CD20 monoclonal antibody 
containing human IgG1 kappa constant regions, with murine variable regions, 
mediates complement-dependent cell lysis and antibody-dependent cellular 
cytotoxicity (Reff et al., 1994). It is used to treat leukaemias and lymphomas and in 
transplant rejection therapy. 
Immunoliposomes have antibodies attached to the liposome surface. There are 
different chemical reactions which can be used to conjugate antibodies to 
liposomes. Modification of the antibody amine groups is the procedure most 
frequently use to produce antibody-liposome conjugates. Early procedures were 
described using crosslinking agents, such as l-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC), in the presence of preformed liposomes 
containing a lipophilic carboxylic acid (Endoh et al., 1981). DCC (N,N'-
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dicyclohexylcarbodiimide) can also be used for crosslinking to carboxylic acid, 
because it has the same chemical features as EDC.  
A different method for antibody-liposome conjugation involves the use of 
hetereobifunctional crosslinkers e.g. SATA (N-hydroxysuccinimide ester) which 
efficiently introduces a unique and selective reactive function, such as a protected 
thiol. Antibodies which have been activated by these crosslinkers can, after 
deprotection, where appropriate, react with a maleimide-activated lipid group in the 
liposome bilayers.  
In this research, immunoliposomes were prepared using two different methods: (a) 
reverse-phase evaporation (REV) and (b) co-incubation methods. In both methods, 
antibody was firstly conjugated to phospholipid which was then used in 
immunoliposome preparation. Herceptin®-liposomes were prepared using reverse-
phase evaporation (REV). The REV method was already described in detailed. In 
the co-incubation method liposomes were firstly prepared and then co-incubated 
with previously conjugated lipid-antibody linkage, leading to immunoliposomes 
generation. DSPE-PEG-COOH phospholipid was first esterified using DCC and 
NHS reagent and then conjugated with antibody. For example, 2C5 monoclonal 
antibody was conjugated to DSPE-PEG-COOH phospholipid and co-incubated with 
previously prepared liposomes to generate immunoliposomes. Rituximab-liposomes 
were also prepared using the co-incubation method. In vitro studies of Rituximab-
liposomes with RAMOS (human Burkitt’s lymphoma) and L428 (Hodgkin’s disease-
derived) cancer cell lines were performed. RAMOS and L428 cell lines were kindly 
donated by Dr. Dermot Walls, School of Biotechnology, Dublin City University. 
Avastin®, a humanized monoclonal antibody was used as a negative control for 
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Rituximab monoclonal antibodies. It recognizes and blocks VEGF-A (vascular 
endothelial growth factor-A) (Los et al., 2007). 
Once liposomes or immunoliposomes were formulated and generated they were 
characterized for their size and surface charge. Liposomes were investigated for 
their hydrodynamic diameter which was measured using scattered light off from the 
surface of the particles with photon correlation spectroscopy (PCS). The surface 
charge of the liposomes was obtained by measuring their zeta potential 
(electrokinetic potential). 
Optimization of methods for the production of both liposomes and immunoliposomes 
was essential in order to develop the best liposomal nanoparticles for long-term 
usage in human multiple myeloma imaging. 
 
3.2 Results 
3.2.1 Generation and characterisation of fluorescently-labelled liposomes 
Fluorescently-labelled liposomes were produced and purified as described in section 
2.2.2.3. The free (i.e. non-encapsulated) fluorescent dye was separated from 
fluorescent liposomes using size exclusion chromatography on Sephadex G-25. 
Fractions were collected from the column and the fluorescence was measured using 
the Tecan Safire 2 plate reader (Figure 3.1).  
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Figure 3.1 Elution profile of samples containing fluorescently-labelled 
liposomes after size exclusion chromatography on Sephadex G-25.  
The column dimensions were 0.5 × 6 cm. Fractions of 0.5 mL were collected and the 
fluorescence recorded (excitation at 492 nm; emission at 521 nm). 
 
The FITC dye penetrates the Sephadex G-25 beads due to its small size while the 
larger liposomes are excluded from the beads and were eluted in fractions 2-5. The 
diameter of fluorescently-labelled liposomes was estimated using Photon 
Correlation Specroscopy (PCS). An average diameter of 121 nm was determined for 
the liposomes, as shown in Figure 3.2. 
 
Figure 3.2 PCS analysis of fluorescently labelled liposomes. 
Two major populations of particles with diameters of approximately 20 nm (A) for 
micelles and 121 nm (B) for liposomes. 
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3.2.2 Preparation and purification of fluorescently-labelled 2C5 antibody-
conjugated-liposomes 
This section contains a physical comparison between liposomes and antibody-
conjugated-liposomes. 
Liposomes were prepared by lipid film hydration, as described in section 2.2.2.2. 
The lipid film was hydrated  using 1 mL of 0.1 M PBS, pH 7.4 (without any 
fluorescent dye). Briefly, a lipid film was prepared using 64.5 mol% of egg PC, 30 
mol% of cholesterol, 5 mol% of DSPE-PEG-COOH and 0.5 mol% of rhodamine-PE. 
The lipid film was hydrated, heated to 50°C and vortexed to form liposomes anf then 
extruded through a 100 nm polycarbonate membrane. The size of these liposomes 
was estimated to be 182 nm with a zeta potential of -52.11 mV, which indicates that 
liposomes are stable. The zeta potential indicates the degree of repulsion between 
adjacent, similarly charged particles in dispersion. For molecules and particles that 
are small enough, a high zeta potential (higher than 30 mV or lower that –30 mV) 
will confer stability, e.g., the solution or dispersion will resist aggregation, whereas, 
when the potential is low, attraction exceeds repulsion and the dispersion 
flocculates.  
Then, immunoliposome were prepared using co-incubation method. 2C5 
monoclonal antibody was used for immunoliposome preparation. 2C5 antibody 
binds strongly to cancer cell lines which have higher number of nucleosomes 
attached to their outer cell membrane compared to normal non-cancer cells 
(Iakoubov et al., 1995). Firstly, antibody was linked to DSPE-PEG-COOH 
phospholipid (section 2.2.3.4). In details, 2C5 antibody (0.6 mg) was conjugated to  
2 mol% of DSPE-PEG-COOH and subsequently 2C5-antibody-conjugated-
phospholipid was co-incubated with the previously prepared liposomes (composed 
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of 64.5 mol% of egg PC, 30 mol% of cholesterol, 3 mol% of DSPE-PEG-COOH and 
0.5 mol% of rhodamine-PE) overnight at 4°C. Lipid composition for immunoliposome 
preparation is presented in Table 3.1.  
 
Table 3.1 Lipids used for preparation of fluorescently-labelled 2C5-antibody-
conjugated-liposomes. 
 
Compound 
 
Molecular 
weight  
[g] 
 
Weight taken [mg] 
 
Moles 
 
Molar ratio of 
lipid to other 
lipids 
Egg PC  790.12 4.00 5.20*10-6 64.5 mol%  (1) 
Cholesterol  386.65 0.93 2.42*10-6 30 mol% 
(0.47) 
DSPE-PEG-
COOH 
  2,847.78 0.67 2.36*10-7 3 mol% (0.05) 
Rhodamine-PE   1,176.93 0.05 4.03*10-8 0.5 mol% 
(0.01) 
DSPE-PEG-
COOH 
  2,847.78 0.46 1.61*10-7 2 mol% (0.03) 
TOTAL                                  6.11 
 
After co-incubation the fluorescently-labelled 2C5-antibody-conjugated-liposomes 
were dialyzed against PBS, pH 7.4, (‘cut-off’ 300,000 Da) for 2 days at 4°C to 
remove unbound antibody. The size and zeta potential of fluorescent 2C5-antibody-
conjugated-liposomes were determined by PCS. 
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Figure 3.3 Comparison of size and zeta potential of fluorescently-labelled 
liposomes and fluorescently-labelled 2C5-conjugated-liposomes.  
The diameter of prepared antibody-conjugated-liposomes increased from 182 nm to 
195.9 nm and the zeta potential decreased from -52.11 to -32.65 mV. The diameter 
of 2C5-conjugated-liposomes increased compared to antibody-free-liposomes due 
to the antibody presence on the liposome surface. The zeta potential of 2C5-
liposomes decreased compared to antibody-free-liposomes the former due to the 
positive charge from amine groups present on antibodies. 
 
The size of prepared immunoliposomes was 196 nm with a zeta potential of -32.65 
mV. The zeta potential of the liposomes decreased from -52.11 mV to -32.65 mV 
after immunoliposomes were generated, due to the positive charge of antibodies 
(Figure 3.3). It indicates that antibody attachment to liposome changes liposome 
properties in particle diameter and charge. 
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3.2.3 Preparation of fluorescently-labelled antibody-conjugated-liposomes – 
Reverse Phase Evaporation (REV) method  
 
3.2.3.1 Fluorescently-labelled Herceptin®-antibody-conjugated-liposome pre-
paration and purification 
Firstly, Herceptin®-liposomes were prepared using the reverse phase evaporation 
method. The procedure for this method was described in section 2.2.3. 
Briefly, DSPC, cholesterol and rhodamine-PE were resuspended in chloroform and 
the DSPE-PEG-COOH lipid was esterified and conjugated with 1.33 mg Herceptin® 
antibody. The Herceptin®-antibody-conjugated-phospholipid complex was buffered-
ex-changed with 0.1 M PBS, pH 7.3. Then, Herceptin®-antibody-conjugated-
phospholipid was put onto the lipid solution. An aqueous and an organic phase, 
were observed. Then the mixture was sonicated to generate an emulsion. 
Any organic solvent remaining was slowly evaporated using a Rotovap R-200 
apparatus and the aqueous solution was ultracentrifuged to separate 
immunoliposomes from free antibody. The immunoliposomes were then extruded 
through a 100 nm polycarbonate membrane. The protein concentration in the 
immunoliposome sample was estimated using the micro Lowry assay with 
Peterson’s modification.  
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Figure 3.4 Determination of antibody concentration in Herceptin®-conjugated-
liposomes after ultracentrifugation.  
Immunoliposomes were ultracentrifuged twice and antibody concentration was 
estimated. 1.33 mg of Herceptin® monoclonal antibody was used for immuno-
liposome preparation. Herceptin®-conjugated-liposomes were ultracentrifuged twice 
to separate them from unbound antibody and the supernatants were collected (S1-
supernatant 1; S2-supernatant 2). It was estimated that there are 0.71 mg/mL of 
Herceptin® antibodies attached to liposomes; 0.06 mg/mL of unbound Herceptin® 
antibodies in S1 and 0.02 mg/mL of unbound Herceptin® antibodies in S2. 
 
1.33 mg/mL of Herceptin® antibody was used for immunoliposome preparation and 
it was estimated that there was 0.71 mg/mL of antibody (Figure 3.4) in the 
immunoliposome sample. 0.06 mg/mL unbound antibody was found in supernatant 
1 and 0.02 mg/mL is supernatant 2 after two steps of ultracentrifugation showing a 
53% recovery of the antibody. Approximately 0.54 mg/mL of antibody was lost 
during the preparation procedure indicating that the reverse-phase evaporation 
(REV) method is not a very efficient method for immunoliposome preparation.  
 
 
Optimization of Liposome and Immunoliposome Preparation 
 138 
3.2.4 Fluorescently-labelled immunoliposomes – co-incubation method for 
immunoliposome preparation 
The co-incubation method for immunoliposome preparation was performed (section 
2.2.3.4) and compared with the reverse phase evaporation method. For optimization 
of this preparation procedure Rituximab monoclonal antibodies were used, as they 
were kindly donated by the Mater Misericordiae Hospital for use for research 
purposes. Rituximab is a chimeric monoclonal antibody that binds to CD20 which is 
primarily found on B cells (Reff et al., 1994). The interaction of Rituximab was first 
tested with RAMOS (human Burkitt’s lymphoma) and L428 (Hodgkin’s disease-
derived) cell lines by flow cytometry to determine their suitability for use in 
immunoliposome binding studies. 
 
3.2.4.1 Determination of positive/negative cell lines for Rituximab monoclonal 
antibody binding 
Binding of the Rituximab monoclonal antibody to RAMOS (human Burkitt’s 
lymphoma) and L428 (Hodgkin’s disease-derived) cells were tested by flow 
cytometry, as described in section 2.2.4. RAMOS and L428 cells (106) were 
incubated with 1 µg/mL, 5 µg/mL, and 10 µg/mL of Rituximab for 30 min at 4ºC. The 
cells were then washed with PBS, pH 7.4, and incubated with a 1:2,000 dilution of 
Cy5 labelled-anti-human IgG secondary antibody for 30 min at 4ºC. Cells were 
washed three times with FACS buffer (0.1 M PBS, pH 7.4; 2% (v/v) FBS; 0.05% 
(w/v) NaN3) and immediately analyzed on a FACS Calibur instrument  
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Figure 3.5 FACS analyses of RAMOS (human Burkitt’s lymphoma) and L428 
(Hodgkin’s disease-derived) cell lines for CD20 protein expression. 
RAMOS and L428 cell lines were treated with 10 µg/mL, 5 µg/mL, 1 µg/mL of 
Rituximab antibody. A 1:2,000 dilution of anti-human IgG-Cy5 conjugated was used 
as the secondary antibody. 
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No binding was observed using 1 µg/mL, 5 µg/mL or 10 µg/mL of Rituximab 
antibody with the L428 cell line (Figure 3.5). The RAMOS cell line was positively 
stained using these three different Rituximab concentrations. Thus, it was shown 
that the RAMOS cell line is CD20-positive and L428 is CD20-negative. 
 
3.2.4.2 Preparation and purification of fluorescently-labelled Rituximab-
conjugated-liposome  
The procedure was in details described in detail in section 2.2.3.4. Briefly, 64.5 
mol% of egg PC, 30 mol% of cholesterol, 3 mol% of DSPE-PEG-COOH and 0.5 
mol% of rhodamine-PE was used to prepare a lipid film (Table 3.1). The lipid film 
was hydrated using 1 mL of 0.1 M PBS, pH 7.4 and vortexed. It was then extruded 
through a 100 nm polycarbonate membrane for liposome generation.  
The Rituximab antibody (0.6 mg) was conjugated to 2 mol% of DSPE-PEG-COOH 
by firstly esterifing the DSPE-PEG-COOH using DCC and NHS. A forty molar 
excess of this esterified lipid was conjugated to the Rituximab monoclonal antibody 
by incubation in 0.1 M PBS, pH 8.5, overnight at 4°C. This Rituximab-conjugated-
phospholipid solution was dialyzed using 3,500 Da dialysis tubing against 0.1 M 
PBS, pH 7.4 for  2 h to remove DMSO, in which esterified lipid was resuspended 
and subsequently co-incubation with the previously prepared liposomes overnight at 
4°C. Liposomes were composed of 64.5 mol% egg PC, 30 mol% cholesterol,           
3 mol% DSPE-PEG-COOH, 0.5 mol% rhodamine-PE and prepared by lipid film 
hydration followed by extrusion through 100 nm polycarbonate membrane 
Fluorescently-labelled-liposomes were dialyzed against PBS, pH 7.4, (‘cut-off’ 
300,000 Da) for 2 days at 4°C to remove unbound antibody. 
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3.2.4.3 FACS analyses of fluorescently-labelled Rituximab-conjugated-
liposomes 
Fluorescently-labelled Rituximab-conjugated-liposomes (0.1 mg/mL of lipids) were 
incubated with 106 RAMOS and L428 cells for 1 h at 37ºC in serum-free medium. 
Cells were washed 3 times with 0.1 M PBS, pH 7.3 and resuspended in FACS buffer 
(0.1 M PBS, pH 7.4; 2% (v/v) FBS; 0.05% (w/v) NaN3) and immediately analyzed. 
Avastin®-conjugated-liposomes were used as a negative control and were prepared 
using the co-incubation method. Avastin® is a humanized monoclonal antibody 
which recognizes and blocks VEGF-A (vascular endothelial growth factor-A) (Los et 
al., 2007). 
It had previously been determined that Avastin® antibodies did not bind to either 
RAMOS or L428 cells (personal communication, Ferdia Bolster). 
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Figure 3.6 In vitro studies demonstrating specific binding of antibody-
conjugated-liposomes to cells expressing the associated target antigen.  
Fluorescent liposomes conjugated with either Rituximab, Avastin® (negative control 
antibody) or no antibody (blank lipo) was incubated with RAMOS and L428 cell 
lines. Analyses were performed in triplicate and the results were normalized for 
comparison purposes with blank liposomes and Avastin®-antibody-conjugated-
liposomes. 
The results are the mean ± the standard deviation and the experiment was 
performed in triplicate.  
* Significantly different from control (Avastin®-conjugated-liposomes) (Student’s t-
test, 0.01<p<0.05 
 
Fluorescence obtained from both cell lines after incubation with blank liposomes 
was taken as 1. Based on this, fluorescence of other samples was calculated 
(Figure 3.6). The RAMOS cell line bound Rituximab-conjugated-labelled-liposomes 
to 2.5 much larger degree than the L428 cell line. Using Student’s t-test there was a 
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significant difference (0.001<p<0.01) in fluorescence between Avastin®-conjugated-
liposomes (negative control) and Rituximab-conjugated-liposomes which bound to 
the RAMOS cell line. This shows that the Rituximab-labelled liposomes bound 
specifically to the RAMOS cell line. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Optimization of Liposome and Immunoliposome Preparation 
 144 
Discussion 
In this study, liposomes and antibody-conjugated (immuno)-liposomes were 
produced containing 5 mol% (w/v) PEGylated phospholipid. PEG content between 
5-10 mol% was used as it was found to be sufficient to prolong circulation life-time in 
vivo and prevent liposome opsonization by the reticuloendothelial (RES) system 
(Klibanov et al., 1990). The optimum cholesterol concentration for long-term 
circulating liposomes was 30 mol% or more. Therefore, 30 mol% of cholesterol was 
used for liposome and immunoliposome preparation (Bedu et al., 1996). Cholesterol 
acts as a spacer between the phospholipids of the liposome membrane thus 
reducing PEG chain-chain interactions (Strijkers et al., 2005). 
Immunoliposomes were prepared using two separate methods, reverse-phase 
evaporation and co-incubation. In both cases, antibody was coupled to the terminal 
end of the PEG chain, which contained a carboxylic acid group, to increase antibody 
accessibility to cancer cells. The term immunoliposome was coined to describe a 
liposome conjugated to an antibody or portions of an antibody (Siwak et al., 2002). 
Maruyama et al. (1995) showed that liposomes which contained antibody attached 
to PEG demonstrated improved binding to their target when compared to liposomes 
combined with antibody attached directly to the lipid bilayer. The main aim of this 
research was to conjugate anti-CD138 antibodies to liposomes, because CD138 
was determined to be a good marker for myeloma, due to its expression on majority 
of malignant plasma cells in bone marrow (Wijdenes et al., 2002). Ultimately, anti-
CD138 antibodies will be used, however, due to the high cost of anti-CD138 
antibodies, Herceptin, 2C5 and Rituximab were used during the optimisation steps 
for liposome generation.  
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During this project, the REV method was used for Herceptin®-conjugated-
liposomes. This method allows the preparation of liposomes having by a high 
aqueous space to lipid ratio and facilitates entrapment of large quantities of material 
(Szoka and Parahadjopoulos, 1978). In Herceptin®-conjugated-liposomes prepared 
by the REV method 0.89 mg/mL of antibody was conjugated. Thus, it was found that 
the REV method was effective for immunoliposome preparation. The main drawback 
of this method is the exposure of the antibody to an organic solvent, which may lead 
to its denaturation. Secondly, the REV method leads to unpredictible and 
heterogenous size distribution of liposomes (between 100-1000 nm) (Duzgunes, 
1983).  However, this could be overcome by filtration through a 200 nm filter, which 
gives a more uniform vesicle population of between 120-300 nm with no loss of 
lipids (Szoka and Papahadjopoulos, 1978). 
In comparison to the REV method, the co-incubation method does not involve any 
solvent usage, thus removing issues off potential antibody denaturation. Erdogan et 
al. (2006) successfully prepared 2C5-conjugated-liposomes using the co-incubation 
method and successfully targeted them for in vitro and in vivo studies (Erdogan et 
al., 2008). In this research, it was found that liposomes conjugated with 2C5 
antibody showed an increase in size and a decrease in zeta potential. Singh et al. 
(1996) also noticed an increase in liposome size after antibody conjugation from 195 
to 259 Å. Mayer et al. (1998) demonstrated that after adding PEG-PE in liposome 
preparation, the zeta potential decreased from 25-30 mV to 7-10 mV, due to the 
negative charge of the PEG-PE.  
The binding ability of Rituximab-conjugated-liposomes (immunoliposomes), 
prepared by co-incubation method was tested in vitro. Rituximab is a monoclonal 
antibody which recognizes CD20 protein primarily found on B cells. Lapalombella et 
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al. (2008) prepared Rituximab-liposomes with encapsulated oligonucleotides to 
target CLL (chronic lymphocytic leukaemia). They found that the CD20 surface 
antigen internalization enhanced delivery of an oligonucleotide incorporated into 
anti-CD20-conjugated-liposomes.  
In this study, FACS analyses were performed to assess the success of 
immunoliposome targeting. Rituximab-conjugated-liposomes were successfully 
targeted to the CD20-expressing RAMOS cell line to a significantly greater extent 
than to control liposomes with a non-specific antibody-conjugated and in comparison 
to blank liposomes (no-conjugated antibody-liposomes). 
The results reported in this chapter signify that the methodology for 
immunoliposome preparation was successfully developed. Reverse phase 
evaporation and co-incubation methods are both efficient for targeted-liposome 
preparation. However, because of a few drawbacks associated with the REV 
method described above, the co-incubation method will be used for CD138-
liposome preparation to be described in Chapters 4. 
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4.1 Introduction 
Human multiple myeloma is as yet an incurable malignancy of B plasma cells in 
bone marrow. The current diagnostic method of this cancer is invasive biopsy, which 
is painful for the patient. Also, diagnosis is often too late to enhance patient survival. 
The main aim of this project was to prepare an applicable minimally non-invasive 
diagnostic tool for faster diagnosis of multiple myeloma in humans, which would, in 
turn, improve patient prognosis. It should be a novel minimally non-invasive 
diagnostic method for multiple myeloma in humans.The principal aim of this chapter 
was to describe the binding ability of targeted nanoparticles (anti-CD138-
fluorescently-labelled liposomes) to human multiple myeloma cancer cells in vitro.  
Human multiple myeloma is a cancer of plasma cells. Myeloma starts when plasma 
cell becomes abnormal and starts to proliferate repeatedly. Over time, as the cancer 
develops, plasma cells become detectable in the blood and the cancer can spread 
to ‘multiple’ site in the body, hence the name multiple myeloma (MM). MM is a 
malignancy that accounts for slightly more than 10% of all haematological 
malignancies (Kyle et al., 2004). It usually evolves from an asymptomatic pre-
malignant stage of clonal plasma cell proliferation called ‘monoclonal gammopathy 
of undetermined significance’ (MGUS) (Kyle et al., 2002). In some other patients, an 
intermediate asymptomatic but more advanced premalignant stage, referred to as 
‘smoldering multiple myeloma’ (SMM) is clinically recognized (Kyle et al., 2007). 
Wijdenes et al., (1996) reported that CD138 (syndecan-1) is a good marker for 
human multiple myeloma cancer using B-B4 monoclonal anti-CD138 antibodies in 
routine malignant bone marrow section. Luque et al. (1998) also reported the 
presence of overexpressed CD138 protein on malignant B cells in peripheral blood 
in multiple myeloma patients. The protein bears heparan sulfates and sometimes 
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chondroitan sulfates. The ectodomain contains five putative glycosaminoglycan 
(GAG) attachment sites, and a putative protease cleavage site at its C-terminus 
(Bernfield et al., 1992). Hence, anti-CD138-targeted immunoliposomes were used 
as a diagnostic agent for human multiple myeloma malignancy. Immunoliposomes 
are commonly used particles to target different malignancies. Erdogan et al. (2006) 
successfully targeted pegylated 2C5-liposomes, containing gadolinium ions, to 
target murine Lewis lung carcinoma (LLC) and human mammary adenocarcinomas 
(MCF-7, BT20) in vitro and to LLC in vivo (Erdogan et al., 2008).  
This chapter describes the physical characterisation of anti-CD138-conjugated-
liposomes as well as the binding ability of anti-CD138-conjugated-liposomes to 
human multiple myeloma cell lines in vitro. The binding characteristics of targeted 
anti-CD138-conjugated-liposomes to cancer cell lines were studied using FACS and 
FLISA analyses.  
To estimate the cell binding ability of immunoliposomes, in vitro binding studies were 
performed. Three cell lines (U266, RPMI8226 and L428) were used. U266 and 
RPMI8226 are human multiple myeloma cells and L428 is a Hodgkin’s disease-
derived cancer cell line. It was shown that the Hodgkin’s disease-derived cell line, 
L428, does not express CD138 protein on its surface. 
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4.2 Results 
4.2.1 Evaluation of CD138 surface expression on U266 and RPMI8226 human 
multiple myeloma cell lines and L428 Hodgkin’s disease-derived cancer cells 
In order to check CD138 protein expression level on U266 and RPMI8226 human 
multiple myeloma cancer cell lines, flow cytometry was performed. It was expected 
that both cell lines would express CD138 protein on the surface, because both are 
malignant plasma cells. U266 is an IgE- whereas RPMI8226 is an IgG-secreting 
myeloma. These two different human multiple myeloma cell lines (2x106 cells) were 
incubated with 0.25 µg/mL of FITC-labelled anti-human CD138 antibody from clone 
B-A38 (AbD Serotec). A FITC-labelled mouse IgG1κ isotype control, clone MOPC-21 
(AbD Serotec) was also incorporated. Incubation was carried out for 30 min at 4°C. 
After washing with 0.1 M PBS, pH 7.4, samples were analyzed using the FACS 
Calibur instrument. Fluorescence data were collected and analysed using CellQuest 
software (Becton Dickinson). 
 
Targeted anti-CD138 (Syndecan-1)-liposomes and in vitro studies 
 151 
 
Figure 4.1 Estimation of CD138 protein expression levels on cells.  
FACS analyses of U266 and RPMI8226 human multiple myeloma cell lines. 1) 
RPMI8226 + FITC-labelled IgGκ isotype control; 2) RPMI8226 + FITC-labelled-anti-
human CD138 antibody 3) U266 + FITC-labelled IgGκ isotype control; 4) U266 + 
FITC-labelled-anti-human CD138 antibody. The U266 human multiple myeloma 
showed 84.3% staining with anti-human CD138 antibodies wherease RPMI8226 
showed 4.6% of staining. 
 
It was estimated that the expression levels of CD138 protein was 84.2 % on the 
U266 human multiple myeloma cell line and 4.6 % on the RPMI8226 cell line (Figure 
4.1). The experiment was repeated with U266 and RPMI8226 human multiple 
myeloma cell lines and the L428 Hodgkin’s disease-derived cell line. The aim of this 
experiment was to find a negative cell line which does not express CD138 protein on 
the surface. The same concentration of FITC-labelled anti-human CD138 antibody 
was tested on these cancer cell lines.  
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Figure 4.2 Estimation of CD138 protein level on cells (1).  
U266, RPMI8226 and L428 cell lines were incubated with anti-human CD138:FITC 
labelled antibodies. Mouse IgG κ isotype:FITC antibody was used as a control. 
U266 multiple myeloma cells demonstrated much higher staining with anti-CD138 
antibodies than RPMI8226 or L428 cell lines. 
 
Cancer cell lines without incubation with any antibody and cells incubated with 
isotype control antibody were used as negative controls. Each cell line has its own 
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fluorescence (autofluorescence). However, cells incubated with isotype control 
antibody is the appropriate negative control. It was confirmed that U266 cell line 
expresses CD138 at a very high level, whereas RPMI8226 expresses CD138 in 
much lower amounts. The L428 Hodgkin’s disease-derived cell line does not 
express any CD138 protein on its surface as no additional fluorescence was 
observed compared to cells incubated with isotype control antibodies (Figure 4.2). 
The results were normalized and are presented in Figure 4.3. 
 
Figure 4.3 Estimation of CD138 protein level on cells (2).  
U266, RPMI8226 and L428 cell lines were tested to determine CD138 protein 
expression levels. U266 cells express CD138 protein at a much higher level than 
RPMI8226. It was found that L428 does not express CD138 protein on the surface. 
Mouse IgG κ isotype:FITC antibody was used as an isotype control.  
It was estimated using Student’s t-test that there was a significant difference (p 
value<0.05) between U266 cells incubated with isotype control antibody and U266 
cells incubated with anti-CD138:FITC antibody. The results are the mean ± the 
standard deviation and the experiment was performed in triplicate. 
*** Significantly different from control (mouse IgG κ isotype:FITC antibody) 
(Student’s t-test, p<0.001) 
 
It was estimated that there was a significant difference (p<0.001) between U266 
human multiple myeloma cancer cells incubated with mouse IgG κ isotype:FITC 
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antibody and with anti-CD138 antibody in the level of fluorescence detected. There 
was not a significant difference between other groups.  
 
4.2.2 Preparation of fluorescently-labelled anti-CD138-conjugated-liposomes - 
Reverse Phase Evaporation (REV) method 
Fluorescently labelled-anti-CD138-conjugated-liposomes were prepared using the 
reverse-phase evaporation (REV) method, as described in section 2.2.3.3. 
The immunoliposome formulation used is outlined in Table 4.1. 60 mol% of DSPC, 
30 mol% of cholesterol, 0.1 mol% of rhodamine-PE and 9.9 mol% of DSPE-PEG-
COOH was used for the preparation of the fluorescently-labelled anti-CD138-
conjugated-liposomes. An estimated 0.22 mg of esterified lipid was used for 
conjugation to 0.2 mg of anti-CD138 antibody. Immunoliposomes were 
ultracentrifuged two times to remove unbound antibody (section 2.2.3.5). After 
ultracentrifugation immunoliposomes were re-extruded. 
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Table 4.1 Lipids used for anti-CD138-conjugated-liposome preparation. 
Compound Molecular 
weight 
[g] 
Weight used [mg] Moles Molar ratio of 
lipid to other 
lipids 
DSPC 790.12 4.50 5.70*10-6 60 mol% (1) 
Cholesterol 386.65 1.10 2.85*10-6 30 mol% (0.5) 
DSPE-PEG-
COOH 
 2847.78 2.68 9.40*10-7 9.9 mol% 
(0.17) 
Rhodamine-PE  1176.93 0.01 9.46*10-9 0.1 mol% 
(0.002) 
TOTAL                                  8.29 
 
4.2.2.1 Size and zeta potential determination using Photon Correlation 
Spectroscopy (PCS) 
It was found that the average size of the prepared anti-CD138-conjugated-liposome 
was 99.05 nm in diameter with a polydispersity index (PDI) of 0.055 (Figure 4.4) 
using the HPPS Malvern/Zetasizer. Size measurement was determined in triplicate. 
Figure 4.4 Size distribution by intensity plot for a liposome sample (Z-Avg = 
99.05 nm, PDI = 0.055).  
Average size of liposomes in solution was 99.05 nm with low polydispersity index 
(PDI), which indicates a monodisperse solution. 
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Photon Correlation Spectroscopy (PCS) also provides zeta potential information. 
The zeta potential number of anti-CD138-conjugated-liposomes was -38 mV, which 
indicates good particle stability (Figure 4.5). Colloids with high zeta potential 
(negative or positive; more than ±30) are electrically stabilized while colloids with 
low zeta potentials tend to coagulate or flocculate (ASTM Standard D, 1985). 
Figure 4.5 Zeta potential distribution of the anti-CD138 conjugated-liposomes.  
The zeta potential of anti-CD138-conjugated-liposomes was -38 mV. 
 
 
4.2.2.2 Protein determination in anti-CD138-conjugated-liposomes 
Anti-CD138-conjugated-liposomes were prepared using the reverse-phase 
evaporation method (REV). These immunoliposomes (IL) were purified from free 
antibodies by ultracentrifugation, as described in section 2.2.3.5. Samples were 
analyzed for protein content using the micro Lowry assay with Peterson’s 
modification (section 2.2.3.8).  
A calibration curve was drawn and used to determine protein concentration in the 
relevant samples. Approximately 103 µg/mL of antibody was found to be present on 
prepared immunoliposomes and approximately 24.32 µg/mL unbound anti-CD138 
antibody was found in supernatant S1 (Figure 4.6). 
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Figure 4.6 Determination of antibody concentration in anti-CD138-conjugated-
liposomes after ultracentrifugation.  
200 µg/mL of anti-CD138 antibody was used for immunoliposome preparation. Each 
preparation of anti-CD138-conjugated-liposomes was ultracentrifuged to remove 
free antibody and supernatants were collected (S1-supernatant 1; S2-supernatant 
2). It was estimated that there was 103.18 µg/mL of anti-CD138 antibody attached to 
liposomes. It was found that there was 24.32 µg/mL of unbound anti-CD138 
antibody in S1 and 0 µg/mL in S2. 
 
 
4.2.2.3 Calculation of the number of antibody molecules per liposome 
FIRST APPROACH: 
The number of antibody molecules coupled per liposome was calculated based on 
the measured concentration (CAB) of antibody (grams per mol of lipid) and diameter 
of the immunoliposomes (R). The assumption was that liposomes are approximately 
spherical. From this and literature values for specific volume (VLs) of 1.25 nm
3, bilayer 
thickness (db1) of 3.7 nm (Enoch and Strittmatter, 1979) and the molecular mass of 
the antibody (MAb) of 150 kDa, the number of antibodies-coupled to the liposome was 
calculated according to the formula below (Adrian et al., 2007):  
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n = Π/6 * CAB * (3db1 * R
2 - 3R * db1
2 + db1
3) * MAB
-1 * VLs
-1 
where, 
CAB is the concentration of antibody in immunoliposomes [g/mol of lipids] 
db1 is the liposome bilayer thickness, which is 3.7 [nm] 
R is the liposome diameter 
MAB is the molecular mass of antibody, which is 150,000 Da 
VLs is the literature value for specific lipid volume, which is 1.25 nm
3 
 
Anti-CD138-conjugated-liposomes were characterised by determining protein content 
using the micro Lowry assay with Peterson’s modification. It was determined that in 
prepared immunoliposomes 103 µg/mL of antibody was present. The diameter of 
prepared immunoliposomes was found to be 99 nm. 
To identify the CAB value, antibody concentration was converted from µg/mL to 
antibody/mol of lipids. To do this, the molar concentration of lipids in liposomes was 
initially calculated as follows: 
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After adding all molar concentrations of lipids, it was found that the total 
molar lipid concentration was 4.75 mM. 
To determine the amount of antibody present, the following calculations were carried 
out: 
103.18 µg Ab  1 mL 
103.18 * 10-3 g of Ab  1,000 mL (1 L) 
103.18 * 10-3 g of Ab  4.75 * 10-3 mole of lipids 
21.72 g of Ab / 1 mole of lipids 
In this way, the concentration of antibody (CAB) was calculated to be 21.72 g of 
antibody per 1 mole of lipids. 
 
The number of antibodies coupled to the liposome, according to formula mentioned 
above, was calculated as follows: 
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No. Ab / 1liposome = 3.14 / 6 * 21.72 (3 * 3.7 * (99)2 – 3 * 99 * (3.7)2 + (3.7)3) * 1 / 
150,000 * 1 / 1.25 = 6.3 Ab / liposome 
 
This is equivalent to ~6-7 antibodies per liposome. 
SECOND APPROACH: 
In this approach it was assumed that the size of an immunoliposome was 99 nm and 
that it was unilamellar. 
To calculate antibody numbers per liposome, firstly the number of lipid molecules in 
the liposome and number of liposomes per 1 mL of solution has to be calculated 
(Hutchinson et al., 1989). 
The number of lipid molecules in the unilamellar liposome was calculated according 
to the Equation 1: 
 
N tot =  
 
where, 
4 Π (d / 2) 2 is the surface area of the “monolayer” of the liposome, assuming it is   
spherical 
d is the diameter of the liposome 
a is the lipid head group area and 
h is the thickness of the bilayer (~ 5 nm) 
 
[ 4 Π (d / 2) 2 + 4 Π [ d / 2 – h ] 2  
 
a 
            Equation 1 
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Table 4.2 Dimension of lipid head groups. 
Lipid Component Area [nm2] 
DSPE-PEG Head group 9 
PC Head group 0.75 
Cholesterol Head group  0.029 
 
Cholesterol makes a negligible contribution to the surface area occupied by polar 
head groups because of its small size (0.029 nm2) (Table 4.2). The only polar 
functional group on cholesterol is the single hydroxyl group. 
It was decided to take 60 mol% DSPC and 9.9 mol% DSPE-PEG-DSPE-COOH for 
immunoliposome preparation. 
  
a = 1.34 [nm2] 
In the above equation the surface area of both monolayers in a unilamellar 
liposome are added together. Then the total lipid area is divided to the average of 
head group area of DSPC and DSPE-PEG-COOH lipid molecule. 
For unilamellar liposomes, which are 100 nm in diameter and with 5 nm of bilayer 
thickness, above equation is simplified to: 
 
N tot =  
 
              0.75 [nm2] * 60 mol% + 9 [nm2] * 9.9 mol% 
                100 mol% 
a = 
          1.35 [nm2] 
 
    42,381 lipids / liposome 
 
= 
4 Π * 2500 [nm2] + 4 Π * 2025 [nm2] 
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It was estimated based on Equation 1 that there are 42,381 lipids per single 
liposome. 
Ntot = 42,381 lipids / liposome 
 
The number of liposomes in 1 ml of solution was calculated according to Equation 
2: 
 
N liposomes  =  
 
where, 
N liposomes is the number of liposomes in 1 mL of solution 
M lipid  is the molar concentration of lipid 
Ntot is the total number of lipids per liposome (section 3.2.5) 
NA is Avogadro’s number which is equal to 6.02*10
23 particles 
For immunoliposome preparation, 60 mol% of DSPC, 30 mol% of cholesterol, 9.9 
mol% of DSPE-PEG-COOH and 0.1 mol% of Rhodamine-PE were used. The total 
amount of lipids used was 8.29 mg (Table 2.8 in section 2.6.3.2). Finally, liposomes 
were suspended in 2 mL of 0.1 M PBS, pH 7.4.  
To find out, how many liposomes are in 1 mL of solution, the molar concentration of 
lipids had to be calculated first, as follows: 
 M lipid × NA 
 
 N tot × 1000 
            Equation 2 
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where, 
Cm is the molar concentration 
n is the moles number 
ms is amount of lipid taken for preparation 
M is the molecular weight of lipid 
V is the volume of the suspension 
After adding all lipid molar concentrations, a total molar lipid concentration of 4.75 
mM was determined. 
The amount of liposomes in 1 mL of solution (N liposomes) was calculated as follows: 
 
 
One molecule of whole antibody has a molecular weight of 150 kDa. Antibody 
concentration in purified immunoliposomes was previously determined to be 141.88 
 4.75 * 10-3 * 6.02 * 1023  
                                                           
       42,381.1 * 1000 
Nliposomes  = = 6.74 * 10
13 liposomes / mL 
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µg/mL. Based on this, it can be calculated that in the anti-CD138-conjugated 
liposomes solution there was 9.5*10-10 moles of antibody.  
 
1 mole of Ab is equivalent to 150,000 g/L, therefore 
103.18*10-6 g/L = x moles of Ab in immunoliposomes 
x = 6.8 * 10-10 mole of Ab in immunoliposomes 
This number has to be multipled by Avogadro’s number. It was estimated that in 1L 
solution there are 5.69*1014 antibodies. 
 
6.8 * 10-10 mole of Ab * 6.02*1023 = 4.09 * 1014 antibody molecules 
 
To find out how many antibody molecules are present on one liposome, 4.09 * 1014 
antibody molecule number has to be divided by number of liposomes in solution 
(6.07 * 1013 liposomes; section 3.2.6). 
 
 
Based on this, it was calculated that there were ~ 6-7 antibody molecules per 
liposome. This is similar to the previous number calculated using another approach. 
This confirms that the two approaches produce the same value and hence that it 
does not matter if the calculation is based on the volume or on the surface area of the 
bilayer. The AB/liposome value obtained is effectively determined by CAB and is 
subject to the assumption that the preparation is quantitative. 
4.09 * 1014 (number of antibodies) 
      6.07 * 1013  (number of liposomes) 
= 6.74 Ab / 1 liposome 
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4.2.2.4 Cell binding experiment - FLISA (Fluorophore - Linked Immunosorbent 
Assay) for fluorescently-labelled anti-CD138-conjugated-liposomes (REV 
method) 
Fluorophore-Linked Immunosorbent Assay (FLISA) was performed to characterise 
fluorescently-labelled anti-CD138-conjugated-liposomes, prepared by the REV 
method. 
Fluorescently-labelled immunoliposomes were incubated with a human multiple 
myeloma cell lines (U266 and RPMI8226) according to the procedure described in 
section 2.2.3.9. Different concentrations of immunoliposomes were incubated with 
106 human multiple myeloma cells.  
 Figure 4.7 Binding of fluorescently-labelled anti-CD138-conjugated liposomes 
to human multiple myeloma cell lines (U266 and RPMI8226).  
The anti-CD138-conjugated-liposomes used in this assay were prepared using the 
REV method. Different dilutions of anti-CD138-conjugated-liposomes were 
incubated with the cancer cell lines in vitro. 
 
The higher fluorescence observed after incubation of immunoliposomes with U266 
human multiple myeloma cells, shows better binding compared to the RPMI8226 
cell line. It was calculated that there were ~ 6-7 anti-CD138 antibodies present on 
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each liposome. As a negative control multiple myeloma cell lines (U266 and 
RPMI8226) were incubated with fluorescently-labelled blank liposomes (plain 
liposomes; without antibody). Fluorescence obtained from cell lines incubated with 
plain liposomes was subtracted from fluorescence obtained from cell lines incubated 
with fluorescently-labelled anti-CD138-conjugated-liposomes. Fluorescence was 
measured using the Tecan Safire 2 spectrophotometer (excitation 540 nm; emission 
625 nm). 
 
4.2.3 Fluorescently-labelled anti-CD138-conjugated-liposomes - co-incubation 
method for immunoliposome of production 
Fluorescently-labelled anti-CD138-conjugated-liposomes were prepared using the 
co-incubation method, as described in section 2.2.3.4. This method of 
immunoliposome preparation was performed to compare it with the reverse-phase 
evaporation method.  
A lipid film was created using 64.5 mol% of egg PC, 30 mol% of cholesterol, 3 mol% 
of DSPE-PEG-Metoxy and 0.5 mol% of rhodamine-PE (Table 4.3). The lipid film was 
hydrated with 1 mL 0.1 M PBS, pH 7.4, by vortexing and sonicating for 30 min in a 
water-bath at 25ºC. The liposomes were extruded through a 100 nm polycarbonate 
membrane and co-incubated with DSPE-PEG-CO-NH-anti-CD138 antibody overnight 
at 4ºC. Monoclonal anti-CD138 antibody (0.2 mg) and a 40 molar excess of esterified 
DSPE-PEG-COOH lipid (2 mol%) were used. The total amount of lipids used for anti-
CD138-conjugated-liposome preparation was 2.04 mg. 
 
 
Targeted anti-CD138 (Syndecan-1)-liposomes and in vitro studies 
 167 
Table 4.3 Anti-CD138-conjugated-liposome lipid formulation.  
The following lipids were used in defined molar ratios for immunoliposome 
preparation.  
Compound Molecular 
weight 
[g] 
Weight used [mg] Moles Molar ratio of 
lipid to other 
lipids 
Egg PC 790.12 1.33 1.68*10-6 64.5 mol% (1) 
Cholesterol 386.65 0.31 8.02*10-7 30 mol% 
(0.47) 
DSPE-PEG-
Metoxy 
 2805.54 0.23 8.20*10-8 3 mol%  (0.05) 
Rhodamine-
PE 
 1176.93 0.02 1.70*10-8 0.5 mol%  
(0.01) 
DSPE-PEG-
COOH 
 2847.78 0.16 5.62*10-8 2 mol% (0.03) 
TOTAL                                  2.04 
 
First fluorescently-labelled liposomes were prepared and then co-incubated with      
2 mol% of DSPE-PEG-COOH conjugated with anti-CD138 monoclonal antibody. 
Fluorescently-labelled liposomes (blank liposomes; with no-conjugated antibody) 
were prepared as a negative control. The following lipids were used in defined molar 
ratios for liposome preparation. Liposomes were prepared by lipid film formation and 
hydration using 1 mL 0.1 M PBS, pH 7.4. 64.5 mol% of egg PC, 30 mol% of 
cholestrol, 5 mol% of DSPE-PEG-Metoxy and 0.5 mol% of rhodamine-PE were used 
for the two described formulations (Tables 4.3 and 4.4).  
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Table 4.4 Formulation for generation of fluorescently-labelled liposomes.  
Compound Molecular 
weight 
[g] 
Weight used [mg] Moles Molar ratio of 
lipid to other 
lipids 
Egg PC 790.12 4.00 5.06*10-6 64.5 mol% (1) 
Cholesterol 386.65 0.94 2.35*10-6 30 mol% 
(0.47) 
DSPE-PEG-
Metoxy 
2805.54            1.14 4.07*10-7 5 mol% (0.01) 
 
Rhodamine-PE 1176.93 0.05 4.33*10-8 0.5 mol% 
(0.01) 
TOTAL                                  6.14 
 
 
4.2.3.1 Protein determination in anti-CD138-conjugated-liposomes 
Anti-CD138-conjugated-liposomes were prepared using the co-incubation method. 
Immunoliposomes (IL) were purified from free antibodies by dialysis, through 
300,000 Da membrane, as described in section 2.2.3.6. Samples were analyzed 
using the micro Lowry assay with Peterson’s modification (section 2.2.3.8).  
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Figure 4.8 Determination of antibody concentration in anti-CD138-conjugated- 
liposomes after dialysis.  
200 µg/mL of anti-CD138 antibody was used for immunoliposome preparation using 
the co-incubation method. It was estimated that there was 122.5 µg/mL of anti-
CD138 antibody attached to liposomes.  
 
A calibration curve was drawn and used to determine protein concentration in the 
samples. Approximately, 122.5 µg/mL of antibody was found to be present on the 
prepared immunoliposomes (Figure 4.8). It was found that 77.5 µg/mL of anti-
CD138 antibody did not bind to liposomes and was removed from the 
immunoliposome sample by dialysis. The effectiveness of antibody coupling was 
61.25%.  
 
4.2.3.2 Calculation of the number of lipid molecules per liposome 
Previously, the number of antibodies bound to liposomes prepared using REV 
method was calculated (section 4.2). This process was repeated for the co-incubation 
approach.  
In this approach it was assumed that the size of an immunoliposome was 100 nm 
and that it was unilamellar. 
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To calculate antibody numbers per liposome, firstly the number of lipid molecules in 
the liposome and number of liposomes per 1 mL of solution had to be calculated 
(Hutchinson et al., 1989). 
The number of lipid molecules in the unilamellar liposome was calculated according 
to Equation 1: 
 
N tot =  
 
where, 
4 Π (d / 2) 2 is the surface area of the “monolayer” of the liposome, assuming it is   
spherical 
d is the diameter of the liposome 
a is the lipid head group area and 
h is the thickness of the bilayer (~ 5 nm) 
 
Table 4.5 Dimension of lipid head groups. 
Lipid Component Area [nm2] 
Egg PC Head group 0.75 
DSPE-PEG Head group 9 
PE Head group 0.37 
Cholesterol Head group  0.029 
 
[ 4 Π (d / 2) 2 + 4 Π [ d / 2 – h ] 2  
 
a 
            Equation 1 
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Cholesterol makes a negligible contribution to the surface area occupied by polar 
head groups because of its small size (0.029 nm2) (Table 4.5). The only polar 
functional group on cholesterol is the single hydroxyl group. 
64.5 mol% of egg PC, 30 mol% of cholestrol, 5 mol% of DSPE-PEG-Metoxy and 0.5 
mol% of rhodamine-PE were used for immunoliposome preparation. 
 
 
 
a = 0.94 [nm2] 
In the above equation the surface area of both monolayers in a unilamellar 
liposome are added together. Then the total lipid area is divided to the average of 
head group area of DSPC and DSPE-PEG-COOH lipid molecules. 
For unilamellar liposomes, which are 100 nm in diameter with a 5 nm bilayer 
thickness, the above equation is simplified to: 
 
N tot =  
 
It was estimated, based on Equation 1, that there are 60,461 lipids per single 
liposome. 
Ntot = 60,461 lipids / liposome 
The number of liposomes in 1 ml of solution was calculated according to Equation 
2: 
          0.94 [nm2] 
 
60,461 lipids / liposome 
 
==
= 
4 Π * 2500 [nm2] + 4 Π * 2025 [nm2] 
0.75 [nm2] * 64.5 mol% + 9 [nm2] * 5 mol% + 0.37 [nm2] * 0.5 mol%  
                                                           
 
                        
                                         100 mol%  
a  = 
Targeted anti-CD138 (Syndecan-1)-liposomes and in vitro studies 
 172 
 
N liposomes  =  
 
where, 
N liposomes is the number of liposomes in 1 mL of solution 
M lipid  is the molar concentration of lipid 
Ntot is the total number of lipids per liposome (section 3.2.5) 
NA is Avogadro’s number which is equal to 6.02*10
23 particles 
 
For immunoliposome preparation, 64.5 mol% of egg PC, 30 mol% of cholestrol, 5 
mol% of DSPE-PEG-Metoxy and 0.5 mol% of rhodamine-PE were used. The total 
amount of lipids used was 2.05 mg (Table 4.3 in section 4.2.7). Finally, liposomes 
were suspended in 0.5 mL of PBS buffer, pH 7.3.  
 
To find out, how many liposomes are 1 mL of solution, the molar concentration of 
lipids had to be first calculated, as follows: 
 M lipid × NA 
 
 N tot × 1000 
            Equation 2 
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where, 
Cm is the molar concentration 
n is the number of moles of lipid 
ms is amount of lipid taken for preparation 
M is the molecular weight of lipid 
V is the volume of the suspension 
After adding all lipids molar concentrations, a total lipid concentration of 5.32 mM 
was found. 
Then, the amount of liposomes in 1 mL of solution (N liposomes) is calculated as 
follows: 
 
 5.32 * 10-3 * 6.02 * 1023  
                                                           
       60,461 * 1000 
Nliposomes  = = 5.3 10
13 liposomes / mL 
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One molecule of whole antibody has a molecular weight of 150 kDa. Antibody 
concentration in purified immunoliposomes solution was previously determined to be 
122.5 µg/mL. Based on this, it can be calculated that in an anti-CD138-conjugated-
liposome solution 8.2*10-10 moles of antibody are present.  
 
1 mole of Ab is equivalent to 150,000 g/L, therefore 
122.5*10-6 g/L = x moles of Ab in immunoliposomes 
x = 0.82 * 10-9 mole of Ab in immunoliposomes 
This number has to be multipled by Avogadro’s number. It was estimated that in 1L 
solution there are 5.69*1014 antibodies. 
 
8.2 * 10-10 mole of Ab * 6.02*1023 = 49.36 * 1013 antibody molecules 
 
To find out how many antibody molecules are present on one liposome, 4.94 * 1014 
antibody moles has to be divided by number of liposomes in solution   (5.30 * 1013 
liposomes). 
 
 
Based on this, it was calculated that there were ~ 9-10 antibody molecules per 
liposome.  
 
4.94 * 1014 (number of antibodies)  
      5.30 * 1013  (number of liposomes) 
= 9.3 Ab / liposome 
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4.2.3.3 Cell binding experiment – FACS analyses for fluorescently-labelled 
anti-CD138-conjugated-liposomes (co-incubation method) of production 
To characterise fluorescently-labelled anti-CD138-conjugated-liposomes, FACS 
analyses were performed. Anti-CD138-conjugated-liposomes were prepared, as 
described in section 2.2.3.4. A lipid film was prepared from egg PC, cholesterol, 
DSPE-PEG-Metoxy and Rhodamine-PE lipid, hydrated with 1 mL 0.1 M PBS, pH 
7.3, and extruded through a 100 nm polycarbonate membrane.  The liposome 
solution was co-incubated with previously prepared DSPE-PEG-CO-NH-anti-CD138. 
Immunoliposomes were dialysed against 0.1 M PBS, pH 7.3, for 2 days (‘cut-off’ 
300,000 Da) to remove free antibody. 
Five hundred thousand cells from each of the cell lines, RPMI8226, U266 and L428, 
were treated with 0.5 mg/mL of liposomes for 1.5 h at 37 ºC in 'serum-free' medium. 
Cells were washed three times with 0.1 M PBS, pH 7.3, and immediately analyzed 
on the FACS Calibur instrument (Figure 4.9).  
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Figure 4.9 Binding assay of fluorescently-labelled anti-CD138-conjugated-
liposomes in vitro.  
Blank liposomes (Plain lipo; without antibody). Previously, it was estimated that 
U266 expresses CD138 protein at 84.3%. Anti-CD138-conjugated-liposomes (anti-
CD138-lipo) used for this binding experiment were prepared using the co-incubation 
method. The results are the mean ± the standard deviation and the experiment was 
performed in triplicate. 
** Significantly different from control (Blank liposomes) (Student’s t-test, 
0.001<p<0.01) 
 
This experiment clearly demonstrated that fluorescently-labelled anti-CD138-
conjugated liposomes bind to a much greater degree to the U266 myeloma than to 
controls or the other cell lines tested. Results were normalized. Fluorescence levels 
obtained from the three cell lines used after incubation with blank liposomes was 
adjusted to 1. The fluorescence obtained from the other samples was expressed 
relative to this value. It was estimated, using Student’s t-test, that there was a 
significant difference (p value<0.05) between U266 cells incubated with blank 
liposomes and U266 cells incubated with anti-CD138-conjugated-liposomes. 
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Discussion 
The overall objective of this project was to prepare anti-CD138 targeted 
nanoparticles (e.g. anti-CD138-conjugated-liposomes) for use in minimally non-
invasive diagnosis of multiple myeloma using MRI. 
The main aim of this chapter was to describe the preparation of targeted anti-CD138 
(syndecan-1)-conjugated-liposomes by two different methods and determination 
their physical characteristics (size, zeta potential and number of antibody molecules 
linked per liposome). This chapter described also the binding ability of anti-CD138-
conjugated-liposomes to human multiple myeloma cancer cells in vitro. 
It was found that the U266 human multiple myeloma cell line was positively stained 
(84.3%) using anti-CD138, clone B-A38, compared to 2% with the mouse IgG1 
isotype. This is with agreement with other researchers. Sun et al. (2008) performed 
U266 staining with the anti-CD138, clone B-B4, and reported 95.2% positively 
stained cells compared to 5.3% in the mouse IgG1 isotype control. It was found that 
the U266 cell line was an ideal line to examine anti-CD138-conjugated-liposome 
interactions. The specific association of immunoliposomes with their target cells is a 
necessary requirement for the required active targeting strategy. 
Two methods were used for anti-CD138-conjugated-liposomes preparation (reverse 
phase evaporation (REV) and co-incubation method). It was shown using the FLISA 
assay that fluorescent anti-CD138-conjugated-liposomes prepared by the REV 
method bound to the U266 cell line to a significantly greater extent than to the 
RPMI8226 cell line. 
Maruyama et al. (1990) successfully prepared 34A-liposomes for in vivo targeting in 
mice using the REV method. They tested PEGylated immunoliposomes with 
antibody attached to the distal terminus of PEG chain. They assessed that 30 
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antibody molecules were conjugated per liposome. In this study, anti-CD138 
antibody was also conjugated to the terminus of the PEG chain and it was 
determined that 6-7 antibody molecules was linked per liposome (Adrian et al., 
2007). It was determined by the micro Lowry assay with Peterson’s modification 
(Peterson, 1977) that 142 µg/mL of anti-CD138 antibody was conjugated to 
liposomes after initially taking 200 µg/mL of antibody per reaction.   
The co-incubation method was also tested for immunoliposome preparation. 
Erdogan et al. (2006) successfully used the co-incubation method to prepare 
targeted 2C5-liposomes-Gd-loaded PAP to murine Lewis lung carcinoma (LLC) in 
vitro as well as in vivo (Erdogan et al., 2008). Using ELISA, they demonstrated that 
targeted 2C5-conjugated-liposomes bound to a greater extent (more than 2 fold) to 
cancer cells than plain liposomes. 
In this study, it was found that fluorescently-labelled anti-CD138-conjugated-
liposomes bound at a 4.5-fold significantly greater extent to the U266 cell line 
compared to fluorescently-labelled non-targeted liposomes. (i.e. blank liposomes; 
plain liposomes; without antibody) using flow cytometry. It was found that ~ 9-10 
antibody molecules of anti-CD138 antibody were linked per liposome in the co-
incubation method of production. 
Both production methods were effective for immunoliposome preparation which was 
shown by the ability of the antibody-conjugated-liposomes to bind cancer cells in 
vitro (FLISA assay and FACS analyses). However, the main drawback of the REV 
method is the exposure of the antibody to an organic solvent which may lead to 
denaruration of the protein. Secondly, losses of the material during immunoliposome 
preparation are high, which decreases the amount of final product. The co-
incubation method does not involve any solvent usage which prevents significantly 
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antibody denaturation. Preliminary studies indicate that it also results in higher levels 
of antibody attachment. 
FACS analyses were also carried out by other researchers to observe the binding 
ability of immunoliposomes with cells in vitro (Roth el al., 2007; Lopes de Menezes 
et al. 2000; Beduneau et al. 2007; Mamot et al., 2005) indicating the approach used 
is accepted and is recommended as a method used to ensure the association 
between conjugated-liposomes with a relevant antibody and the targeted cells.  
In conclusion, the research in this chapter shows that multiple myeloma cells can be 
targeted by anti-CD138 antibody-conjugated-liposomes to a significant extent. This 
valuable information now leads us to the next step, in which targeted anti-CD138-
conjugated-liposomes can be loaded with paramagnetic contrast agent (e.g. 
gadolinium) and used for a minimally non-invasive diagnostic purpose for human 
multiple myeloma. Both methods (REV and co-incubation) were effective for 
targeted liposome preparation, but because of a few drawbacks associated with the 
REV method, it was decided to work with co-incubation in further experiments. 
The development of this potentially novel diagnostic method will be further described 
in Chapter 5.  
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5.1 Introduction 
The main aim of this chapter was to prepare sufficient contrast agent for minimally 
non-invasive diagnosis of multiple myeloma in humans. The current diagnostic 
method for this cancer involves invasive biopsy, which is painful for the patient. The 
bone marrow section is then immunochemically examined using anti-CD138 
antibodies. Currently, magnetic resonance imaging (MRI) is an established 
minimally non-invasive clinical imaging modality which is capable of producing 
three-dimentional images of tissues containing water with a high degree of spatial 
resolution. MRI relies primarily on registering and interpreting differences in image 
contrast between tissues, normal or pathological, which represent the anatomical 
expression of disease. However, MRI can be also achieved through a combination 
of imaging and active targeting of a contrast agent to disease-specific markers 
enabling minimally non-invasive, specific detection of biochemical markers. Thus, 
molecular, magnetic resonance imaging seeks to improve diagnostic accuracy 
through the visualization of processes or components that cause disease (Lanza et 
al., 2003). There are also different imaging methods like PET (position emission 
tomography) and SPECT (single position emission computed tomography) (Kairemo 
et al., 2008). Each modality has advantages and disadvantages. SPECT and PET 
have high sensitivity (10-11-10-12 mol/L for PET and 10-10-10-11 mol/L for SPECT) but 
low spacial resolution and poor anatomical definition. MRI, in contrast, exhibits good 
spatial resolution but low sensitivity of 10-3-10-5 mol/L. The low sensitivity of MRI 
scans can be overcome by using contrast agents with high relaxivity. These agents 
consist of molecules which incorporate a paramagnetic metal ion, most commonly 
gadolinium (Gd) or iron (Fe). The former class includes a paramagnetic agent, 
mainly Gd, which increase R1 and R2 relaxation rates. However, the best 
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visualization is obtained using T1-weighted images because the percentage change 
in R1 in tissue is much greater than in R2. Superparamagnetic contrast agents (e.g. 
Fe) generally lead to a much larger increase in R2 than in R1 and are best seen with 
T2-weighted scans. Paramagnetic agents directly affect water protons in their close 
vicinity and are highly dependent on local water flux. Hence, the influence of these 
agents is very local and they should ideally be in contact with water with adequate 
exchange rates. In contrast, superparamagnetic agents affect the magnetic field 
independent of their environment and, thus, their influence in terms of contrast 
extends well beyond their immediate surroundings (Lanza et al., 2004). The 
gadolinium-loaded contrast agents currently on the market require a tissue 
concentration of 10-7 mol/g to obtain sufficient contrast in the resulting image (Gupta 
and Weissleder, 1996; Lanza et al., 2004). This level is too high for imaging sparse 
molecular biomarkers expressed in the living body since typical receptors are 
normally present in low concentrations of 10-9 to 10-13 mol/g (Strijkers et al., 2005). 
Therefore, method development is needed to increase the number of Gd moieties 
bound per contrast agent molecule. There have been a number of reports 
concerning the conjugation of Gd chelates to macromolecules such as dendrimers, 
linear polymers, and proteins, as well as the use of liposomes as Gd-chelate carriers 
(Kobayashi et al. 2001; Hueber et al., 1998; Langereis et al. 2004). There are 
different agents which can be used for this purpose e.g. solid lipid nanoparticles, 
liposomes, micelles, nanocrystals, carbon nanotubes. Liposomes were chosen to be 
nanoparticles used to target human multiple myeloma because they are a versatile 
tool used traditionally in drug and gene delivery, and are easly adapted for use in 
vitro, ex vivo and in vivo. The overall liposome properties can be adjusted using 
parameters such as lipid composition, head group charge, and lipid tail size.  
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The traditional method of encapsulating contrast agents, such as the clinically used 
Gd chelates, has the disadvantage that the entrapped agents easily 'leak' out of 
liposomes prior to reaching the target site. This problem can be avoided by chelation 
of Gd with molecules like DTPA-BSA, DOTA-DSA or DTPA-PLL-NGPE that can 
easily be inserted into the bilayer of liposomes. In this way, Gd can be anchored to 
the liposome surface instead of being entrapped in the liposome lumen. 
Kamaly et al. (2008) used bimodal paramagnetic and fluorescent liposomes for 
cellular and human ovarian cancer imaging by enhanced permeation and retention 
(EPR) mechanisms due to the porous nature of the endothelial cell layer. Similarly, 
Mulder et al. (2005) prepared bimodal (paramagnetic and fluorescent) liposomes 
actively targeted to αvβ3 integrin site on HUVEC (human umbilical vein endothelial 
cells) human endothelial cells in vitro and in vivo. Erdogan et al. (2008) successfully 
targeted pegylated 2C5-liposomes, containing gadolinium-loaded polychelating 
amphiphilic polymer (PAP), to murine Lewis lung carcinoma (LLC) in vivo and 
human mammary adenocarcinomas (MCF-7, BT20) in vitro (Erdogan et al., 2006). 
They also demonstrated that these targeted liposomes showed better and faster 
targeting in in vivo imaging than non-targeted contrast liposomes. PAP contains 
several groups which can chelate several Gd ions per polymer molecule and can be 
firmly incorporated into the liposomal membrane. Torchilin et al. (1994) showed that 
the PAP complex generates up to 11 NH2 groups, which are available to undergo 
reaction with DTPA which can subsequently be loaded with Gd ions. Erdogan et al. 
(2006) confirmed that PAP-loaded pegylated liposomes are capable of carrying 
higher amounts of 111In radiotracer than similar liposomes loaded with the 
monomeric chelate, DTPA-PE.  
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In this project, two compounds were used: Gd-DTPA-BSA and Gd-PAP. Gd-DTPA-
BSA chelates one Gd ion per molecule and is an amphiphilic phospholipid 
composed of a hydrophilic head and a hydrophobic tail, which allow phospholipid 
incorporation into liposome membranes. Contrast liposomes (containing Gd-DTPA-
BSA and Gd-PAP) were prepared and analyzed. In theory liposomes containing Gd-
PAP should show higher signals than liposomes containing Gd-DTPA-BSA, due to 
the ability of PAP to carry more metal ions. 
Anti-CD138-Gd-conjugated-liposomes were then used as a targeted contrast agent 
for imaging human multiple myeloma in vitro. 
 
5.2 Results 
5.2.1 Synthesis of polychelating amphiphilic polymer (PAP) 
Before preparation of contrast liposomes, polychelataing amphiphilic polymer (PAP) 
was first synthesized, as described in section 2.2.6. Briefly, poly(ε-carbobenzyoxy-l-
lysine) (poly(CBZ)-lysine) was conjugated to 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(glutaryl) (NGPE) using EDC and NHS. NGPE-PLL-CBZ 
was deprotected from CBZ to expose NH2 groups for conjugation with DTPA 
anhydride (Figure 5.1). Subsequently, NGPE-PLL (Poly(l-lysine)-DTPA was 
chelated by gadolinium ions and dialysed to separate it from free ions.  
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Figure 5.1 Polychelating amphiphilic polymer (PAP) synthesis.  
Poly(CBZ)Lys was conjugated with NGPE and then CBZ was deprotected from 
NGPE-Poly(CBZ)Lys. The deprotected compound was then linked with DTPA. 
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5.2.2 Relaxometric analysis of contrast Gd-DTPA-BSA-liposomes and Gd-PAP-
liposomes based on estimated gadolinium concentration 
Contrast liposomes were prepared using lipid formulations of 63.25 mol% (w/v) of 
egg PC, 30 mol% (w/v) of cholesterol, 5 mol% (w/v) PEG2000-PE and 1.75 mol% 
(w/v) of Gd-DTPA-BSA or 1.75 mol% (w/v) of Gd-PAP, as described in section 2.2.7 
(Table 5.1 and Table 5.2). A lipid film was prepared and hydrated with 1 mL of 0.1 M 
PBS, pH 7.3.  
 
Table 5.1 Lipid formulation used to prepare contrast liposomes (1.75 mol% 
(w/v) Gd-DTPA-BSA). 
Compound Molecular 
weight 
[g] 
Weight taken 
[mg] 
Moles Molar ratio of 
lipid to other 
lipids 
Egg PC  790.12 4.00 5.19*10-6 63.25 mol%  
(1) 
Cholesterol  386.65 0.95 2.46*10-6 30 mol% 
(0.47) 
PEG2000-PE  2,805.50 1.15 4.10*10
-7 5 mol%  (0.08) 
Gd-DTPA-BSA  1,068.60 0.15 1.40*10-7 1.75 mol% 
(0.03) 
TOTAL                                  6.25 
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Table 5.2 Lipids used for contrast liposomes (1.75 mol% (w/v) Gd-PAP) 
preparation. 
Compound Molecular 
weight 
[g] 
Weight taken  
[mg] 
Moles Molar ratio of 
lipid to other 
lipids 
Egg PC     790.12 4.00 5.19*10-6 63.25 mol%  
(1) 
Cholesterol     386.65 0.95 2.46*10-6 30 mol% 
(0.47) 
PEG2000-PE   2,805.50 1.15 4.10*10
-7 5 mol% (0.08) 
Gd-PAP 11,370.0 1.59 1.40*10-7 1.75 mol%  
(0.03) 
TOTAL                                  7.70 
 
Dilutions of both types of contrast liposomes were prepared and T1 relaxation times 
measured using a 5 mHz RADX NMR Analyzer. The relaxation time (T1) is the time 
needed for the 1H magnetisation to return from its non-equilibrium state to 
equilibrium. Paramagnetic contrast agents like gadolinium have an ability to shorten 
the T1 relaxation time of surrounding water 
1H nuclei, resulting a bright signal on the 
image. Relaxation rate (R1) is the reciprocal of relaxation time (1/T1). It was 
expected that liposomes containing Gd-PAP-liposomes will show a higher R1 
relaxation rate than Gd-DTPA-BSA-liposomes, because DTPA-BSA phospholipid 
chelates one gadolinium ion per molecule (Figure 5.2), whereas PAP can chelate up 
to 11 gadolinium ions per molecule (Torchilin et al. 1994).  
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Figure 5.2 Relaxivity studies of contrast liposomes.  
Different concentrations of contrast liposomes (Gd-PAP-liposomes and Gd-DTPA-
BSA-loaded monochelated liposomes) were analyzed using the 5 mHz RADX NMR 
Analyzer. T1 relaxation times [ms] were measured. Relaxation rate (R1) [1/s] was 
plotted against lipid-containing gadolinium concentration [mM] (top graph). On the 
bottom graph, relaxation rate (R1) was plotted against estimated gadolinium 
concentration in analysed samples. Gd-PAP-liposomes showed a higher relaxation 
rate than Gd-DTPA-BSA liposomes. The results are the mean ± the standard 
deviation and the experiment was performed in triplicate. 
 
The effectiveness of the gadolinium as a contrast agent to shorten the T1 or T2 
relaxation times of the water protons can be quantified by the concentration 
independent relaxivity, r1 or r2, which is defined as the change in R1 or R2 relaxation 
rate per unit concentration of the contrast agent. In this case, r1 relaxivity was 
assessed based on R1 relaxation rate and estimated gadolinium concentration. The 
r1 relaxivity is a slope of curve presented on the bottom plot (Figure 5.2) (R1 
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relaxation rate vs estimated gadolinium concentration). It was showed that r1 
relaxivity of Gd-PAP-liposomes is higher (3.19 mM-1s-1) than the r1 relaxivity of Gd-
DTPA-BSA-liposomes (0.49 mM-1s-1). The r1 relaxivity value in this experiment was 
calculated based on the premise that the PAP molecule chelates 11 ions of 
gadolinium and is probably inaccurate. A more accurate measurement of 
relaxometry using a known concentration of Gd, was then carried out, as described 
in section 5.2.3. 
 
5.2.3 Relaxometric analysis of Gd-DTPA-BSA-liposomes and Gd-PAP-
liposomes based on the determined gadolinium concentration 
5.2.3.1 Determination of gadolinium content in Gd-DTPA-BSA-liposomes and 
Gd-PAP-liposomes 
Contrast liposomes were prepared using a formulation of 63.25 mol% (w/v) of egg 
PC, 30 mol% of cholesterol, 5 mol% (w/v) PEG2000-PE and 1.75 mol% (w/v) of Gd-
DTPA-BSA or 1.75 mol% (w/v) of Gd-PAP, as described in section 2.2.7 (Tables 5.3 
and 5.4). A lipid film was prepared and hydrated with 2.2 mL of distilled water for 
Gd-DTPA-BSA-liposomes and 0.7 mL distilled water for Gd-PAP-liposomes. The 
liposomes were extruded through a 100 nm polycarbonate membrane and their size 
was determined using Photon Correlation Spectroscopy (PCS). The size of the Gd-
DTPA-BSA liposomes was determined to be 171.2 nm PDI (0.23) while Gd-PAP-
liposomes were 175.1 nm (PDI 0.22).  
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Table 5.3 Lipid formulation used to prepare contrast liposomes (1.75 mol% 
(w/v) Gd-DTPA-BSA). 
Compound Molecular 
weight 
[g] 
Weight taken 
[mg] 
Moles Molar ratio of 
lipid to other 
lipids 
Egg PC  790.12 240.00 3.1*10-4 63.25 mol%  
(1) 
Cholesterol  386.65 56.80 1.46*10-4 30 mol% 
(0.47) 
PEG2000-PE  2,805.50 70.00 2.5*10
-5 5 mol%  (0.08) 
Gd-DTPA-BSA  1,068.60 9.32 8.72*10-5 1.75 mol% 
(0.03) 
TOTAL                              376.12 
 
Table 5.4 Lipids used for contrast liposomes (1.75 mol% (w/v) Gd-PAP) 
preparation. 
Compound Molecular 
weight 
[g] 
Weight taken  
[mg] 
Moles Molar ratio of 
lipid to other 
lipids 
Egg PC     790.12 24.00 3.12*10-5 63.25 mol%  
(1) 
Cholesterol     386.65 5.68 1.46*10-5 30 mol% 
(0.47) 
PEG2000-PE   2,805.50 7.00 2.49*10
-6 5 mol% (0.08) 
Gd-PAP   11,370.0 9.92 0.87*10-6 1.75 mol%  
(0.03) 
TOTAL                                46.6 
 
Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-AES) was 
performed for a precise determination of gadolinium. The gadolinium content in 
contrast liposomes (Gd-DTPA-BSA-liposomes and Gd-PAP-liposomes) was then 
determined using Inductively Coupled Plasma-Atomic Emission Spectroscopy (ICP-
AES). Firstly, a calibration curve of GdCl3 was made (Figure 5.3). ICP-AES analyses 
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of both contrast liposomes resuspended in 0.2 % (v/v) Triton X-100 (to break down 
liposome vesicles) were carried out.  
Figure 5.3 Calibration curve based on gadolinium chloride (GdCl3) salt 
standards solutions (0 – 20 mg/L). 
 
The gadolinium content of the contrast liposomes were determined using the 
calibration curve and it was calculated that there are 2.7 mM of Gd in Gd-DTPA-
BSA-liposomes and 16.5 mM in Gd-PAP-liposomes. The difference in gadolinium 
concentration found was as expected since PAP can carry more gadolinium ions per 
molecule compared to the DTPA-BSA molecule. 
Additionally, to calculate r1 relaxivity value, NMR analyses of contrast liposomes 
were carried out to determine T1 relaxation time of water protons. 
 
5.2.3.2 Calculation of relaxivity value of contrast liposomes 
The effectiveness of the gadolinium as a contrast agent to shorten the T1 or T2 
relaxation times of the water protons can be quantified by the concentration 
Magnetic resonance relaxation studies on magnetoliposomes 
 192 
independent relaxivities, r1 or r2, which are defined as the change in R1 or R2 
relaxation rate per unit concentration of the contrast agent. NMR analyses of 
contrast liposomes were carried out to determine T1 relaxation time of water protons. 
Taking into account T1 relaxation time measurments and gadolinium concentration, 
relaxivity of contrast liposomes was calculated using the following equation: 
 
where, 
r1 is the relaxivity of contrast agent (nominal value-concentration independent) 
R1 obs is the observed relaxation rate in the presence of enhancement 
R1 H2O is the relaxation rate of water protons 
[Gd] is the concentration of gadolinium contrast agent in [mM] 
Relaxivity is expressed in [mM-1s-1] unit.  
The relaxivity (r1) value was calculated, based on gadolinium content determination. 
An important quality criterion for MRI contrast agents is their molar relaxivity. A 
Nuclear Magnetic Resonance Dispersion (NMRD) profile was drawn (relaxivity (r1) in 
relation to Larmour Frequency (MHz)). The r1 relaxivity is a nominal value, 
independent of gadolinium concentration, which demonstrates contrast agents as 
sensitive enough for potential use in real samples.  
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Figure 5.4 Relaxivity profile of Gd-DTPA-BSA-liposomes and Gd-PAP-
liposomes.  
Diameter of Gd-DTPA-BSA-liposomes was 171.2 nm (PDI 0.23) and of Gd-PAP-
liposomes was 175.1 nm (PDI 0.22). 
 
It was shown that r1 relaxivity of Gd-PAP-liposomes is significantly higher that r1 
relaxivity of Gd-DTPA-BSA-liposomes. Based on Figure 5.4 it was determined that 
the r1 relaxivity of Gd-PAP-liposomes is approximately 20 mM
-1s-1 over a Larmour 
frequency range of 0.01-10 MHz and approximately 37 mM-1s-1 at the most common 
clincal magnetic field (of 60 MHz). The relaxivity of Gd-DTPA-BSA-liposomes was 
found to be approximately 15 mM-1s-1 over a Larmour frequency range of 0.01-10 
[MHz] and approximately 20 mM-1s-1] at 60 MHz. These results indicated that 
liposomes containing Gd-PAP are better contrast agents than liposomes containing 
Gd-DTPA-BSA.  
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5.2.4 Magnetic resonance imaging of Gd-DTPA-BSA-liposomes and Gd-PAP-
liposomes 
Contrast liposomes were prepared using lipid formulations of 63.25 mol% (w/v) of 
egg PC, 30 mol% of cholesterol, 5 mol% (w/v) PEG2000-PE and 1.75 mol% (w/v) of 
Gd-DTPA-BSA or 1.75 mol% (w/v) of Gd-PAP (Tables 5.5 and 5.6). The lipid film 
was hydrated in 1 mL of 0.1 M PBS, pH 7.3, and the liposomes were extruded 
through a 100 nm polycarbonate membrane. The average size of prepared contrast 
liposomes was determined using PCS to be 150 nm (PDI 0.23) for Gd-DTPA-BSA-
liposomes and 118 nm (PDI 0.10) for Gd-PAP-liposomes. 
 
Table 5.5 Lipid formulation used to prepare contrast liposomes (1.75 mol% 
(w/v) Gd-DTPA-BSA). 
Compound Molecular 
weight 
[g] 
Weight taken 
[mg] 
Moles Molar ratio of 
lipid to other 
lipids 
Egg PC  790.12 60.00 7.79*10-5 63.25 mol%  
(1) 
Cholesterol  386.65 14.20 3.66*10-5 30 mol% 
(0.47) 
PEG2000-PE  2,805.50 17.50 6.23*10
-6 5 mol%  (0.08) 
Gd-DTPA-BSA  1,068.60  2.33 2.18*10-6 1.75 mol% 
(0.03) 
TOTAL                                 94.03 
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Table 5.6 Lipids used for contrast liposomes (1.75 mol% (w/v) Gd-PAP) 
preparation. 
Compound Molecular 
weight 
[g] 
Weight taken  
[mg] 
Moles Molar ratio of 
lipid to other 
lipids 
Egg PC     790.12 60.00 7.79*10-5 63.25 mol%  
(1) 
Cholesterol     386.65 14.20 3.66*10-5 30 mol% 
(0.47) 
PEG2000-PE   2,805.50 17.50 6.23*10
-6 5 mol% (0.08) 
Gd-PAP   11,370.0 24.80 2.18*10-6 1.75 mol%  
(0.03) 
TOTAL                               116.50 
Ten µL of each preparation was resuspended in 2 mL distilled water and magnetic 
resonance imaging was carried out in a 1.5 T of electromagnetic field scanner 
(Gyroscan Intera; Philips, Netherlands) at Cappagh Hospital, Dublin, Ireland (Figure 
5.5).  
 
 
 
 
 
 
 
 
Figure 5.5 T1-weighted images of contrast liposomes (containing 1.75 mol% 
(w/v) Gd-DTPA-BSA or Gd-PAP phospholipid) using Magnetic resonance 
imaging (MRI) in a 1.5T electromagnetic field. 
 
 
Gd-PAP- 
liposomes  
Gd-DTPA-BSA- 
liposomes    H2O 
1                           2                         3 
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As can be seen in Figure 5.5 Gd-PAP-containing liposomes are significantly brighter 
compared to Gd-DTPA-BSA-liposomes on the MRI scan. Gd-DTPA-BSA-liposomes 
showed a similar MR image to water protons indicating that these liposomes do not 
contain a sufficient amount of Gd ions to give a measurable signal on T1-weighted 
images. In contrast, Gd-PAP-liposomes contain a sufficient amount of Gd in order to 
give a measurable signal in a MRI instrument used for patient analysis indicating 
that Gd-PAP-liposomes are sensitive enough for potential use in real clinical 
samples. 
 
5.2.5 Stability studies of contrast liposomes 
Contrast liposomes containing 1.75 mol% Gd-DTPA-BSA and Gd-PAP were 
prepared as described in section 2.2.7 (Table 5.1 and 5.2). Size measurements 
were performed over 14 days using PCS for Gd-DTPA-BSA-liposomes and over 19 
days for Gd-PAP-liposomes using PCS (Figure 5.6). 
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Figure 5.6 Size distribution of Gd-DTPA-BSA-liposomes and of Gd-PAP-
liposomes.  
It was found that contrast liposomes containing 1.75 mol% (w/v) Gd-DTPA-B-BSA or 
Gd-PAP were stable over 14 days and 19 days, respectively. 
 
The diameter of contrast Gd-DTPA-BSA-liposomes was 187 nm on day 1 and did 
not significantly change over the 14 days of the study. For Gd-PAP-liposomes the 
diameter was 149 nm on day 2 after preparation and did not change over 19 days.  
The charge of prepared contrast Gd-DTPA-BSA-liposomes was also measured by 
PCS. It was estimated that zeta potential of prepared contrast liposomes was -40.15 
mV and was stable over 12 days indicating that Gd-DTPA-BSA-loaded liposomes 
are stable (Figure 5.7). 
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Figure 5.7 Zeta potential of contrast liposomes containing 1.75 mol% (w/v) Gd-
DTPA-BSA.  
The charge of contrast liposomes was stable over 12 days. The zeta potential of Gd-
DTPA-BSA-liposomes was approximately –40 mV with variations in the 5-7 mV 
range. The results are the mean ± the standard deviation and the experiments were 
performed in triplicate. There was no significant difference between the values over 
the time frame of the experiment. 
 
Based on size and zeta potential, no aggregation of contrast liposomes was 
observed.  
 
5.2.6 In vitro studies of targeted contrast anti-CD138-conjugated-liposomes 
Contrast anti-CD138-conjugated-liposomes (containing 1.75 mol% Gd-DTPA-BSA 
or 1.75 mol% Gd-PAP phospholipid) were prepared, using 63.25 mol% (w/v) of egg 
PC, 30 mol% of cholesterol, 5 mol% (w/v) PEG2000-PE and 1.75 mol% (w/v) of Gd-
DTPA-BSA or 1.75 mol% (w/v) of Gd-PAP (Tables 5.7 and 5.8).  
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Table 5.7 Formulation for generation of fluorescently-labelled anti-CD138 
contrast Gd-DTPA-BSA-liposomes.  
Compound Molecular 
weight 
[g] 
Weight used 
[mg] 
Moles Molar ratio 
of lipid to 
other lipids 
Egg PC    790.123 1.33 1.68*10-6 62.75 mol% 
(1) 
Cholesterol   386.65 0.31 8.10*10-7 30 mol% 
(0.48) 
DSPE-PEG-
Metoxy 
2,805.54            0.23 8.10*10-8 3 mol% 
(0.048) 
 
FITC-PE 1,136.41   0.015 1.30*10-8 0.5 mol% 
(0.008) 
Gd-DTPA-
BSA 
  1,068.6 0.05 4.70*10-8 1.75 mol% 
(0.03) 
DSPE-PEG- 
COOH 
2,847.78 0.15 5.40*10-8 2 mol% 
(0.032) 
TOTAL                                2.09 
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Table 5.8 Formulation for generation of fluorescently-labelled anti-CD138 
contrast Gd-PAP-liposomes.  
Compound Molecular 
weight 
[g] 
Weight used 
[mg] 
Moles Molar ratio 
of lipid to 
other lipids 
Egg PC    790.123 1.33 1.68*10-6 62.75 mol% 
(1) 
Cholesterol    386.65 0.31 8.10*10-7 30 mol% 
(0.48) 
DSPE-PEG-
Metoxy 
2,805.54           1.14 8.10*10-8 3 mol% 
(0.048) 
 
FITC-PE 1,136.41 0.015 1.30*10-8 0.5 mol% 
(0.008) 
Gd-PAP 11,370.0 0.53 4.70*10-8 1.75 mol% 
(0.03) 
DSPE-PEG-
COOH 
2,847.78 0.15 5.40*10-8 2 mol% 
(0.032) 
TOTAL                                2.57 
 
Blank liposomes were also prepared as a negative control.  
Anti-CD138 contrast liposomes (0.5 mg/mL) were incubated with human multiple 
myeloma cancer cells (U266; RPMI8226) and L428 Hodgkin’s disease-derived 
cancer cell line for 1.5 hours at 37°C in vitro. FACS analyses of contrast liposomes 
were carried out as described in section 2.2.5 and the results are shown in Figures 
5.8 and 5.9. 
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Figure 5.8 In vitro studies of contrast anti-CD138-conjugated-Gd-DTPA-BSA-
loaded liposomes.  
Blank liposomes (plain liposomes, Blank lipo); liposomes without antibody attached) 
were incubated with multiple myeloma cells lines (U266; RPMI8226) and a 
Hodgkin’s disease-derived cancer cell line (L428). Previously, it was estimated that 
U266 expresses CD138 protein at 84.3%. The L428 cell line does not express 
CD138. Anti-CD138-conjugated-Gd-DTPA-BSA-loaded liposomes (anti-CD138-Gd-
PAP-lipo) used for this binding experiment were prepared using the co-incubation 
method. The results are the mean ± the standard deviation and the experiment was 
performed in triplicate. 
* Significantly different from control (Blank-liposomes) (Student’s t-test, 
0.01<p<0.05) 
 ** Significantly different from control (Blank-liposomes) (Student’s t-test, 
0.001<p<0.01) 
 
Contrast anti-CD138-conjugated-Gd-DTPA-BSA-liposomes bound significantly to 
human multiple myeloma cell lines (U266; RPMI8226) in comparison to plain 
liposomes. Figure 5.8 indicates that they did not bind to L428, the Hodgkin’s 
disease-derived cancer cell line. 
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Figure 5.9 In vitro studies on contrast anti-CD138-conjugated-Gd-PAP-loaded 
liposomes.  
Blank liposomes (plain liposomes, Blank lipo); liposomes without antibody attached) 
were incubated with multiple myeloma cells lines (U266; RPMI8226) and Hodgkin’s 
disease derived cancer cell line (L428). Previously, it was estimated that U266 
expresses CD138 protein at 84.3%. L428 Hodgkin’s disease derived cancer cell line 
is a negative cell line for CD138 protein. Anti-CD138-conjugated-Gd-PAP-loaded 
liposomes (Anti-CD138-Gd-PAP-lipo) used for this binding experiment were 
prepared using the co-incubation method. The results are the mean ± the standard 
deviation and the experiment was performed in triplicate. 
 * Significantly different from control (Blank-liposomes) (Student’s t-test, 
0.01<p<0.05) 
 
Similar to results shown in Figure 5.8 the contrast anti-CD138-conjugated-Gd-PAP-
liposomes bound significantly to human multiple myeloma cell lines (U266; 
RPMI8226) when compared to plain liposomes but did not bind to L428 Hodgkin’s 
disease-derived cancer cell line (Figure 5.9). Anti-CD138-conjugated-Gd-DTPA-
BSA-loaded and anti-CD138-conjugated-Gd-PAP-loaded-liposomes bound 
approximately 2.5 fold and 3 fold, respectively, more strongly to U266 human 
multiple myeloma cells than did plain liposomes.  
A significant difference was not observed in the binding of anti-CD138-conjugated-
Gd-DTPA-BSA and anti-CD138-conjugated-Gd-PAP-liposomes to the U266 human 
multiple myeloma cell line based on FACS analysis (Figure 5.8 and Figure 5.9). 
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5.2.7 Magnetic resonance imaging of anti-CD138-conjugated-Gd-DTPA-BSA-
liposomes and anti-CD138-conjugated-Gd-PAP-liposomes 
Contrast anti-CD138-conjugated-liposomes (containing 1.75 mol% Gd-DTPA-BSA 
or 1.75 mol% Gd-PAP phospholipid) were prepared in 1 mL 0.1 M PBS, pH 7.3, 
(Tables 5.9 and 5.10). Anti-CD138-conjugated-liposomes were prepared by the co-
incubation method and extruded trough a 100 nm polycarbonate membrane. 
 
Table 5.9 Formulation for generation of contrast anti-CD138-conjugated-Gd-
DTPA-BSA-liposomes.  
Compound Molecular 
weight 
[g] 
Weight used 
[mg] 
Moles Molar ratio 
of lipid to 
other lipids 
Egg PC    790.123            10 1.68*10-6 63.75 mol% 
(1) 
Cholesterol   386.65 2.4 8.10*10-7 30 mol% 
(0.48) 
DSPE-PEG-
Metoxy 
2,805.54            1.7 8.10*10-8 3 mol% 
(0.048) 
 
Gd-DTPA-
BSA 
  1,068.6 0.39 4.70*10-8 1.75 mol% 
(0.03) 
DSPE-PEG- 
COOH 
 2,847.78            1.2 5.40*10-8 2 mol% 
(0.032) 
TOTAL                              15.69 
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Table 5.10 Formulation for generation of fluorescently-labelled anti-CD138 
contrast Gd-PAP-liposomes.  
Compound Molecular 
weight 
[g] 
Weight used 
[mg] 
Moles Molar ratio 
of lipid to 
other lipids 
Egg PC   790.123 10 1.68*10-6 62.75 mol% 
(1) 
Cholesterol 386.65 2.4 8.10*10-7 30 mol% 
(0.48) 
DSPE-PEG- 
Metoxy 
 2,847.78            1.7 8.10*10-8 3 mol% 
(0.048) 
 
Gd-PAP  11,370.0 4.1 4.70*10-8 1.75 mol% 
(0.03) 
DSPE-PEG-
COOH 
  2,847.78 1.2 5.40*10-8 2 mol% 
(0.032) 
TOTAL                               19.4 
 
The size of prepared contrast immunoliposomes was 151.1 nm (PDI 0.098) for anti-
CD138-conjugated-Gd-DTPA-BSA-liposomes and 112.5 nm (PDI 0.251) for anti-
CD138-conjugated-Gd-PAP-liposomes. 50 µL of each immunoliposome preparation 
was diluted in 1.8 mL of distilled water and analyzed using MRI, at 1.5 T.  
 
 
 
 
 
 
 
 
Magnetic resonance relaxation studies on magnetoliposomes 
 205 
 
 
 
 
 
 
 
 
 
 
Figure 5.10 T1-weighted images of contrast anti-CD138-conjugated-liposomes 
(containing 1.75 % (w/v) Gd-DTPA-BSA or Gd-PAP phospholipid) using 
Magnetic resonance imaging (MRI).  
Imaging was performed in an electromagnetic field of 1.5 T. 
 
Figure 5.10 indicates that anti-CD138-conjugated-Gd-PAP-containing liposomes are 
brighter compared to anti-CD138-conjugated-Gd-DTPA-BSA-liposomes on MRI 
scanning. Anti-CD138-conjugated-Gd-DTPA-BSA-liposomes showed a similar MR 
image to water protons. Anti-CD138-conjugated-Gd-PAP-liposomes contain 
sufficient quantities of Gd to give measurable signals in a clinical MRI system. Anti-
CD138-conjugated-Gd-DTPA-BSA-liposomes do not contain sufficient Gd ions to 
give a measurable signal on T1-weighted images. Magnetic resonance scans 
visualized that anti-CD138-conjugated-liposomes containing Gd-PAP are better 
contrast agents than anti-CD138-conjugated-liposomes containing Gd-DTPA-BSA 
phospholipid. This indicates that anti-CD138-conjugated-Gd-PAP-liposomes are 
sensitive enough for potential use in real clinical samples. 
 
 
Magnetic resonance relaxation studies on magnetoliposomes 
 206 
5.2.8 Magnetic resonance imaging of anti-CD138-conjugated-Gd-DTPA-BSA-
liposomes and anti-CD138-conjugated-Gd-PAP-liposomes – in vitro studies 
Contrast anti-CD138-conjugated-liposomes (containing 1.75 mol% Gd-DTPA-BSA 
or 1.75 mol% Gd-PAP phospholipid) were prepared, using 63.25 mol% (w/v) of egg 
PC, 30 mol% of cholesterol, 5 mol% (w/v) PEG2000-PE and 1.75 mol% (w/v) of Gd-
DTPA-BSA or 1.75 mol% (w/v) of Gd-PAP (Tables 5.8 and 5.9).  
In vitro studies of contrast anti-CD138-conjugated-liposomes with human multiple 
myeloma cancer cell lines were carried out in order to examine immunoliposome 
binding ability. Contrast immunoliposomes (containing 1 mg/mL lipids) were 
incubated with cancer cell lines for 1 hour in ‘serum-free’ medium at 37°C. Cells 
were subsequently washed three times at 3,000 g for 5 min with 0.1 M PBS, pH 7.3 
using Z 233 MK-2 centrifuge, and finally resuspended in 0.5 mL 0.1 M PBS, pH 7.3.  
Interaction of contrast anti-CD138-liposomes was visualized using MR imaging at 
1.5 T (Figure 5.11).  
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                                        Figure 5.11 T1-weighted image studies of contrast anti-CD138-liposomes (containing 1.75 % (w/v)                
                                        Gd-DTPA-BSA or Gd-PAP phospholipid) using magnetic resonance imaging (MRI) in vitro. 
Lane 1: L428 Hodgkin’s disease-derived cells incubated with anti-CD138-Gd-DTPA-BSA-liposomes 
(mean pixel intensity of 34, as shown in insert); Lane 2: L428 Hodgkin’s disease-derived incubated with 
anti-CD138-Gd-PAP-liposomes (mean pixel intensity of 48, as shown in insert); Lane 3: U266 human 
multiple myeloma cell line incubated with anti-CD138-Gd-DTPA-BSA-liposomes (mean pixel intensity of 
45, as shown in insert); Lane 4: U266 human multiple myeloma cell line incubated with anti-CD138-Gd-
PAP-liposomes (mean pixel intensity of 66, as shown in insert); Lane 5: RPMI8226 human multiple 
myeloma cell line incubated with anti-CD138-Gd-DTPA-BSA-liposomes (mean pixel intensity of 42, as 
shown in insert); Lane 6: RPMI8226 human multiple myeloma cell line incubated with anti-CD138-Gd-
PAP-liposomes (mean pixel intensity of 57, as shown in insert). 
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These scans (Figure 5.11) indicated that contrast anti-CD138-conjugated-liposomes 
containing Gd-PAP gave stronger contrasts than anti-CD138-conjugated-liposomes 
containing Gd-DTPA-BSA. Anti-CD138-conjugated-Gd-PAP-liposomes bound more 
strongly to the U266 human multiple myeloma cancer cell line than to the L428 
Hodgkin’s disease-derived cell line. Anti-CD138-conjugated-Gd-DTPA-BSA-
liposomes do not contain sufficient Gd ions to give a measurable signal on T1-
weighted images. Magnetic resonance scan indicated that anti-CD138-conjugated-
liposomes containing Gd-PAP are better contrast agents than anti-CD138-
conjugated-liposomes containing Gd-DTPA-BSA phospholipids. This implies that 
anti-CD138-conjugated-Gd-PAP-liposomes are sufficiently sensitive for potential use 
in real clinical samples. 
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Discussion 
Currently, magnetic resonance imaging (MRI) is an established minimally non-
invasive clinical imaging modality which is capable of producing three-dimensional 
images of tissues containing water with a high spacial resolution. The main 
drawback of MRI is very low sentitivity which can be overcome by contrast agent 
usage. Paramagnetic agents directly affect water protons in their close vicinity and 
are highly dependent on local water flux. Hence, the influence of these agents is 
very local and they should ideally be in contact with water with adequate exchange 
rates. Such contrast agents shorten the T1 relaxation time and thus increase 
longitudinal and transverse relaxation rates (R1 and R2) (Aime et al., 2002).  
In this study, contrast liposomes were prepared using Gd-loaded-DTPA-PLL-NGPE 
(PAP) and Gd-loaded-DTPA-BSA. Due to the presence of a larger number of Gd 
ions (one Gd ion per DTPA-BSA to 11 Gd ions per PAP), Gd-loaded-PAP-liposomes 
showed increased relaxation rates when compared to Gd-DTPA-BSA-liposomes. 
These results are in agreement with studies carried out by Erdogan et al. (2006). 
They demonstrated that liposomes loaded with Gd via membrane-incorporated 
polychelating amphiphilic polymer (PAP) significantly increased the Gd content and 
relaxation rate R1 of PEGylated liposomes.  
T1 relaxation times were measured using a 5 MHz RADX NMR Analyzer. It was 
shown that liposomes containing Gd-PAP showed a higher relaxivity value (3.19 
[mM-1s-1]) compared to liposomes containing Gd-DTPA-BSA phospholipid (0.49 
[mM-1s-1]). The r1 relaxivity value in this experiment was calculated based on the 
premise that the PAP molecule chelates 11 ions of gadolinium. Subsequently, more 
detailed NMR studies were performed, and the gadolinium concentration in the 
liposomes was determijned using Inductively Coupled Plasma – Atomic Emission 
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Spectroscopy (ICP-AES). Based on this approach, the r1 relaxivity of Gd-PAP-
liposomes was found to be 37 mM-1s-1 compared to 20 mM-1s-1 for Gd-DTPA-BSA-
liposomes, at 60 MHz. Hence, liposomes containing Gd-PAP phospholipid are better 
contrast agent than liposomes containing Gd-DTPA-BSA, per Gd ion, an effect that 
is amplified if the relaxivity per lipid is considered. It is likely that the values fro the 
second study is more reliable as the Gd concentration was determined directly. 
Stability tests on contrast liposomes (containing Gd-DTPA-BSA) found that they are 
stable in solution for 14 days while liposomes containing Gd-PAP are stable for 19 
days. 
In a related study Weissig et al. (2000) reported that 1.75 mol% (w/v) is an optimal 
Gd-PAP molar fraction for preparing contrast liposomes. Further increases in Gd-
PAP did not increase the molecular relaxivity. They explained that a higher 
polychelate concentration brings molecules of amphiphilic polychelators close to 
each other thus decreasing the degree of exposure of Gd atoms to water.  
The interaction of contrast anti-CD138-conjugated-liposomes with human multiple 
myeloma cells was visualized on a T1-weighted image by MRI. Kamaly et al. (2008) 
also performed T1-weighted images of Gd-loaded-DOTA-DSA-liposomes and HeLa 
cells after liposome internalization. They observed successful Gd-labelling which 
was indicated by reduction of T1 values, relative to controls. 
In conclusion, the results reported in this chapter show that polychelating 
amphiphilic polymer (PAP) is capable of chelating many gadolinium ions per 
molecule which increase the relaxation rate (R1) of surrounding water protons. This 
phenomenom was first shown by Torchilin’s group (Weissig et al., 2000), and can 
potentially strongly increase the sensitivity of human multiple myeloma images 
obtained in humans. The findings described in this chapter will hopefully contribute 
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to the preparation of novel minimally non-invasive contrast agents for the diagnosis 
of this malignancy. 
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6.1 Introduction 
The main aim of this project was to prepare minimally non-invasive diagnostic test 
for human multiple myeloma (MM). Multiple myeloma is characterised by 
uncontrolled proliferation of malignant plasma cells within the marrow. Normal bone 
marrow consists of no more than 4% of plasma cells, whereas in unhealthy bone 
marrow there can be more than 10% plasma cells.  
Wijdenes et al. (2002) identified CD138 (syndecan-1) as a marker for multiple 
myeloma cancer cells, due to its expression in the majority of malignant plasma cells 
in bone marrow. However, in healthy bone marrow, syndecan-1 is only expressed 
on precursor B lymphocytes and is lost before maturation (Sanderson et al., 1989). 
Terminally differentiated plasma cells express relatively few surface antigens and do 
not express very common B cell markers, such as CD19 and CD20. Multiple 
myeloma can appear during plasma cell maturation, when CD38 and CD138 are not 
lost and are expressed at high levels (Rawstron et al., 2006).  
Ridley et al. (1993) suggested that CD138 plays a major role in plasma cell 
adhesion to bone marrow stroma, especially to collagen type I. It is a glycoprotein 
expressed on simple epithelia (150-250 kDa), stratified epithelia (80-150 kDa), 
mesenchymal cells (220-300 kDa) and lymphocytes (80-150 kDa). The size of the 
CD138 protein depends on the glycosaminoglycan pattern of the molecule. In 
particular, the smallest isoform, with an avarage molecular size of about 92 kDa, has 
been described on stratified keratinocytes (Sanderson and Bernfield, 1988; 
Bernfield, 1993). The protein is composed of three domains (Figure 6.1), the 
extracellular domain - ectodomain (251 residues), transmembrane domain (25 
residues) and intracellular domain (34 residues). The transmembrane domain and 
part of the extracellular domain contain hydrophobic sequences. The expected 
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molecular weight of monomeric syndecan-1 is 35 kDa (non-glycosylated form of 
syndecan-1; core protein). Additionally, a high molecular weight form of the protein 
may often be seen, and may be the mature form of syndecan-1 with all of its 
glycosaminoglycan (GAG), heparan and chondroitan sulfate additions. 
The extracellular domain contains five putative glycosaminoglycan (GAG) 
attachment sites. A glycosaminoglycan is a mucopolysaccharide, which is a long 
unbranched polysaccharide consisting of a repeating disaccharide unit (hexose or 
hexuronic acid and hexosamine). The protein bears heparan sulfate and sometimes 
chondroitan sulfates residues. Heparan sulfate is a linear polysaccharide, which 
interacts with a number of ligands like growth factors, components of the 
extracellular matrix, cell-cell adhesion molecules, protease inhibitors, lipid binding 
proteins, blood-coagulation factors and pathogens (Bernfield et al., 1992; Carey et 
al., 1997). It was shown that the extracellular domain of CD138 protein diverged 
rapidly when comparing CD138 sequences of different species. There are some 
constant regions of the extracellular sites, e.g. the position of the potential GAG 
attachment and cleavage sites. The transmebrane and intracellular domains are 
conserved (Bernfield et al. 1992). 
There are different clones of anti-CD138 antibodies recognising human syndecan-1 
e.g. mouse B-B2, B-B4, MI15, 1D4, 104-9 and DL-101. Gattei et al. (1998) 
investigated the reactivity of anti-CD138 monoclonal antibodies with either intact 
native proteoglycans or a recombinant non-glycosylated form of syndecan-1 (core 
protein). They reported the capability of a number of anti-CD138 monoclonal 
antibodies to recognize the human syndecan-1 molecule by way of epitopes 
localized at the core protein level. They identified that B-B4, 1D4 and MI15 
recognize the same or closely related epitopes within the ectodomain of syndecan-1 
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core protein. Dore et al. (1998) identified different epitopes recognized by B-B2 
monoclonal antibodies (Figure 6.1).  
1 - 87 aa
1 - 253 aa
 
Figure 6.1 Epitopes on the syndecan-1 amino acid sequence (Adapted from 
Dore et al., 1998).  
Hydrophobic sequences of the extracellular part of syndecan-1 and transmembrane 
region are boxed in white. Glycosaminoglycan sites are underlined and B-B2 and B-
B4 antibody epitopes are boxed in grey.  
 
This chapter descibes the production of a recombinant CD138 protein fragment 
composed of 1-87 or 1-253 amino acids, because human CD138 antigen is not 
available commercially (Figure 6.2).  A 253 aa (1-253 aa) CD138 protein fragment 
was produced because the extracellular part of the protein contains two different 
epitopes recognized either by B-B2 or B-B4 monoclonal antibodies. It was decided 
to work with the MI15 clone of monoclonal anti-CD138 antibodies because it is able 
to recognize native and recombinant forms of syndecan-1. The MI15 monoclonal 
anti-CD138 antibody recognizes the same or closely related epitope to the B-B4 
antibody and does not recognize the B-B2 epitope located on the 1-87 aa protein 
fragment.  This antibody was, therefore, used to detect the expression of the  
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recombinant CD138 protein fragment.  An eighty seven (1-87 aa) CD138 protein 
fragment was also produced as a negative control for MI15 monoclonal antibodies. 
Expression of a recombinant CD138 protein will enable large-scale production of the 
antigen which can then be used for immunisation to generate polyclonal, monoclonal 
or recombinant antibodies. Moreover, CD138 antigen can be used to evaluate the 
specific binding ability of anti-CD138-conjugated-liposomes to the CD138 antigen.   
 
6.2 Results 
6.2.1 Cloning and expression of the CD138 gene fragment in pQE60 vector 
The pQE60 vector allows high level protein expression with a His-tag located on the 
C-terminus. The primers were designed, as described in section 6.2.1.1, so that they 
contain a restriction site for NcoI and BamHI enzymes for cloning into pQE60 vector. 
 
6.2.1.1 Optimisation and amplification of CD138 fragments using cDNA as a 
template 
mRNA isolated from RPMI8226 cells, as described in section 2.2.10.1.1, was used 
to obtain cDNA by reverse transcription (section 2.2.10.1.2). Briefly, 211 ng RNA 
was isolated from RPMI8226 human multiple myeloma cancer cells using Trizol 
reagent and chloroform. Then total RNA was reverse transcriped to cDNA. RNA was 
combined with oligo(dt) primers and dNTPs. They were co-incubated for 5 min at 
65ºC and then on ice for 1 min. Oligo(dt) primers consist of short strands (12-18 
bases) of thymine deoxynucleotides that hybridize to the mRNA poly A tail and prime 
reverse transcription. Then, reverse-transcription buffer, MgCl2, DTT, RNaseOut 
inhibitor and Superscript III reverse-transcriptase were added to the previously 
prepared mixture. Reverse-transcription was performed for 50 min at 50ºC and 
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terminated at 85ºC for 5 min and 63 ng of cDNA was used as a template for 
amplification of CD138 gene fragments (261 bp and 759 bp gene fragments) using:  
 
Sense primer with NcoI restriction site 
5' TAT CCA TGG AT AGG CGC GCG GCG CTC TG 3' 
 
Anti-sense primer 1 (1-261 bp) with BamHI restriction site 
5' GAT GGA TCC AGC TGT AGC CTC CAG GCC GGT 3' 
 
Anti-sense primer 2 (1-759 bp) with BamHI restriction site 
5' GAT GGA TCC CAG CAC CTC TTT CCT GTC CA 3' 
 
The CD138 gene fragment was amplified, as described in section 2.2.10.1.3, using 
sense primer and anti-sense primer 1 for amplification of 261 bp gene fragment (87 
aa) and sense primer and anti-sense primer 2 for amplification of the 759 bp (253 aa) 
fragment.  
Optimization of CD138 gene fragment amplification was carried out. Different 
temperatures (58ºC and 59ºC) for the PCR annealing step were tested.  
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Figure 6.2 Optimization of CD138 protein fragment amplification by PCR. 
Lane 1 contains a 1 kB marker for determination of gene sizes; Lanes 2 and 3 are 
negative controls (without DNA); Lane 2 contains primers for 1-261 bp gene 
amplification; Lane 3 contains primers for 1-759 bp gene amplification; Lanes 4 and 5 
consist of amplified 1-261 bp (consistent with a 87 aa protein) CD138 gene fragment; 
Lanes 6 and 7 consist of amplified 1-759 bp CD138 gene fragments. Both gene 
fragment amplifications were performed at 95ºC / 30 s for DNA denaturation, 58ºC / 
30 s for annealing and 72ºC / 45 s for elongation. 
 
It was observed that 95ºC / 30 s for DNA denaturation, 58ºC / 30 s for annealing and 
72ºC / 45 s for elongation were optimal for 1-261 bp of the CD138 gene amplification. 
These conditions were not optimal for amplification of 1-759 bp of the CD138 gene 
fragment, due to the small amount of final product observed in lane 6 and 7 (Figure 
6.2).  
Different temperatures were tested for 1-759 bp of CD138 gene amplification. 
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Figure 6.3 Optimization of CD138 protein fragment amplification using cDNA as 
a template. 
Lanes 1 and 4 contain a 1 kB marker for determination of gene sizes; Lane 2 
contains an amplified 1-261 bp CD138 gene fragment (consistent with a 87 aa 
derivative of CD138); Lane 3 contains an amplified 1-759 bp (consistent with a 253 
aa protein) CD138 gene fragment. The CD138 gene fragment (1-261 bp) was 
amplified at 95ºC / 30 s for DNA denaturation, 58ºC / 30 s for annealing and 72ºC / 
45 s for elongation and the CD138 gene fragment (1-759 bp) was amplified at 95ºC / 
30 s for DNA denaturation, 59ºC / 30 s for annealing and 72ºC / 45 s for elongation. 
 
Finally, it was determined that 59ºC / 30 s for annealing and then 72ºC / 45 s for 
elongation for the 1-759 bp gene fragment was effective. This cycle was repeated 30 
times. 
PCR products were run on a 1% (w/v) agarose gel (Figure 6.3) and both products 
yielded bands of the correct size. After the optimization step, CD138 gene fragments 
were amplified on a large-scale, as shown in Figure 6.4.  
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Figure 6.4 Amplification of CD138 (syndecan-1) gene fragments using cDNA 
as a template.  
Lanes 1 and 4 contain a 1 kB marker for determination of gene sizes; Lane 2 
consists of a PCR product with 1-261 bp (consistent with a 87 aa protein fragment) 
and Lane 3 consists of a PCR product with a 1-759 bp gene fragment (consistent 
with a 253 aa protein fragment).  
 
6.2.1.2 CD138 gene fragment cloning process 
The CD138 gene fragment was digested using NcoI and BamHI and cloned into 
predigested pQE60 using T4 DNA ligase, as described in sections 2.2.10.1.5 and 
2.2.10.1.6. Ligation was performed at room temperature and the final ligated product 
was ethanol-precipitated before use in transformation. pQE60 vectors, containing the 
insert, were transformed into XL10-Gold or RosettaTM bacterial cells. XL10-Gold cells 
were used because of their ability to transform large DNA molecules with high 
efficiency. They are deficient in all known restriction systems thus keeping the insert 
stable and improving the quality of miniprep DNA isolation. RosettaTM E.coli was used 
for CD138 protein fragment expression as this strain enhances the expression of 
eukaryotic proteins because it contains the pRARE plasmid with rare codons.  
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6.2.1.3 Analysis of CD138 cloning process by colony pick PCR or plasmid 
amplification 
Colony pick PCR was performed on 7 clones to verify the presence or absence of the 
CD138 gene fragment in the pQE60 vector in XL-10 Gold E. coli cells. The PCR 
product was run on a 1% (w/v) agarose gel (Figure 6.5).  
 
Figure 6.5 Screening of clones for CD138 gene fragment by colony pick PCR.  
Lanes 1-4 include different clones (1,2,3,4) of transformed E. coli XL10-Gold cells 
with the pQE60 vector / 1-261 bp gene fragment; Lane 5 contains transformed E.coli 
XL10-Gold cells with the empty pQE60 vector; Lane 6 contains 1 kB ladder for 
determination of gene fragment size; Lanes 7-9 contain clones (1,4,5) of transformed 
E.coli XL10-Gold cells with pQE60 vector with the 1-759 bp gene fragment; Lane 10 
contains transformed E.coli XL10-Gold cells with an empty pQE60 vector. 
 
 
It was shown that clones 1,2,3 and 4 were positive for the 1-261 bp of CD138 gene 
fragment and 1,4,5 were positive for the 1-759 bp CD138 gene fragment.  
Plasmid DNA was isolated from ten clones of XL10-Gold transformants, containing 1-
261 bp or 1-759 bp CD138 gene fragments, as detailed in section 2.2.10.1.4. 1 µg of 
plasmid DNA was used in PCR on these clones. 
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Figure 6.6 Amplification of CD138 gene fragment using pQE60 plasmid DNA as 
a template.  
Lanes 1 and 2 are PCR products with 1-261 bp (consistent with a 87 aa derivative of 
CD138) CD138 gene fragment (clones 1 and 2 were isolated from the transformed 
E.coli RosettaTM cell line); Lanes 3-6 consist of amplified 1-261 bp CD138 gene 
fragments (clones 1,2,3 and 4 from E.coli XL10-Gold cells); Lane 7 consists of a 
negative control (pQE60 vector without the CD138 insert); Lane 8 contains 1 kB 
ladder for determination of gene fragment size; Lanes 9-11 consist of a 1-759 bp 
(consistent with a 253 aa derivative of CD138) CD138 gene fragment (clones 1,2 and 
3 were isolated from the transformed E.coli RosettaTM cell line); Lanes 12-15 consist 
of an amplified 1-759 bp CD138 gene fragments (clones 1,2,3 and 4 isolated from 
E.coli XL10-Gold cells); Lane 16 is a negative control (pQE60 vector without CD138 
insert). 
 
It was found that clones 1,2,3 and 4 of the XL10-Gold E.coli cells contained the 
pQE60 vector with the 1-261 bp gene fragment and clones 1,2,3 and 4 of the XL10-
Gold E.coli cells contained the 1-759 bp CD138 gene fragment. 
It was also found that clones 1 and 2 of the RosettaTM E.coli cells contained the 
pQE60 vector with the 1-261 bp CD138 gene fragment, and clones 1 and 2 of the 
RosettaTM E.coli cells contained the pQE60 vector with the 1-759 bp gene (Figure 
6.6). 
Lane 15 consists of an amplified 1-759 bp CD138 gene fragment but the amount of 
the amplified gene is much smaller than in other samples. This is because of the 
differences in expression level between clones. Additional gene bands appeared 
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between 2,000 and 5,000 bp. The band which relates to the plasmid which was 
used as a template for CD138 gene fragment amplification is found at 3,431 bp. 
 
6.2.1.4 Expression of the CD138 protein fragment in bacterial cells 
Both CD138 (syndecan-1) protein fragments were expressed in E.coli XL10-Gold 
and RosettaTM cells following induction with 1 mM IPTG, as described in section 
2.2.10.5. The cells were lysed and the presence of CD138 was determined by 
Western blotting using the monoclonal anti-human CD138 clone MI15 antibody, as 
detailed in section 2.2.10.7. 
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Figure 6.7 Screening for CD138 protein fragment expression by Western 
blotting. 
The presence of CD138 protein fragment was determined by Western blotting using 
monoclonal anti-human CD138 primary antibodies and alkaline phosphatase 
conjugated goat anti-mouse IgG secondary antibody. Lane 1: PageRulerTM Plus 
Prestained Protein Ladder for determination of protein size; Lane 2: negative 
control, E.coli RosettaTM cells without transformed plasmid; Lane 3: E.coli RosettaTM 
cells with transformed pQE60 vector with the 1-759 bp CD138 gene fragment 
(consistent with a 253 aa derivative of CD138) clone 1; Lane 4: E.coli RosettaTM 
cells with transformed the pQE60 vector with the 1-261 bp CD138 gene fragment 
(consistent with a 87 aa derivative of CD138) clone 1. 
 
 
Expression of CD138 protein fragment (253 aa) was unsuccessful in E.coli XL10-
Gold cells. However, the CD138 protein fragment was detected in the lysate after 
induction with 1 mM IPTG, in the E.coli RosettaTM cell line containing the XL10-Gold 
with the 1-759 bp CD138 gene fragment (Figure 6.7). The CD138 gene fragment (1-
759 bp) generates a 253 aa protein and it was calculated that the molecular weight 
of that CD138 protein fragment is approximately 28 kDa, with theorectical pI of 4.36. 
The Western blot showed that CD138 protein fragment was detected using a 
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monoclonal anti-human CD138 antibody (clone MI15) but the molecular weight of 
the detected protein was ~57 kDa. It appears that the 253 aa CD138 protein 
fragment dimerized. For a better understanding, characterisation of the CD138 
protein was performed using ExPASy program (ProtParam tool). ExPASy (Expert 
Protein Analysis System) is maintained by the Swiss Institute of Bioinformatics and 
serves as a main resource for proteomics tools and databases. This programme 
analyzes protein sequences, structures and two-dimensional gel electrophoresis. It 
was determined that the 253 aa CD138 protein fragment is unstable. Studies on 
instabilities indicate that when an instability index is smaller than 40 the protein is 
designated as stable and when value is above 40 it infers that the protein may be 
unstable. The instability index computed for the CD138 protein, consisting of 253 aa, 
was 49.76 so the protein fragment was assessed as unstable. Dimerization may 
transform the CD138 protein fragment from an unstable to a stable form.  
After expression of the 87 aa CD138 protein, it was shown that the 87 aa CD138 
protein fragment was not detected by the anti-human CD138 monoclonal antibody 
clone, MI15, after protein induction of RosettaTM E.coli cells containing 1-261 bp 
gene fragment (consistent with a 87 aa), because epitope recognized by MI15 
monoclonal anti-CD138 antibody is not among CD138 protein fragment composed 
of 1-87 aa.  
 
6.2.1.5 Purification of 253 aa CD138 protein fragment 
Expression of the CD138 protein fragment (consistent with a 253 aa derivative of 
CD138) in E. coli RosettaTM cells, containing the pQE60 vector with an insert, was 
induced using 1 mM IPTG. The CD138 protein fragment was purified using affinity 
chromatography (Ni+-NTA), as described in section 2.2.10.8. The CD138 protein 
fragment contained a His-tag on the C-terminus, which enabled the protein to bind 
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to the nickel resin. The His-tag fused to the CD138 recombinant protein has a high 
affinity for nickel ions which are immobilized on sepharose beads. Sodium acetate 
(pH 4.4) was used to elute His-tagged proteins from the column.  
 
  
Figure 6.8 Western blotting of the 253 aa CD138 protein fragment. 
Purification of expressed CD138 protein fragment in RosettaTM 
Lane 1: Lysate - CD138 protein fragment not purified; Lane 2: PageRulerTMPlus 
Prestained Protein Ladder for determination of protein fragment size; Lane 3: ’flow-
through’ 1; Lane 4: ’flow-through’ 2; Lane 5: eluted 253 aa CD138 protein fragment. 
 
The majority of the CD138 protein fragment was found in the ’flow-through’, which 
means that protein did not bind to the resin. Some of the CD138 protein fragment 
bound to the nickel resin and was eluted, but several bands were formed on 
Western blotting with the MI15 monoclonal anti-CD138 antibody (Figure 6.8). This 
may be due to proteolytic breakdown. Purification of the CD138 protein fragment 
was performed using 0.1 M PBS, pH 7.4 / 0.5 M NaCl / 20 mM imidazole / 8mM 
urea, in the sonication and running buffers. NaCl was used to eliminate any protein-
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protein interactions and to avoid any ion exchange effects. Urea was used to 
maintain denaturating conditions for His-tagged proteins to enable protein 
linearization. Sodium acetate at low pH was used for the elution step. Some of 
CD138 protein fragment was found in the elution fraction but the majority of the 
protein was found in the ‘flow-through’ which means that the protein was not binding 
to the Ni+-NTA resin. Therefore, purification procedure of CD138 protein fragment 
was unsuccessful using the conditions described above.  
 
6.2.2 Cloning of CD138 gene fragment in pQETriSystem  
The pQE60 vector can only be used in prokaryotic cells and protein expression in 
prokaryotic cells does not allow for any post-translational modification (e.g. 
glycosylation). Production of the native, glycosylated form of CD138 protein is very 
important as it is the best form to use for immunization and, subsequently, for 
antibody generation. This enables comparison with the non-glycosylated form of 
CD138. Eukaryotic expression systems give post-translational modification of 
proteins and would enable comparison of anti-CD138 antibody binding 
characteristics to non-glycosylated and glycosylated forms of the CD138 protein. 
The pQETriSystem vector enables protein expression in insect or mammalian cells 
and can be use to obtain post-translational modifications.  
The pQETriSystem II vector also has a C-terminal His-tag sequence for ease of 
purification. To perform the cloning into the pQETriSystem II vector, primers were 
designed so that the sense primer contains a restriction site for SacI and anti-sense 
for Hind III enzyme.  
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Sense primer with SacI restriction site extra bases 
5' - TAT GAG CTC ATG AGG CGC GCG GCG CTC TG – 3'  
Anti-sense primer (1-759 bp) with HindIII restriction site 
5' - GAT AAG CTT CAG CAC CTC TTT CCT GTC CA – 3' 
 
Gene fragment amplification was carried out, as described in section 2.2.10.1.3. 
Briefly, the PCR conditions used were 95ºC / 30 s for DNA denaturation, 59ºC / 30 s 
for annealing and 72ºC / 45 s for elongation for the 1-759 bp CD138 gene fragment. 
This cycle was repeated 30 times. 
The CD138 gene fragment was cloned into a SacI HindIII digested pQETriSystem II 
vector and transformed into XL10-Gold E.coli cells. 
 
6.2.2.1 Analysis of CD138 cloning process by colony pick PCR and enzymatic 
digestion 
The CD138 gene fragment was cloned into pQETriSystem II vector and transformed 
into E. coli XL10-Gold cells. Colony pick PCR was carried out on 7 clones to assess 
the success of the cloning process. The PCR product was run on a 1% (w/v) agarose 
gel (Figure 6.9).  
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Figure 6.9 Screening of clones for the CD138 gene fragment by colony pick 
PCR.  
Lane 1 contains a negative contol (PCR without cells); Lanes 2 and 10 contain 1 kB 
ladder for determination of gene fragment size; Lanes 3-9 contain clones (1,2,3,4,5,6 
and 7) of transformed E. coli XL10-Gold cells with the pQETriSystem II with the1-759 
bp CD138 gene fragment. 
 
It was shown that clones 1,4 and 5 of pQETriSystem II vector / 759 bp were positive 
for the 1-759 bp gene fragment (Figure 6.9). 
Restriction analysis of the pQETriSystem II vector was performed, as a second 
confirmation of the cloning process. Briefly, plasmid DNA was isolated from 4 clones 
of XL10-Gold transformants, containing the 1-759 bp CD138 gene fragment, as 
described in section 2.2.10.1.4. The plasmid was digested using SacI and HindIII 
enzymes for 1.5 h at 37°C to confirm presence or absence of the CD138 fragment 
(Figure 6.10).  
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Figure 6.10 Restriction analyses of pQETriSystem II vector containing an 
inserted 1-759 bp CD138 gene fragment. 
Lanes 1 and 8 contain 1 kB ladder for determination of gene fragment size; Lanes 2-4 
contain digested the pQETriSystem II vector with the 1-759 bp CD138 gene fragment 
clone 1; Lane 2 contains the pQETriSystem II vector with the 1-759 bp CD138 gene 
fragment clone 1 digested with SacI only; Lane 3 contains the pQETriSystem II vector 
with the 1-759 bp CD138 gene fragment -  digested with HindIII only; Lane 4 contains 
the pQETriSystem II vector with the 1-759 bp CD138 gene fragment digested with 
both SacI and HindIII enzymes; Lanes 5-7 include the pQETriSystem II with the 1-759 
bp CD138 gene fragment clone 2 digested as before using both SacI and HindIII 
enzymes; Lane 9 contains the pQETriSystem II with the 1-759 bp CD138 gene 
fragment clone 4 digested with both enzymes; Lane 10 contains the pQETriSystem II 
with the 1-759 bp CD138 gene fragment clone 5 digested with both enzymes. 
 
It was found that clones 1,2,4 and 5 of XL10-Gold cells contain the pQETriSystem II 
vector with the insert composed of the 759 bp gene fragment of CD138. 
Thus, the CD138 gene fragment, composed of 1-759 bp, was successfully cloned 
into pQETriSystem II vector and this vector can be now used for transfection into 
mammalian cells for the expression of the glycosylated form of CD138.  
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Discussion 
The main aim of the research, described in this chapter, was to produce the CD138 
(syndecan-1) protein fragment in a recombinant form as the protein is not available 
commercially. Large-scale production of the CD138 protein fragment would enable 
immunization which could lead to the generation of polyclonal, monoclonal or 
recombinant antibodies. Production of both the non-glycosylated and glycosylated 
forms of the CD138 protein would enable comparisons between anti-CD138 
antibodies generated to both forms and would be useful for targeting multiple 
myeloma.  
This is the first attempt at the production of CD138 protein fragment in a prokaryotic 
cell system. Gattei at al. (1998) previously produced the glycosylated form using a 
‘cell-free’ system. Their 'cell-free' system resulted in a cleaner lysate compared to 
the bacterial system used in this study. They produced the glycosylated form 
whereas the prokaryotic system only allowed protein core production with no 
modifications.  However, protein production in a 'cell-free' system is time consuming 
and expensive compared to the use of prokaryotic cells, which is easy and cheap. 
The CD138 protein fragment could also be used for the evaluation of anti-CD138-
liposome binding capacity. At the moment human multiple myeloma cancer cells are 
used as a target to determine the ability of these liposomes to bind CD138. CD138 
protein fragment production would allow the performance of kinetic studies with anti-
human CD138-liposomes using Biacore1000. Using this approach estimation of the 
lowest concentration for anti-CD138-conjugated-liposomes to be used for imaging 
can be determined.  
Gattei et al. (1998) found that B-B4, MI15 and 104-9 anti-CD138 antibodies 
recognize the recombinant non-glycosylated form of the CD138 protein. The 
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molecular mass of the detected recombinant CD138 protein (310 aa) was 70 kDa. 
These clones of anti-human CD138 antibodies also recognize the glycosylated form 
of the CD138 protein.  
The extracellular portion of the CD138 protein fragment, composed of 253 aa, is 
recognized by MI15 monoclonal antibody. Epitopes recognized by the MI15 
monoclonal anti-CD138 antibody are between amino acids 107-110 (Dore et al., 
1998). A second fragment of CD138 of 1-87 aa was produced as a negative control, 
because this fragment does not contain the epitope recognized by the monoclonal 
CD138 antibody, MI15.  
Advances in genetic engineering have greatly facilitated the expression of 
mammalian proteins in prokaryotic systems such as E.coli (Makrides, 1996; Tolia 
and Joshua-Tor, 2006). Expression of CD138 protein fragment was unsuccessful in 
XL10-Gold E.coli cells, however, CD138 protein fragment was detected after 
induction in the RosettaTM E.coli strain, using Western blotting. The choice of E.coli 
strain plays an important role in expression of recombinant proteins. The RosettaTM 
E.coli strain was designed to enhance the expression of eukaryotic proteins. This 
strain contains the pRARE plasmid with rare codons. The RosettaTM strain possess 
tRNAs for AGG, AGA, AUA, CUA, CCC, GGA codons. Thus, RosettaTM strains 
provide for ‘universal’ translation, which might otherwise be limited by the codon 
usage of E. coli. The pRARE plasmid, in the RosettaTM stain, can co-exist with the 
expression plasmid. However, the highly concentrated proteases of the intracellular 
environment may also alter some characteristics of the final expressed product, 
prohibiting the expression of some bioactive proteins in E.coli. The RosettaTM strain 
does not contain the Lon protease, and another outer membrane protease, OmptT. 
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The absence of these two key proteases reduces degradation of proteins expressed 
(Sorensen and Mortensen, 2005; Ratelade at al., 2009).   
The calculated mass of the CD138 protein fragment, composed of 253 aa, should 
be around 28 kDa, but the mass observed on Western blotting was approximately 
57 kDa. This is probably as a result of dimerisation. This finding is in the agreement 
with other researchers, who observed a 70 kDa molecular mass for the CD138 
protein product (310 aa) on Western blotting while 35 kDa was the predicted mass 
(Bernfield et al., 1992; Carey, 1997). CD138 forms SDS-resistant dimers. However, 
dimerization was not a problem with CD138 protein fragment production, because 
the relevant epitope was still recognized by the MI15 monoclonal anti-CD138 
antibody.  
CD138 protein fragment (253 aa) was successfully cloned into the pQE60 vector 
and expressed in the RosettaTM strain. Problems occurred during purification. 
Studies indicated that the CD138 protein fragment generates a stable dimer in a 
denaturating environment, but dimer formation does not prevent binding of the MI15 
anti-CD138 monoclonal antibody. Purification of the CD138 protein fragment, 
however, still needs to be further optimized. Dimerisation of the recombinant CD138 
fragments could result in the unavailability of the His-tag for binding to the Nickel 
resin. For IMAC purification, decreasing the pH of the running buffer, as the pI of 
CD138 protein fragment is 4.36, would help avoid ionic interactions between 
proteins. It was also observed that the protein detected was cleaved into different 
fragments of varying sizes, possibly due to proteases present in the lysate. This 
could be prevented by the use of specific protease inhibitors. 
These preliminary studies showed the successful production of the non-glycosylated 
form of CD138 in bacterial cells. It was shown that the MI15 anti-CD138 monoclonal 
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antibody recognizes the form of the CD138 protein. However, further optimization of 
purification steps are necessary to facilitate larger yields to be obtained which are 
necessary for protein characterisation, kinetic studies, binding studies and 
immunization in multiple hosts (mouse, rabbit and chicken) for recombinant and 
monoclonal antibody production. Production of the CD138 protein fragment would 
be very useful for anti-CD138-conjugated-liposome binding studies.  
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Conclusions 
The main aim of this project was to prepare contrast (gadolinium-loaded) 
nanoparticles which would target the CD138 (syndecan-1) transmembrane 
glycoprotein overexpressed on the surface of human multiple myeloma cells in bone 
marrow. These contrast targeted nanoparticles were designed to be used for 
diagnostic purposes. The main advantage of this approach would be to develop a 
diagnostic agent which can be used for minimally-invasive detection of cancer.  
Immunoliposomes were chosen as nanoparticles for use in this project. Anti-human 
CD138 monoclonal antibodies were successfully conjugated to the carboxylic acid 
group of phospholipids. Two different methods of immunoliposome preparation 
(reverse phase evaporation and the co-incubation method) were optimized and 
used. The size and zeta potential of the immunoliposomes generated were 
measured. The average sizes of liposomes and of immunoliposomes which were 
extruded through 100 nm polycarbonate membranes, were approximately 100 nm. 
The number of antibodies per liposome was calculated to be 6-7 using the reverse 
phase evaporation method and 9 using co-incubation method. In vitro binding 
assays (FACS analyses and FLISA) were carried out to characterise the liposome 
binding to cancer cells. It was found that anti-CD138-conjugated-liposomes were 
targeting significantly more strongly to the U266 human multiple myeloma cancer 
cell line than control liposomes. 
Part of this work was carried out in the Pharmaceutical Biotechnology and 
Nanomedicine Centre in Prof. Vladimir Torchilin’s group at Northeastern University 
in Boston, USA. Polychelating amphiphilic polymer (PAP) was synthesized there 
and loaded with gadolinium ions. PAP can chelate several Gd ions per single 
amphiphilic polymer molecule thus increasing the relaxation effect resulting in 
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improved potential for tissue imaging. Gadolinium ions were first loaded into the 
PAP molecule and contrast liposomes (containing Gd-DTPA-BSA and Gd-PAP) 
were then prepared. Detailed NMR analysis showed that not only does the higher 
Gd content of Gd-PAP aid in enhancing the relaxation in water containing 
liposomes, but that Gd-PAP is also more effective per Gd ion than Gd-DTPA-BSA. 
Stability tests on contrast liposomes (containing Gd-DTPA-BSA) found that they are 
stable in solution for 14 days while liposomes containing Gd-PAP are stable for 19 
days. T1-weighted images of contrast liposomes showed that Gd-PAP-containing 
liposomes are significantly brighter compared to Gd-DTPA-BSA-liposomes on MRI 
scanning. 
Anti-CD138-conjugated contrast liposomes were prepared and binding tested 
against human multiple myeloma cell lines in vitro. Anti-CD138-Gd-DTPA-BSA- and 
anti-CD138-Gd-PAP-liposomes bound approximately 2.5 fold and 3 fold more 
strongly, respectively, to the U266 human multiple myeloma than did control 
liposomes. T1-weighted images of contrast immunoliposomes showed that anti-
CD138-Gd-PAP-liposomes are significantly brighter compared to anti-CD138-Gd-
DTPA-BSA-liposomes on MRI scanning. In vitro interactions of contrast anti-CD138-
conjugated liposomes with cancer cell lines were also performed. MRI scanning of 
these interactions showed that anti-CD138-Gd-PAP-liposomes gave stronger 
contrast than anti-CD138-conjugated-liposomes containing Gd-DTPA-BSA after 
incubation with U266 human multiple myeloma cell line. 
The findings described in this thesis will hopefully contribute to the preparation of 
novel minimally-invasive contrast agents for the diagnosis of human multiple 
myeloma. 
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Future work 
An exact molecular mass assessment of gadolinium-loaded polychelating 
amphiphilic polymer (PAP) will be carried out using Matrix-Assisted Laser 
Desorption / Ionization (MALDI) mass spectrometer. It will allow accurate 
relaxometry analysis of contrast anti-CD138-Gd-PAP-liposomes. 
Contrast anti-CD138-conjugated-liposomes (containing Gd-PAP or Gd-DTPA-BSA) 
will be used in in vivo studies in a multiple myeloma mouse model. Interactions of 
contrast immunoliposomes with cancer cells will be visualized using magnetic 
resonance (MR) scanning in Cappagh Hospital, Radiology Department. In addition, 
significant amounts of glycosylated and non-glycosylated forms of CD138 protein 
fragments will be produced which would enable animal immunization for polyclonal, 
monoclonal and recombinant antibody generation. The generation of better and 
more specific antibodies, in large quantities, would be required for the next phase of 
this work which will require both in vitro and in vivo imaging studies 
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